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1Introduction
The REITOX report 2000 includes the most important information on the state and
developments of drug problems in Germany for the reporting year. It closely follows the
structure and guidelines published by the European Monitoring Centre for Drugs and Drug
Addiction (EMCDDA) in Lisbon. Through the processing and description of the national data
the basis is prepared for the EMCDDA to make comparative use of this information.
Following the EMCDDA new information strategy the data will flow into a trend report on the
situation of the drug phenomenon in Europe. In addition detail information will be made
available in future in data banks. This will make the use of the national working results better
and more easy.
Through a decision taken by the Federal Ministry for Health and the Federal Laender the
focal point activities integrated in 1999 into the DBDD. In this way the generic task and the
national role of the German Focal point has been underlined. The DBDD is hold by the three
partners, which have done this work from the beginning. The Federal Centre for Health
Education (FCHE) with a focus on prevention, the German Council on Addiction Problems
(DHS) with a focus on treatment and the IFT Institute for Therapy Research focussing on
epidemiology are working closely together in this respect. The IFT also is responsible for
management and co-ordination.
Special thanks to Jürgen Töppich (FCHE) for his input in chapter 10 "quality assurance" and
Susanne Schardt (ECDP) for her contributions to chapter 9.5.6 "ethnic minorities". For critical
comments and support we would like to thank all persons from the Federal Ministry for
Health, the Land Ministries, FCHE, DHS as well as Gerhard Bühringer, Tim Pfeiffer and
Martina Tengler from the IFT Institute for Therapy Research.
Roland Simon
Director of the DBDD
2PART I
NATIONAL STRATEGIES: INSTITUTIONAL & LEGAL
FRAMEWORKS
1 Developments in Drug Policy and Responses
1.1 Political framework in the drug field
1.1.1 Objectives and priorities of the national drug policy
In Germany after the change of government in autumn 1998 the office of the Federal
Drug Commissioner moved from the Federal Ministry of the Interior (BMI) to the
Federal Ministry for Health (BMG). This political step shows that in national drug
policy health and social aspects are more predominant as they used to be following
the general rule “help comes before law enforcement”. In the agreement of coalition of
the Federal Government education, prevention, help for drug addicts and law
enforcement were fixed as four major pillars of drugs policy. The latter lies within the
responsibility of the Federal Ministry of the Interior (BMI), its corresponding Land
Ministries and customs.
In March 2000 the Drug Commissioner of the Federal Government Mrs. Nickels
presented her report on drugs and addiction. There prevention is stressed as main
focus of the national drug policy: Preventive interventions should focus on the use of
illegal psychotropic substances but increasingly the abuse of alcohol and tobacco
also. “Health promotion” and “the strengthening of life skills” are concepts placed in
the foreground. A further aim of the Federal Government is to support addiction
treatment which is oriented to efficiency and quality. In accordance with their
psychological, physical and social condition addicts are to be offered individualised
help which is easy to access by a differentiated drugs help system. Therefore help
should range from low threshold services reaching from harm minimisation and
survival to offers that help drug addicts to get abstinent of drugs.
In December 1999 a new “Drugs and Addiction Commission” was called by the
Federal Ministry for Health. This commission replaces the “National Drugs Council”
which was existing since 1992. The new body consists of 14 experts out of in the field
of medicine, psychology, social science, jurisprudence, one representative of people
concerned with drugs as well as a journalist. The function of the commission will be to
give professional advice and to support the Federal Ministry for Health. Its votes have
a consultative character. Firstly the Federal Ministry for Health has asked the body for
3the development of a complete “drugs and addiction concept” in order to improve
prevention as well as for the creation of elements for a new national action plan.
This year the national programme for addiction research will end. It has been
supported by the Federal Ministry for Education and Research (BMBF) since 1994.
Models of early stages of addiction development and persons who stopped their drug
abuse without professional help were part of the field of analytical epidemiology. The
neurobiological basis of causes, prevention and therapy in drug addiction were part of
this programme, too. Last projects will end in the course of the year 2000. Another
priority is now to support research co-operation units in addiction research which was
announced in October 1999. Due to recent scheduling projects will be starting at the
beginning of 2001. Between research and supply the goal is to strengthen its bonds
and the transfer of research results as well as to build up long lasting structures of co-
operation.
1.1.2 Basic elements of drug policy at national, regional and local level
In Germany due to its federal structure drug policy is defined on national as well as on
Laender level. The parliament and the Federal government as giver of a decree decides - in
adequate in co-ordination with the Bundesrat (Federal Chamber of German Laender) - on the
legal basis of drug policy. The Federal government initiates measures for demonstration
projects in addiction prevention and in the field of treatment and care for addicts. The
international co-operation against drug abuse and trafficking is also in its domain. The
Federal Ministry for Health is competent for the international co-operation in the drug field as
well as for the development and implementation of the international conventions on addictive
substances, further on also for international activities in the field of health care and
prevention. The Federal Ministry of the Interior is responsible for initiatives concerning public
safety.
Whereas drug legislation lies predominantly within the responsibility of the Federal
Government it is implemented by the 16 Federal Laender. As well as the Federal
Government they are authorised to propose acts, which will be decided by the
Chamber of the German laender. The application of drug laws by Federal Laender
includes mainly law enforcement and monitoring of the circulation of narcotics as far
as not in the responsibility of the Federal Centre for Drugs and Medical Devices
(BfArM).
 Co-ordination with the bodies responsible for health and pension insurance are tasks of the
Federal Laender, too. In the interest of a perfect co-ordination of drug policy nearly all
Federal Laender have installed a Drug or Addiction Commissioner. Their task basically is to
bring together and co-ordinate the measures of different branches (health, social, youth,
culture, interior, justice) for example through interministerial work-groups. They also are
4networking between drug help and general health related and social services.
 Furthermore municipalities play an important role in the field of drugs and addiction. The
municipalities are the bodies responsible for social funds, which cover the basic financial
needs of persons, which are not covered by other systems like pension and health insurance
or unemployment insurance. The municipalities are funding a considerable part of
counselling and social care especially in out-patient and low threshold activities. Costs
associated with (secondary) diseases and detoxification are covered by health insurance,
rehabilitation is paid for by pension insurance. Both of the bodies are Non-Governmental
Organisations (NGO’s), they are covered by their members. From their contributions
detoxification, in-patient and in parts out-patient treatment and after care is financed. The law
is only defining the framework of these institutions, especially in the Code of Social Law.
 For arrangement and co-ordination of drug related activities at federal and Laender level
there are regular meetings of the Ongoing Working group of Federal and Land Drug
Commissioners. Representatives of other relevant institutions are also included, which
ensures an exchange of information and experience between federal and Laender level and
NGOs.
1.1.3 Specific issues of particular interest
1.1.3.1 Developments at national level
Different recent activities of the German Federal Government and their implementation
at national, regional or local level will be described below. Those interventions chosen
are of strategic importance or innovative from a drug policy point of view regarding
concept or implementation.
Rooms for drug use
At the end of February 2000 German Federal Parliament and Federal Chamber of
German Laender agreed upon a law, which is expected to create a safe legal position
for drug consumption rooms. §10a of the third amendment of the Narcotic Law (BtMG)
contains a catalogue of minimum requirements for rooms, as well as for medical and
social care. The first aim is to reduce the risks of drug intake through appropriate
framework conditions and legalise staff activities. It has also been clarified that staff is
forbidden to actively support drug consumption. When opening drug consumption
rooms abstinence-oriented counselling and treatment have to be offered to opiate
addicts and arranged if wanted. Each Land government is free to allow drug
consumption rooms and to create corresponding rules. It is up to the Land
government to pass a decree and fulfil by that requirements for a permission of drug
5consumption rooms. The mentioned legal preconditions have to be installed in the
Federal Laender within two years after coming into force of the new decree. This has
taken place in Hamburg (April 2000) and in North Rhine-Westphalia (September 2000).
Heroin supported treatment
During the last 10 years through the fast extension of low threshold and mainly of
substitution based treatment a differentiated and high quality system of drug
treatment has been developed. A big portion of drug users can be reached and helped
in different ways. Still it has to be stated, that this offer does not reach a certain group
of drug addicts, which is characterised by health impairments, health risks, severe
addiction and low motivation for treatment. These experiences have been made also
in other countries and have caused further considerations on other methods of help.
This has caused the model on heroin substitution under physicians' control in
Switzerland. Based on results and experiences from the study in Switzerland and now also
from the Netherlands a clinical multi-centre study on ambulatory heroin supported treatment
of heroin addicts will be designed in Germany. The study will include the clinical trial of
heroin based prescriptions. Such a clinical trial of medicines is needed to find out
pharmacological effects of a substance, which is not allowed by Pharmaceutical Law until
now. In addition it is expected to clarify, how far opiate addicts who have hardly been
reached by therapeutic measures could be
Ø stabilised in their health, psychological and social situation,
Ø integrated definitely into the help system,
Ø kept within the help system and
Ø motivated for further treatment
through heroin supported treatment.
It will also be studied, if and how
Ø heroin supported treatment can be implemented into the treatment offered to opiate
addicts and
Ø risks for public security can be limited.
Furthermore the study will examine the development of drug use for opiate addicted clients,
their motivation for treatment and the psycho-social consequences as well as the
consequences of heroin supported treatment for public order and penal law. On the basis of
Par. 3,2 of the Narcotic Law the Federal Centre for Drugs and Medical Devices can permit
such a scientific study. For such a study the regulations of national and international narcotic
law as well as the rules of the Pharmaceutical Law (Arzneimittelgesetz) to protect humans in
clinical trials as well as the Regulations for the Test of Pharmaceutics (Arzneimittelprüflinien)
and the rules of good clinical practise have to be respected.
6In February 1999 with Ministry for Health responsible a co-ordination group was created
composed from representatives of interested municipalities and the Laender as well as a
representative of the Federal Medical Association. This group has developed a framework
concept in which general targets of the trial, its legal basis and different other questions
concerning its content have been laid down in consensus. On the basis of this framework
concept a call for tender was agreed upon between all participants and published in the
meanwhile in the Federal Gazette and in the internet. Until the 3rd of January 2000 three
research institutions have presented project concepts according to the call for tender.
As the examining committee was not able to give the contract to any of the
competitors, two of them were asked to develop a design for the study. Until the 9th of
July both study designs were proposed. In an expert meeting at the 29th of August
both designs were examined thoroughly. At the 15th of September the steering group
consisting of Federal Government, Federal Laender and cities met in order to discuss
the study designs and the results of the expert meeting. An ethical commission and
the Federal Centre for Drugs and Medical Devices (BfArM) will take their stand on the
chosen research design.
The beginning of the project is planned to be in 2001. Its term will be three years.
Participating cities are Frankfurt am Main, Karlsruhe, Hamburg, Hanover, Köln, Essen
and München. The city of Düsseldorf was quitting the model, because the political
majorities changed in the town council after communal elections in autumn 1999.
Costs of the model on heroin supported treatment will be covered by Federal
Government, Federal Laender and the cities. Whereas the Federal Government will
finance the scientific evaluation and half of the case-management (that means staff
which is organising additional help if needed), the cities will cover all expenses on the
scene as well as parts of the case-management and examining physicians.
Substitution
With help of the Third Amendment of the Narcotic Law (3. BtMG-ÄndG) which was
passed on the 28th of February 2000 (see “Rooms for Drug Use“) there are further
possibilities to establish regulations for the prescription of substitution substances.
They foresee a registration system for substituted patients. It should help to combat
multiple prescriptions by attending several physicians as well as an increasing
availability of methadone on the black market. The so called “central substitution
register” will be placed at the Federal Centre for Drugs and Medical Devices (BfArM).
A decree will regulate all details, that means what kind of information on the
substitution based treatment of each patient will be registered and in which way data
will be processed. Furthermore medical doctors who are prescribing substitution
substances are since then legally obliged to obtain an additional qualification called
7"Suchtmedizinische Grundversorgung“ which was already decided by the Federal
Chamber of Physicians on the 11th of September 1998. For this guidelines were
already worked out by the Federal Chamber of Physicians.
Narcotic addicts substituted with codeine/dihydrocodeine are to be substituted with
methadone. This change could not be realised by physicians before the 30th of July
1998 as planned in the 10th amendment of the Narcotic Law Regulations (BtM-ÄndV).
The deadline was prolonged several time, finally until the 1st of January 2000. Since
the beginning of 2000 the use of codeine as a substitution substance is regulated in
the framework of a decree and is possible only in exceptional cases.
The Federal Drug Commissioner approves in her drug report a wider range of
substitution substances to proceed alternatives in certain cases where methadone
can not be used. On the German market methadone and buprenorphine are meanwhile
permitted for substitution purposes. First clinical studies are expected to bring
experience with levoalphaacetylmethadol (LAAM) and finished levomethadone in
substitution treatment. For opiate addicts who have an especially strong will to finish
their drug abuse the Federal Ministry for Health recommends the use of opiate
antagonists. Physicians are asked to examine regularly if the used opiate antagonists
as a remedy do make sense in individual cases.
Cannabis based pharmaceutics
Cannabis in the form of hashish or marihuana as well as the main active substance
tetrahydrocannabinol (THC) are subject to international conventions on psychotropic
substances ratified by Germany and are covered by the Narcotic Law. The Federal
Republic of Germany is bound by the Single Convention from 1961 about addictive
substances (Art. 4, Letter C) to restrict the use of cannabis products only for medical and
scientific purposes. Following the regulations of the Law on Pharmaceutics (§1 AMG)
reproducible quality, effectiveness and harmlessness of the active substance of cannabis
have to be proofed before ist active substances can be added to the list of narcotics which
can be circulated as well as prescribed. Illegally acquired hashish or marihuana may vary
in active substances and may contain other added substances which are harmful.
Therefore they can be dangerous and strongly reduced in pharmacological quality and
must not be circulated according to Narcotic Law. The Law on Pharmaceutics has the
possibility for pharmacies to provide single patients with allowed imported drugs. At
present small amounts of finished marinole and nabilone are imported from the USA
and GB.
8On January 20th 2000 the Federal Constitutional Court refused to decide over a petition
of eight patients, who wanted to use cannabis products without prosecution in order
to ease their pain. The judges explained that they first have to take legal actions. The
reason given for the decision was that medical supply is a "public purpose" which can
permit the circulation of cannabis products in single cases according to §3 Abs.2
BtMG. This permission is within the discretion of the Federal Centre for Drugs and
Medical Devices (BfArM) and has to be decided there first.
Cannabis and penal law
The German government also has intensified the discussion on the legal position of
non-medical use (possession and purchase) of cannabis products. The Federal
Constitutional Court has requested the Laender already in 1994 to use uniform
conditions and limits for the prosecution of an offence when cannabis for personal
use is not prosecuted. The "small amounts" and further legal requirements to stop
prosecution are still defined differently in the regulations of the Land justice
administrations. For cannabis it varies between 5 and 30 gram, for heroin between 0,5
and 6g. In the practice of courts and public prosecutors nation-wide more than 90% of
all criminal procedures with a maximum of 10g cannabis are suspended however
(Aulinger 1998).
Children of families with drug problems
Children of addicted parents are at an especially high risk of getting mentally ill
themselves. To find out the best support for parents and children in self-help group
settings the Federal Ministry for Health promoted a model project of the German
Guttempler Orden. German Caritas, too plans a special drugs prevention manual for
children of afflicted families. This kind of programmes is well established in the USA
and could also be used in Germany. The Germany Council on Addiction Problems
(DHS) organised an expert meeting "children of addicts". A summarising
documentation of its results is recently done.
Migrants and drug use
This is a field that has not been noticed for a long time - there is only few data out of
the fields of epidemiology and treatment, and there is not much knowledge about the
use and efficacy of special prevention and treatment programmes, too. Therefore the
Federal Ministry for Health has assigned several expert reports. First results will be
available at the end of the year.
91.1.3.2 Developments at Laender level
In principle in the Federal Laender there are the same strategies to deal with addiction
and drug problems as at national level. Prevention for demand reduction are in the
fore. Counselling and therapy are basic elements in the existing drug help system of
the Federal Laender, aids for survival and harm reduction interventions are
increasingly established. Law enforcement as an undeniable intervention is used in all
Federal Laender to reduce supply and criminal drug trafficking. Depending on the
drug policies of the Laender governments as well as on scope and appearance of the
local drug problem the focus on these interventions is different. Drug commissioners
of the Laender were asked for recent information on approaches and activities in the
Laender by the DBDD. Out of all responding ministries two activities will be described
as examples. This report mainly describes changes and new developments, so
especially the picture of the Laender given here is not representative for all their
activities in the field of drugs.
Hamburg
In April 2000 the Hamburg Land parliament was the first Federal Land to pass the legal
basis for drug consumption rooms according to the requirements of the Third
Amendment of the Narcotic Law (3. BtMG-Änderungsgesetzes). First of all the official
permission regulates the function of the rooms, which is to get in contact with people
who could hardly be reached before, to help them and to give them advice. The aim is
to show them new ways towards further abstinence-oriented counselling and therapy.
There have to be the same standards in all units regarding responsibility, equipment,
care and medical supply in case of emergency (for example artificial respiration or
reanimation) as well as interventions to prevent drug related offences. In the eight
Hamburg drug consumption rooms opiate addicts ought to be motivated to treatment
or to substitution aiming at quitting drug use.
Sachsen-Anhalt
Even if the drug problem in the new Laender has yet not grown to the same size as in
the old Laender the developments are followed critically. Some regional studies are
commissioned by the Ministry for Work, Woman, Health and Social Affairs. They are
expected to evaluate the situation in detail and give indications for interventions and
political decisions on Laender level. Following studies were made or are still ongoing:
Ø The sociological-empirical short term study "Drug use in adolescents - Extent,
risks and possibilities for interventions from a street-works point of view",
Ø The study "Drug affinity of teenagers in the techno party scene in Sachsen-
Anhalt",
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Ø The ethnographical study "Patterns of drug careers among illegal drug users in
Sachsen-Anhalt",
Ø The longitudinal study MODRUS II "Modern prevention of drugs and addiction".
These studies give qualitative information on the scope of the drug problem and
trends. Especially ethnographic approaches are expected to provide more insight in
motives and needs of drug users in order to plan interventions appropriately.
1.2 Policy implementation, legal framework and prosecution
1.2.1 Drug laws and punishment
When end of the 60s drug use increased in Germany, the legal situation of drug use was still
ruled by the opium law from 1929. The law was based in parts still on the International
Opium Act from 1925. In 1971 a new Narcotic Law (Betäubungsmittelgesetz BtMG) was
passed. The basis for this were the international conventions on “Narcotic Drugs“ (1961) and
on “Psychotropic Substances“ (1971), which had been passed in the meanwhile. In parts in
reaction to the subsequent worsening of the drug situation the law was amended in 1981.
The aim was to give a more simple and clear structure to the law and to reduce negative
health and social consequences of drug use. In addition, punishment especially for illegal
trafficking and production of drugs should be stiffened. For the first time special
regulations have been edited for drug addicted delinquents. If they are willing
“treatment instead of punishment“ should become possible and punishment should
be remitted or reduced in order to give more weight to the aspect of addiction as an
illness and a burden for total society. In order to convert the UN convention on the illegal
circulation of addictive and psychotropic substances further penal regulations have been
added to the BtMG. Amongst others to set aside chemical substances for illegal production
of drugs has been made a punishable offence. In 1992 another amendment starting in the
Bundesrat (Federal Chamber of German Laender) (took place, which triggered further
essential changes in the BtMG as well as in the Penal Code:
Ø The explicit permission of substitution based treatment for drug addicts (§13 Par. 1
sentence 1 BtMG).
Ø A partial depenalisation of drug users for use related petty cases through
remittment of punishment by public prosecutors without a judge's agreement
(§31a BtMG).
Ø Essential improvements where external drug therapy is started or re-started by a drug
addict who is sentenced to imprisonment.
Ø The possibility to credit periods of therapy if penalty is not executed (§36).
Ø The reduction of the threshold for entering for the principle of “therapy instead of
prosecution“ (§37).
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Ø The legal clarification of the authorisation to deliver syringes to addicts.
Ø The introduction of a right for drug counsellors to refuse to give evidence.
In 1992 and 1994 penalties for heavy delinquency of illegal drug trafficking were increased.
Narcotics (BtM) are according to the German Narcotic Law (Betäubungsmittelgesetz
BtMG) substances included in three schedules. They cover all substances mentioned
in international conventions on addictive substances. Narcotics included in schedule I
and II must not be prescribed or handed out in the framework of medical treatment.
Ø Schedule I: Narcotics which are forbidden generally (no trade allowed)
(for example cannabis, MDMA, heroin)
Ø Schedule II: Narcotics, for which trade is allowed, but which cannot be prescribed
(for example Delta-9-tetrahydrocannabinol (THC), dexamphetamine)
Ø Schedule III: Narcotics, for which trade and prescription are allowed
(for example amphetamines, codeine, dihydrocodeine, cocaine,
methadone, LAAM, morphine and opium)
The prescription of narcotics (from schedule III) as part of a medical treatment has to follow
the special rules of the regulation on the prescription of narcotics (Betäubungsmittelver-
schreibungsverordnung BtMVV). So special narcotics-form-sheets have to be used. They are
also used in the treatment of severe conditions of pain (for example in the treatment of
cancer). Each legal circulation of narcotics is allowed only either on the basis of a licence of
the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und
Medizinprodukte; BfArM) administration or as part of a medical treatment. A licence for
narcotics mentioned in schedule I can be issued by the Federal Institute for Drugs and
Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) only by way of
exception for scientific and other reasons in public interest (§3 Abs. 2). Circulation of
narcotics mentioned in schedules I and II are only issued if the Federal Institute for
Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte;
BfArM) gives a permission for specific circulations (e.g. production, import, export)
(§3 Abs. 1 BtMG) and for each transaction, too (§11 ff BtMG).
Any other circulation is forbidden and punishable (§29 ff BtMG). This means especially
possession, production and growing, import, export, trafficking and free transmission of
drugs. The penalty is tightened (sections 29a, 30, 30a) when in a criminal offence according
to BtMG or others a “not insignificant quantity” of drugs is involved, persons above 21 years
transfer drugs to a person below 18 years, trafficking is done professionally, an offender is a
member of a criminal gang or arms are used. Within amendments as well as for the ongoing
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administration of justice the concern is visible to make a clearer difference legally between
drug users and drug traffickers. While penalties for drug trafficking increased during the last
years, other legal regulations comprise to depenalise drug users partially. Courts or
prosecuting attorneys’ offices should refrain from prosecution and judges should refrain from
penalties, in case only minor guilt would be judged for the offender, only ‘insignificant
quantities‘ of drugs for personal use are involved, there is no public interest in prosecution
and especially others are not endangered of have been harmed.
 In the last two years changes of the regulations on the prescription of narcotics which
are important for the practical work have been made concerning prescription and
delivery of pain killers and substitution substances. According to the 10th Amendment
of the Narcotic Law Regulations (BtMÄndV) which came into force on February 1st
1998 the prescription of codeine, dihydrocodeine and flunitrazepame for patients
addicted to narcotics has exclusively to be done on the special narcotics-form-sheets
already mentioned. Besides exceptions because of medical reasons all patients
addicted to narcotics substituted with codeine or dihydrocodeine should be
substituted with methadone after January 1st 2000. This gradual change of patients
formerly substituted with codeine was obviously causing problems only in single
cases. A study in Hamburg reports that the change was possible without feared
problems but around 20% of clients had problems (Kahlke, J., Verthein, U.,
Farnbacher, G., Schmidt, V & Degkwitz, P. (in print). Besides that there are indications
for drug-related deaths in Bavaria based on problems in methadone supply. Programs
for quick substitution of patients in case of insufficient supply were hardly used at all.
Patients who meet the requirements for autonomous intake of substitution substances
can be handed out recipes with take-away doses for seven days (three days until
then). Furthermore substitution substances can be given in public pharmacies for
immediate use.
 
The 12th and 13th Amendment of the Narcotic Law Regulations (BtM-ÄndV) included a
total of 12 additional designer drugs (amphetamines, methaqualone and phencyclidine
derivates) temporarily in schedule I of the Narcotic Law. At the end of February 2000
the Third Amendment of the Narcotic Law (3. BtMG-Änderungsgesetzes) already
mentioned above was passed with the agreement of the Federal Chamber of the
German Laender (Bundesrat). The law fixes minimum standards for drug consumption
rooms. Each Land government is free to pass a decree and create the requirements
for a permission. The law also contains the possibility for further regulations for the
prescription substitution substances. By establishing a central substitution register
(avoidance of double prescriptions) and training standards still to be definded for
substituting physicians quality in substitution treatment is supposed to be improved.
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1.2.2 Other relevant laws
 Further important regulations in the control of drugs are especially the Money
Laundering Act (Geldwäschegesetzt) and the Precursor Control Act
(Grundstoffüberwachungsgesetz). In several respects the general laws (StGB, StPO) take
considerable influence also in the field of drugs. For example drug related crime is touched in
the General Criminal Code (Strafgesetzbuch StGB). Special regulations are here to be found
in several parts concerning the limited ability of addicts to control their own behaviour. For
drug as well as for alcohol addicts, penalties can be reduced due to the limited ability for
control given. On the other side it is possible to put offenders under custody, if they
tend to use drugs and there is a risk that they may commit further severe offences.
The same is to non-offenders who have been found to be permanently unable to
control their behaviour when serious damages for health or life have to be suspected.
 
 Especially in the field of drug research, but also in treatment of drug addicts the Data
Protection Law (Bundesdatenschutzgesetz  BDSG) plays an important role. It governs all
types of information and data collection. Data collection referring to a person is allowed only
then, if there is a legal basis. Within treatment of drug addicts this means that data, which are
directly related and necessary for treatment can be collected without the patient's consent. In
all other cases (e.g. treatment statistics) the patient's consent is needed, as well as a clear
definition of the purposes of the data collection and use. As there are more than 50 different
Data Protection Commissioners in Germany, who are responsible for diverse regions and
organisations, the interpretation of the data protection law in practice differs. The Social
Security Code defines the framework for the field of treatment. Bodies paying for drug
treatment are the public health insurances and pension insurances: rehabilitation lies mainly
within the responsibility of pension insurance (SGB VI), whereas detoxification has to be paid
by health insurances (SBG V). Special laws have been made in the last years to fight money
laundering, which are concerning all types of profit oriented serious criminal activities and not
only drug related crime.
 
1.3 Developments in public opinion and perception of drug issues
Information about attitudes and opinions on drug use and drugs have been collected
by several representative surveys during the last years. A study (FCHE;
Bundeszentrale für gesundheitliche Aufklärung 2000) showed in 1999 that there is a
stable and high extend of knowledge about routes of infections of AIDS. In HIV testing
there is a lifetime prevalence of 28%. The use of condoms is relatively stable - about
50% of all persons older then 16 years always or often use them.
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In 1997 another Representative Survey on the Use of Psychoactive Substances in the
German Adult Population (BUND) was conducted (Kraus & Bauernfeind 1998) funded by the
Federal Ministry for Health. At the moment a new survey is in progress, results will be
available at the beginning of 2001. In 1997 a total of 8,000 adults from both parts of
Germany were asked about their drug use and were requested to give a general evaluation
on the gravity of drug problems as well as on the consequences of drug use. The majority of
the subjects sees drug problems as a big social problem (Table 1).
Table 1: Judgement of the drug problem in Germany
Judgement of
the drug problem
Gender Age-groups
Total Male Female 18-20 21-24 25-29 30-39 40-49 50-59
N 8,000 4,019 3,981 748 639 651 2,151 1,776 2,035
Big problem (%) 56.3 (4,506) 53.5 59.2 57.3 51.1 48.5 54.8 58.3 60.0
Rather a
problem (%)
25.1 (2,011) 26.2 24.0 23.0 25.6 29.5 25.2 26.4 23.3
Rather no
problem (%)
11.9 (954) 13.1 10.8 15.0 13.0 17.1 12.2 10.5 9.7
No problem (%) 5.0 (399) 6.1 3.9 3.7 8.2 4.0 6.4 3.8 4.3
N.A. (%) 1.6 (130) 1.1 2.2 1.0 2.1 0.9 1.4 1.0 2.8
Coding of the rating: big problem (1, 2), rather a problem (3), rather no problem (4), no problem (5,6) Source:
Representative Survey 1997 (Kraus & Bauernfeind 1998)
67% of the subjects in the west and 64% in the east Laender judged in 1997 the drug
problem as at least as important (“bigger“ or “no difference“) as alcohol related problems
(Table 2). In 1994, 1995 and 1996 in the framework of the Representative Survey three
representative telephone studies were conducted. 55-60% of all subjects in this period
believed that the drug problem would be at least as big as the alcohol problem (bigger or as
big). The increase in percentage might reflect a change in the perception of the size of the
drug problems. Three quarters of all subjects in 1997 state, that they are informed “rather
good“ of “very good“ about the harmful consequences of drug use (Table 3). The age-group
of 18-20 years feels especially well informed. In this group nearly 90% state that they are
informed “rather good“ or “very good“ which is considerable above all other age groups.
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Table 2: Assessment on the drug problem in comparison to alcohol problems: West
and East Germany
West Germany East GermanyDrug problems in
comparison to
alcohol problems Total Male Female Total Male Female
N 6,380 3,209 3,171 1,620 810 810
Bigger (%) 27.1 (1,728) 29.7 24.4 21.8 (353) 24.2 19.4
No difference (%) 40.1 (2,555) 37.2 43.0 43.2 (700) 40.6 45.9
Smaller (%) 31.2 (1,991) 31.9 30.6 34.3 (556) 34.6 34.1
Don't know (%) 1.6 (105) 1.2 2.1 0.6 (11) 0.6 0.7
Source: Representative Survey 1997 (Kraus & Bauernfeind 1998)
Table 3: Information about harmful consequences of drug use
Gender Age-groups
Information
Total Male Female 18-20 21-24 25-29 30-39 40-49 50-59
N 8,000 4,019 3,981 748 639 651 2,151 1,776 2,035
Very good (%) 35.9 (2,868) 36.9 34.8 39.8 44.0 30.7 36.7 37.3 31.4
Rather good
(%)
42.6 (3,404) 42.0 43.1 48.1 38.4 48.6 43.4 41.4 40.0
Rather bad
(%)
16.5 (1,320) 16.3 16.7 9.3 12.5 16.3 15.6 17.5 20.6
Not at all (%) 3.7 (298) 3.7 3.8 1.6 3.7 3.6 3.2 3.2 5.6
N.A. (%) 1.4 (109) 1.1 1.6 1.2 1.4 0.8 1.2 0.6 2.4
Source: Representative Survey 1997 (Kraus & Bauernfeind 1998)
In the Land of Sachsen-Anhalt in autumn 1998 the study Modern Prevention of Drugs and
Addiction (MODRUS) was conducted. Attitudes of about 2500 female and male pupils and of
about 1500 adults (teachers, parents, addiction counsellors, medical doctors and policemen)
were collected on topics of “drugs and addiction“ (Böttcher, Chrapa, Chrapa, Teltscher, &
Voigtländer 1999). About half of the interviewed children and youth in east Germany had
strong interest in the subject while 20% found it less relevant. Important sources of
information on the subject “drugs and addiction“ are for the adolescents the media (TV and
newspapers), but also school lessons and friends (Figure 1). Almost the addictive
substances heroin, cocaine, ecstasy and cannabis were judged as “drugs“ by 90% of the
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subjects, nicotine and alcohol by 60-70%. The majority judged heroin, cocaine, LSD and
ecstasy as very dangerous, but only a quarter of them gave the same judgement for alcohol
and nicotine.
The Drug Affinity Study (DAS) is conducted by the Federal Centre for Health Education at
regular intervals (Christiansen & Töppich 1998). It asks for the use of legal and illegal
substances but also for attitudes and motives which influence substance use almost youth.
Results show, that 74% of the 12-25 year old subjects have neither taken drugs nor plan to
do this in future. In west Germany this rate is 73%, in east Germany even 80%. This general
rate of refusal has been rather stable since the middle of the seventies (Figure 2). In the
1986 and 1989 surveys the negative attitude towards drug use has slightly increased, but
again decreased in the years after.
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Figure 1: Important sources of information on the subject „drugs and addiction“
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Source: MODRUS 1998 (Böttcher, Chrapa, Chrapa, Teltscher & Voigtländer 1999)
Figure 2: Refusal of illegal drugs (1973 - 1997)
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Source: Drug Affinity Study 1997 (Christiansen & Töppich 1998)
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In the Drug Affinity Study in 1997 when youth are asked about the reason of their refusal
when they had been offered illegal drugs for the first time 60% say, they have “no interest in
drugs“. About half of them (51%) are afraid to get addicted or of health risks (46%). In
comparison to 1993/94 fear of addiction and dependence has declined by 4 points (1993/94:
55%). At the same time fear of health consequences and harms has increased by 3 points
(1993/94: 43%). Financial aspects, negative social consequences of loss of prestige have
been mentioned as reasons in both studies only seldom (Figure 3). The Drug Affinity Study
also asks for motives for drug use. In 1997 curiosity is the motive most frequently mentioned
(75%). To relax and to be in high spirits are mentioned as motives in the 1997 as well as in
the 1993/94 survey, 1997 however even more frequent than before. Other frequently
mentioned reasons are in 1997: to reduce inhibitions, to forget everyday life and to make
human contacts easier (Figure 4).
Figure 3: Reasons for the refusal of illegal drugs offered for the first time
(12-25 year old)
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Figure 4: Reasons for drug use (12 - 25 year old with and without drug experiences)
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1.4 Budget and funding arrangements
In 1999 the total budget for drugs and addictions of the Federal Ministry for Health was
about 24 Mio. DM (about 12.3 Mio Euro) (Table 4). This budget includes legal and
illegal substances, resources only for illegal drugs are not available. About 13 Mio. DM
were fixed for activities in the field of prevention. With 6.9 Mio. DM model projects
were funded through Federal budgets. Model projects are often co-financed by
participating Laender, municipalities or project holders (for example the model of
heroin supported treatment, see chapter 1.2). The Federal Ministry for Health
sponsored about 2.3 Mio. DM for research and studies in the field of drugs and
addiction. An additional amount of 47,2 Mio. DM for addiction research came from the
Federal Ministry for Education and Research (BMBF) in the years 1996 until 2000.
In the last years the contribution through Federal Laender tended to increase. Further
funds for research in university settings as well as in the German Research
Association (DFG) are existing. Charities, which are operating in the field of drugs and
addiction, are funded at about 1,6 Mio. DM by Federal budgets: About 1,2 Mio. DM for
the institutional support of the German Council on Addiction Problems (DHS), and
about 0,4 Mio. DM for its single projects and meetings.
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 The Federal Laender have different tasks in the field of drugs and addiction. They are
responsible for general health care and social help defined by the Federal Law on
Social Help (Bundessozialhilfegesetz, BSHG), for measures by the Law on Children
and Youth Help (Kinder- und Jugendhilfegesetz, KJHG), as well as for law
enforcement. This means, that a big share of the public funds spent for prevention,
counselling and partly drug treatment as well as for law enforcement comes from the
Laender and municipality budgets. In all 16 Federal Laender budgets of about 246 Mio.
DM in 1999 and 249 Mio. DM in 2000 were fixed for drugs and addiction. The amount
varies in the Federal Laender between 19.000 and 347.000 DM per 100.000 inhabitants,
depending on size, inhabitants and extent of the drug problem as well as on priorities
in drug policy. Whereas the total costs of law enforcement in Germany are known,
drug-related costs are not available. A study from Harwig and Pies (1995) is not
referred to because of methodological limits.
 
Costs for (secondary) diseases and detoxification are usually covered by health
insurance. Costs for inpatient and increasingly out-patient rehabilitation are covered
by pension insurances. In 1999 German public social and pension insurances
schemes (Gesetzliche Rentenversicherungen GRV) were spending more than 873 Mio.
DM on rehabilitation and other services for addicts (alcohol, pharmaceuticals, drugs).
Whereas the biggest part of costs was needed for inpatient services (79%) and interim
funding (16%) out-patient (3%) or other services play a minor role. According to
statistics of the German public social and pension insurance on alcohol,
pharmaceutics and drug problems it can be estimated roughly that drug addiction
causes about 23% of the total costs in this field.
Acute care is paid by health insurances. Inpatient and increasingly out-patient
rehabilitation measures are paid by public social and pension insurance schemes in
order to bring back someomes's ability to work. For persons with no health or pension
insurance treatments are financed by social help, which is usually covered by
municipalities.
21
Table 4: Drugs and addiction budgets in Germany 1999
Approximate budget for 1999 (in Mio.
DM)
Institution Tasks
Drugs (no further
specification)
Drugs-and
multiple
addiction1
Federal Ministry for Health2 Prevention 12,9
Model projects 6,9
Research and Surveys 2,3
Institutional support of the German Council
on Addiction Problems (DHS)
1,2
Single projects and meeting of the German
Council on Addiction Problems (DHS)
0,4
Federal Laender3 Activities in the field of drugs and addiction 246
Federation of German Pension
Insurance Institutions (VDR)4
Inpatient services 694,9 159,9
Out-patient services 24,2 5,6
Interim funding 136,9 31,5
Other services 17,0 3,9
                                                
1 Factor is the proportion of finished rehabilitations because of drug and multiple addictions of all
finished rehabilitations financed by public pension insurances in 1997 (VDR-Statistik Rehabilitation
1997 und 1999)
2 Source: Dogen- und Suchtbericht 1999 of the Federal Drug Commissioner (BMG 2000)
3 Länderkurzbericht 1999 (BMG 2000)
4 VDR-Statistik Rehabilitation 1999 (VDR 2000)
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PART II EPIDEMIOLOGICAL SITUATION
2 Prevalence, Patterns and Developments in Drug Use
2.1 Main developments and emerging trends
2.1.1 Overview of most important characteristics and developments of drug situation
Since about the end of the sixties in Germany like in other European countries, the use of
drugs like cannabis or heroin started to increase in importance. Obviously in specific groups
opiates and cocaine had been in used in certain groups before - it could not be called a
widespread use though at that time. In the late sixties, the use especially of cannabis and
LSD began to play a more important role. In 1972 a new drug law was set up as a reaction to
the emerging drug problem in society. Cannabis use, which was rather stable for some years
considerably increased. Today cannabis use is spread all over the country and over quite
different social groups. The use of LSD dropped sharply after the seventies and remained
only a minor problem until the middle of the eighties.
Heroin started to be used in Germany already in the seventies to a greater extent. Till today
heroin use is primarily found in metropolitan areas, prevalence rates and seizures in rural
areas are much lower. In the new Laender heroin use is still scarce. With the spread of
heroin drug use became rapidly visible as a social problem. The drug users got addicted
faster and more frequent to the substance than this was true for other drugs. Even if the total
number of heroin users in Germany has always been much lower than for example for
cannabis, a number of social and health problems raised sharply with the increase in heroin
use. The increase in drug related deaths shows this negative development as well as the
sharp increase of drug related crime. The start of the HIV epidemic made the public image of
the heroin user even worse. On the other side, the increase of HIV and AIDS problems
caused a rather fast political and social reaction, installing methadone, needle-exchange and
harm reduction programmes to reduce risk of infection for i.v. drug users. The impact of
these programmes is evaluated quite positive, as the epidemic went on much slower than
expected. The proportion of HIV-positive heroin users has been at a constant level in
the last years (Simon & Palazzetti 1998, 1999; Robert Koch Institut 1999).
Cocaine became more visible around 1980 with very small figures in the beginnings. Since
then it has increased continuously in importance. While until a couple of years ago cocaine
was a favourite secondary drug for heroin users in the first place in the meanwhile you can
find an general increase in cocaine users. The number of cocaine users seems to be
considerably higher than the number of heroin users today. Treatment statistics show, that
persons, who use cocaine without using other drugs in addition, report much less
problematic somatic or social consequences than heroin users. Cocaine is much more
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frequent in urban or metropolitan areas. Cocaine use is still rare in Eastern Germany. East
Berlin however has a special status because it is increasingly unified with the Western part of
the city. While amphetamines played some role in drug use in Germany already in the
eighties, MDMA and related substances became more popular since the end of the eighties.
The latest Representative Survey on the Use of psychoactive Substances in Germany
shows, that ecstasy is the drug used second most in Eastern Germany and third most in
Western Germany. Rather similar to cannabis before, there is a frightening tendency also for
ecstasy users: while in the beginnings monovalent ecstasy use dominating (even if in some
cases combined with cannabis use at a very early stage), recent studies show the parallel
and increasing use of other drugs also in this group, especially speed, LSD and cocaine.
Unlike heroin and cocaine use ecstasy use can be found all over the country and there seem
to be only small differences in prevalence between urban and rural areas. The differences
between Eastern and Western Germany are smaller than for other drugs. Recently increases
in cannabis use have been observed and today it is also widespread in rural areas.
2.1.2 Trends and changing patterns of use and drug users
Epidemiological sources on drug consumption and drug users in Germany are mainly
based on regular representative population surveys and prevalence studies. The Drug
Affinity Study (DAS) conducted by the Federal Centre for Health Education (FCHE;
Bundeszentrale für gesundheitliche Aufklärung) and the “Representative Survey on
the Use of Psychoactive Substances in the German Adult Population (BUND)”
conducted by the Institute for Therapy Research (IFT) are two ongoing surveys since
1973 and 1980, which cover the field of illegal drugs. The Drug Affinity Study (DAS)
covers not only the use of tobacco, alcohol and narcotics but also and above all, the
attitudes and underlying motives of young people in relation to this use. A
representative random sample of persons in the age between 12 to 25 years is
interviewed  through persons at the same age. The size of the sample in the last
survey, 1997, was 3,000 (2,000 in the old Federal Laender and 1,000 in the new Federal
Laender). Since 1973 the study has been carried out at 3-4 year intervals with the
same techniques and to a great extent the same questions, thus facilitating
comparisons between years.
The Representative Survey on the Use of Psychoactive Substances (see chapter 2.2)
was carried out and published the last time in 1997. The latest study is carried out in
2000, results will be available in 2001. The numbers from 1997 show following patterns
of drug use: The most significant group of substances among illegal drugs by
members continues to be cannabis (Kraus & Bauernfeind 1998). Almost 2 million
German citizens (4.5% in the West and 2.3% in the East) aged between 18 and 59 have
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used cannabis in the past 12 months. In Eastern Germany there is an increasing use of
cannabis compared to the representative surveys in 1995. Recent use (last 12 months) is 2
times as frequent among men than among women and is much more widespread in younger
age-groups (18-39 years) (7.8% in the West and 4.5% in the East) than among elder people.
The figures from the new Laender prove that cannabis use has already spread considerably
there.
The use of drugs other than cannabis has become much more significant in comparison to
previous years. This most probably is linked to an increasingly spread of ecstasy use. In
spite of this, reported experiences with drugs mostly still relate to cannabis use. Only around
one third of all persons with drug experience, 6.8% of younger adults (18-39 years) in the
West and 2.5% in the East report, having ever used a drug other than cannabis. Lifetime
experiences with other illegal drugs can be found at mostly between 1.3% (East) and 4.5%
(West) (in case of heroin less than 1%) of the population. In the West amphetamines,
ecstasy, LSD and cocaine are more frequently consumed, in the East ecstasy and
amphetamines. The trends becoming evident in the surveys on drug use are not without
consequences for the treatment area. Thus data from EBIS (i.e. facility based information
system for outpatient centres for the treatment of addicts) and SEDOS (in-patient
centre based documentation system) show that the use of cannabis is becoming more
frequently problematic and relevant to treatment than before. The proportion of people who
predominantly or exclusively undergo treatment for their problems with cannabis is growing
clearly and at a faster rate than the corresponding data on drug use from the surveys. The
percentage of 5.1 % in 1999 nevertheless is still small (Türk & Welsch 2000a).
 Compared to the drugs mentioned above, the trend in the case of heroin and the other
opiates is pursuing a different course. Since around 1992, various surveys - which admittedly
are only appropriate to a limited extent in this area - have shown that the problem is only
slightly increasing or is stagnating. In the treatment area these figures are also stable,
although here it is becoming clear that very marked shifts have taken place in the last few
years within the opiates, these being explained chiefly by the increasing substitution figures.
A new problem for the treatment area concerns clients experiencing considerable problems
with methadone and codeine. Moreover, some results on multiple drug use show that
methadone and codeine users also misuse other substances, chiefly cocaine and cannabis,
to a considerable extent.
 
 Compared to all the other drugs discussed here, cocaine shows extremely stable and
uniform growth. Here too the results from the treatment area are in line with those of the
surveys of drug use. Cocaine continues to be one of the preferred subsidiary-use drugs for
those addicted to opiates, according to the results on multiple substance use. Although it is
found to be the case much more frequently than before that drug users undergo treatment
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exclusively or predominantly because of a problem with cocaine. Some surveys conducted at
rave events, aimed essentially at ecstasy use, show that in this environment there is also a
tremendous increase in cocaine use among very young people.
 
 The results shown allow a description of several types of drug users, even if the groups
cannot always be clearly separated from each other.
· Cannabis users who have been using this drug for a long time. They frequently live
inconspicuously and without great problems, although in the last few years there has been
a marked increase in the number of primary cannabis addictions among the clients treated
in the out-patient area. Long-term users play only a minor role.
· Young groups of users with multiple drug use, which are less specific with regard to the
choice of drug. Cannabis is in first place but ecstasy meanwhile is also used very
frequently. This group is at least partly associated with the rave scene, where MDMA is
particularly active (e.g. at techno and rave parties). Other drugs, however, have also
made their way into this scene. In particular there is evidence of an increase in LSD and
cocaine.
· The group facing the most difficult circumstances continues to be that of heroin addicts.
Alongside heroin, one finds the subsidiary use of cocaine, rarely also of crack. Additionally
addiction to alcohol is a problem in many cases.
· Users of cocaine  who take no further drugs are statistically more common than heroin
users. They are, however, more inconspicuous - according to information from hospitals,
advice centres and other social institutions. In addition to results from surveys among the
general population, it is chiefly the high volumes seized which point to a comparatively
wide distribution of this drug.
2.2 Drug use in the population
In the first place the most important epidemiological data with regard to the consumption of
illegal drugs will be described in general terms. This is advisable because in some studies
no distinction is made in terms of the type of drug or because such a distinction appears
questionable on statistical reasons, given the small number of cases. A brief description of
the current situation for each of the most important illegal drugs is given in the chapters
which follow. With regard to experience with illegal drugs (lifetime, 12 months), comparative
data has been available in Germany since the eighties, this having been obtained on the
basis of representative random samples. The two most important sources are the
Representative Survey on the Use of psychoactive Substances of adults in Germany
(BUND) conducted by the IFT Institute for Therapy Research and the Drug Affinity
Study conducted the Federal Centre for Health Education (FCHE; Bundeszentrale für
gesundheitliche Aufklärung)in the case of young people (cf. inset).
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With regard to experience with drugs (lifetime) among adults aged between 18 and 59,
the latest representative surveys (Kraus & Bauernfeind 1998) reveal that in the old Laender
14.2% of the subjects have used illegal drugs during their lifetime. Taken as a proportion of
the population as a whole, this corresponds to around 5,7 million adults with experience of
drugs. Within this group there are plainly more men with experience of drugs (17.1%) than
women (11.3%). In the group of younger adults aged between 18 and 39, the proportion of
people with experience of drugs is as high as 21.5%. In the new Laender the prevalence
rates are considerably lower. The figure for adults between 18 and 59 with experience of
drugs is 4.8%, representing about 400,000 people (240,000 men, 161,000 women). In this
group the frequency of experience with drugs among men is almost 50% higher as among
women. As in the old Laender, higher prevalence rates are found in the group of younger
adults aged from 18 to 39. The corresponding proportion in the new Laender is 8.9%, more
than half of the level in the old Laender.
In very many cases, experience with drugs means a one-off or only infrequent use of drugs.
After the drug has been “tried” in most cases its use is completely discontinued in the course
of the next few years. Use at some stage during a lifetime is therefore only a rough indicator
of the extent of drug use at a given point in time. The figure includes people who have
reported experience with drugs going back 20 or 30 years. Drug use in the 12 months prior to
the survey therefore serves as a further indication of current user numbers. It emerges that in
the old Laender around 4.9% of people aged between 18 and 59 are to be included in this
group of more recent users. This corresponds to about 2 million adults. Here the figure for
the group of younger adults between 18 and 39 is also markedly higher at 8.6%. The
proportion of men among recent users (1.9:1) is a bit higher than in the case of lifetime
consumption (1.5:1). In the new Laender around 2.7% of adults (representing 224,000)
The Representative Survey on the Use of psychoactive Substances in Germany was conducted for the
first time in 1982. It is a written survey covering the consumption of psychotropic substances, how they
are viewed and other framework data and is conducted on the basis of a representative random sample of
the resident population (“random route”) aged between 18 and 59. The relatively large size of the random
samples (1997:6338 people in the old Laender, 1682 in the new Laender) makes it possible to give highly
reliable information on the use of legal substances, of cannabis and to a certain extent of ecstasy.
General trends at least can be taken from that for ‘hard’ drugs. Changes in the administrative practices of
local authorities and German reunification have made it necessary to alter the method of random
sampling in recent years. In addition, parts of the survey have been  carried out as telephone interviews.
Due to different sampling effects the results are not totally  comparable. The questionnaires themselves
have remained in all essentials identical since 1982. Out of those questioned, 64% in the old Laender and
68.6% in the new Laender were prepared to give information about themselves (quota utilised) (Kraus,
Bauernfeind, Bühringer 1998).
The Drug Affinity Study covers not only the use of tobacco, alcohol and narcotics but also, above all,
current attitudes and underlying motives of young people in relation to this use. A representative random
sample of people between the ages of 12 and 25 was interviewed through personal contact by their
contemporaries. The size of the sample at the last survey in 1997, was 3100 in the old and new Laender.
Since 1973 the study has been carried out at 3-4 year intervals with the same technique and to a large
extent the same questions, thus facilitating comparisons between years. The relatively small size of the
samples, however, means that only a few users of ‘hard’ drugs are to be found among those questioned.
It is therefore difficult to use these figures as a basis for conclusions about this group (Christiansen &
Töppich 1998).
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between 18 and 59 years of age state that they have used illegal drugs within the last 12
months, although the age range within which an appreciable level of drug use is apparent is
very clearly the group from 18 to 39 years, in which the proportion with more recent
experience of drug use is 5.1%. Among recent users the ratio of men to women drops to
around 2.1:1, in the case of lifetime experiences of use to 1.4:1.
Results for experience with drugs (lifetime) among young people (12-17 years) in
Germany are drawn principally from the Drug Affinity Study (Christiansen & Töppich 1998).
The most recent data available consists of results from 1997/98. In the old Laender 11% of
young people have already had experience themselves with illegal drugs. In the new
Laender the corresponding figure meanwhile is at 10%. In a 1993 survey lifetime prevalence
rates were to be found at 8% in Western Germany an 3% in Eastern Germany. A comparison
of the latest prevalence rates to those for years ago reveals that there is an large increase in
the number of youngsters having already used drugs. In the meantime there are nearly no
more differences in youngsters drug experiences between old and new Laender.
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Table 5: Overview of lifetime experiences with illegal drugs - West Germany
Source Age-Group With experience of
use1)
Total population2) Experience of use in
population3)
DAS    ‘97 12-17 11.0% »   4,246,000 »    467,000
BUND ’97 18-20 23.2% »   2,096,000 »    486,000
BUND ’97 21-24 31.0% »   3,100,000 »    961,000
BUND ’97 25-29 21.1% »   5,457,000 » 1,151,000
BUND ’97 30-39 18.1% » 11,615,000 » 2,102,000
BUND ’97 40-49 9.6% »   9,166,000 »    880,000
BUND ’97 50-59 3.3% »   8,804,000 »    291,000
BUND ‘97
(Men)
18-59 17.1% » 20,521,000 » 3,509,000
BUND ‘97
(Women)
18-59 11.3% » 19,716,000 » 2,228,000
BUND ’97 18-39 21.5% » 22,267,000 » 4,787,000
BUND ’97 18-59 14.2% » 40,237,000 » 5,714,000
DAS    ’97
BUND ‘97
12-59 13.9% » 44,484,000 » 6,181,000
Source: Drug Affinity Study 1997 (Christiansen & Töppich 1998); Representative Survey 1997 (Kraus &
Bauernfeind 1998)
1) At least one illegal drug
2) Federal Office of Statistics 1998 (as of 31.12.1996, figures rounded to improve clarity)
3) Projection calculated with reference to total population (only rough approximation); Figures are weighted
and rounded to improve clarity
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Table 6: Overview of lifetime experiences with illegal drugs - East Germany
Source Age-Group With experience of
use1)
Total population2) Experience of use in
population3)
DAS    ‘97 12-17 10.0% » 1,202,000 »    120,000
BUND ’97 18-20 13.4% »    533,000 »     71,000
BUND ’97 21-24 15.8% »    586,000 »     93,000
BUND ’97 25-29 17.2% »    951,000 »   164,000
BUND ’97 30-39 3.0% » 2,316,000 »     69,000
BUND ’97 40-49 0.6% » 2,018,000 »     12,000
BUND ’97 50-59 2.0% » 1.894.000 »     38,000
BUND ‘97
(Men)
18-59 5.6% » 4.277.000 »   240,000
BUND ‘97
(Women)
18-59 4.0% » 4.021.000 »   161,000
BUND ’97 18-39 8.9% » 4,386,000 »   390,000
BUND ’97 18-59 4.8% » 8,298,000 »   398,000
DAS    ’97
BUND ‘97
12-59 5.5% » 9,500,000 »   518,000
Source: Drug Affinity Study  1997 (Christiansen & Töppich 1998); Representative Survey 1997
(Kraus & Bauernfeind 1998)
1) At least one illegal drug
2) Federal Office of Statistics 1998 (as of 31.12.1996, figures rounded to improve clarity)
3) Projection calculated with reference to total population (only rough approximation); Figures are
weighted and rounded to improve clarity
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Table 7: Overview of experiences with illegal drugs in the last 12 months- West
Germany
Source Age-
Group
With experience of
use1)
Total population2) Experience of use in
population3)
DAS    ’97 12-17 10.0% »   4,246,000 »     425,000
BUND ’97 18-20 13.8% »   2,096,000 »     289,000
BUND ’97 21-24 16.3% »   3,100,000 »     505,000
BUND ’97 25-29 8.1% »   5,457,000 »     442,000
BUND ’97 30-39 4.7% » 11,615,000 »     546,000
BUND ’97 40-49 1.3% »   9,166,000 »     119,000
BUND ’97 50-59 0.0% »   8,804,000 ---
BUND ‘97
(Men)
18-59 6.4% » 20,521,000 »  1.311,000
BUND ’97
(Women)
18-59 3.3% » 19,716,000 »      651,000
BUND ’97 18-39 8.6% » 22,267,000 »   1,915,000
BUND ’97 18-59 4.9% » 40,237,000 »   1,972,000
DAS    ’97
BUND ’97
12-59 5.4% » 44,484,000 »   2,397,000
Source: Drug Affinity Study 1997 (Christiansen & Töppich 1998); Representative Survey 1997 (Kraus &
Bauernfeind 1998)
1) At least one illegal drug
2) Federal Office of Statistics 1998 (as of 31.12.1996, figures rounded to improve clarity)
3) Projection calculated with reference to total population (only rough approximation); Figures are weighted and
rounded to improve clarity
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Table 8: Overview of experiences with illegal drugs in the last 12 months - East
Germany
Source Age-Group With experience of
use1)
Total population2) Experience of use in
population3)
DAS     ’97 12-17 9.0% »   1,202,000 »   108,000
BUND ’97 18-20 10.0% »      533,000 »     53,000
BUND ’97 21-24 5.4% »      586,000 »     32,000
BUND ’97 25-29 14.0% »      951,000 »   133,000
BUND ’97 30-39 0.8% »   2,316,000 »     19,000
BUND ’97 40-49 0.0% »   2,018,000 ---
BUND ’97 50-59 0.0% »   1,894,000 ---
BUND ’97
(Men)
18-59 3.6% »   4,277,000 »   154,000
BUND ’97
(Women)
18-59 1.7% »   4,021,000 »     68,000
BUND ’97 18-39 5.1% »   4,386,000 »   224,000
BUND ’97 18-59 2.7% »   8,298,000 »   224,000
DAS    ’97
BUND ‘97
12-59 3.5% »   9,500,000 »   332,000
Source: Drug Affinity Study 1997 (Christiansen & Töppich 1998); Representative Survey 1997 (Kraus &
Bauernfeind 1998)
1) At least one illegal drug
2) Federal Office of Statistics 1998 (as of 31.12.1996, figures rounded to improve clarity)
3) Projection calculated with reference to total population (only rough approximation); Figures are weighted and
rounded to improve clarity
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All in all, the use of drugs other than cannabis is now more important compared to 1990. This
observation is linked to the increasingly spread of ecstasy, which - like cannabis 20 to 25
years ago - has found enormous demand as a result of being firmly anchored in a particular
subculture and having a relatively positive image. In spite of this, in most cases the reported
experiences with drugs still relate to the use of cannabis. Only around a third of people with
drugs experience, 6.8% of younger adults (18-39 years) in the old Laender and 2.5% in the
new Laender state that they have ever used drugs other than cannabis. In Eastern Germany
the proportion of person who have used drugs other than cannabis in the last 12 months
among younger adults (18-39) (1.6%) is still below the West Germany (2.9%). Although a
considerable increase in prevalence has taken place here in recent years.
Table 9: Overview of lifetime experiences with drugs other than cannabis - West
Germany
Source Age-Group Experience with drugs
other than cannabis
Total population1) Experience of use in
population2)
DAS    ’97 12-17 4.5% »    4,246,000 »    191,000
BUND ’97
(Men)
18-59 5.9% »  20,521,000 » 1,211,000
BUND ’97
(Women)
18-59 3.0% »  19,716,000 »    591,000
BUND ’97 18-39 6.8% »  22,267,000 » 1,514,000
BUND ’97 18-59 4.5% »  40,237,000 » 1,811,000
DAS    ’97
BUND ‘97
12-59 4.5% »  44,484,000 » 2,002,000
Source: Drug Affinity Study 1997 (Christiansen & Töppich 1998); Representative Survey 1997 (Kraus &
Bauernfeind 1998)
1) Federal Office of Statistics 1998 (as of 31.12.1996, figures rounded to improve clarity)
2) Projection calculated with reference to total population (only rough approximation); Figures are weighted and
rounded to improve clarity
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Table 10: Overview of lifetime experiences with drugs other than cannabis - East
Germany
Source Age-Group Overview of lifetime
experiences with drugs
other than cannabis –
East Germany
Total population1) Experience of use in
population2)
DAS    ’97 12-17 5.2% »  1,202,000 »     63,000
BUND ’97
(Men)
18-59 2.0% »  4,277,000 »    86,000
BUND ’97
(Women)
18-59 0.7% »  4,021,000 »    28,000
BUND ’97 18-39 2.5% »  4,386,000 »  110,000
BUND ’97 18-59 1.3% »  8,298,000 »  108,000
DAS    ’97
BUND ’97
12-59 1.8% »  9,500,000 »  171,000
Source: Drug Affinity Study 1997 (Christiansen & Töppich 1998); Representative Survey 1997 (Kraus &
Bauernfeind 1998)
1)  Federal Office of Statistics 1998 (as of 31.12.1996, figures rounded to improve clarity)
2) Projection calculated with reference to total population (only rough approximation); Figures are weighted
and rounded to improve clarity
Table 11: Overview of experiences with drugs other than cannabis in the last 12
months - West Germany
Source Age-Group Experience with drugs
other than cannabis
Total population1) Experience of use in
population2)
DAS    ’97 12-17 4.0% »   4,246,000 » 170,000
BUND ’97
(Men)
18-59 2.5% » 20,521,000 » 513,000
BUND ’97
(Women)
18-59 0.8% » 19,716,000 » 158,000
BUND ’97 18-39 2.9% » 22,267,000 » 646,000
BUND ’97 18-59 1.7% » 40,237,000 » 684,000
DAS    ’97
BUND ‘97
12-59 1.9% » 44,484,000 » 854,000
Source: Drug Affinity Study 1997 (Christiansen & Töppich 1998); Representative Survey 1997 (Kraus &
Bauernfeind 1998)
1) Federal Office of Statistics 1998 (as of 31.12.1996, figures rounded to improve clarity)
2) Projection calculated with reference to total population (only rough approximation); Figures are weighted
and rounded to improve clarity
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Table 12: Overview of experiences with other drugs than cannabis in the last 12 month
- East Germany
Source Age-Group Experience with drugs
other than cannabis
Total population1) Experience of use in
population2)
DAS    ’97 12-17 4.0% »   1,202,000 »   48,000
BUND ’97
(Men)
18-59 1.2% »   4,277,000 »   51,000
BUND ’97
(Women)
18-59 0.5% »   4,021,000 »   20,000
BUND ’97 18-39 1.6% »   4,386,000 »   70,000
BUND ’97 18-59 0.8% »   8,298,000 »   66,000
DAS    ’97
BUND ‘97
12-59 1.2% »   9,500,000 » 114,000
Source: Drug Affinity Study 1997 (Christiansen & Töppich 1998); Representative Survey 1997 (Kraus &
Bauernfeind 1998)
1)  Federal Office of Statistics 1998 (as of 31.12.1996, figures rounded to improve clarity)
2) Projection calculated with reference to total population (only rough approximation); Figures are weighted
and rounded to improve clarity
Cannabis
Cannabis is the illegal drug most frequently used in Germany. In the old Laender around
20.1% of adults aged between 18 and 39 have used cannabis at least once during their
lifetime. The corresponding figure in the new Laender is about 7.8% (Representative Survey
1997). Figures for use during the 12 months prior to the interview reveal more recent
developments. 7.8% of the subjects in the old Laender and 4.5% in new Laender have used
cannabis during this period. Thus the difference between the old and the new Laender is now
by no means as great as is found in the case of experiences during a lifetime. Moreover,
experiences of the use of cannabis in the last 5 years in the East have increased more
sharply than in the West, although the group of older people with experience of drugs is
almost completely absent in the new Laender (cf. Table in the appendix). If one bears in
mind that before the opening of the border illegal drugs in the GDR were extraordinarily
difficult to obtain, this fact comes as no surprise. In both parts of Germany the prevalence
rates for cannabis have risen markedly since 1990. Since 1995 the prevalences are visibly
decreasing. In the old Laender only 16.7% of those interviewed (18-39 years) had
experiences of cannabis in 1990 (lifetime prevalence), and in the new Laender the initially
very low figures for 1990 (approximately 1% with cannabis experience) increased as much
as eightfold by 1997 (7.8%).
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Table 13: Overview of experiences with cannabis - West and East Germany
Percentage Absolute NumbersWEST
Source
Age-Group
Lifetime
prevalence
12-month-
prevalence
Lifetime
prevalence
12-month-
prevalence
DAS ’97 12-17 11.0% 8.0% »   467,000 »   340,000
BUND ’97
(Men)
18-59 16.2% 5.9% »3,324,000 »1,211,000
BUND ’97
(Women)
18-59 10.6% 3.0% »2,090,000 »   591,000
BUND ’97 18-39 20.1% 7.8% »4,476,000 » 1,737,000
BUND ’97 18-59 13.4% 4.5% »5,392,000 » 1,811,000
DAS    ’97
BUND ‘97
12-59 13.2% 4.8% »5,858,000 » 2,151,000
Percentage Absolute NumbersEAST
Source
Age-Group
Lifetime
prevalence
12-month-
prevalence
Lifetime
prevalence
12-month-
prevalence
DAS    ’97 12-17 7.0% 6.0% »     84.000 »     72,000
BUND ’97
(Men)
18-59 4.7% 3.2% »   201,000 »   137,000
BUND ’97
(Women)
18-59 3.6% 1.5% »  145,000 »     60,000
BUND ’97 18-39 7.8% 4.5% »   342,000 »   197,000
BUND ’97 18-59 4.2% 2.3% »   349,000 »   191,000
DAS    ’97
BUND ‘97
12-59 4.6% 2.8% »   433.000 »   263,000
Source: Drug Affinity Study 1997 (Christiansen & Töppich 1998); Representative Survey 1997 (Kraus &
Bauernfeind 1998)
36
Ecstasy
Ecstasy has only been of major importance on the German drug market since relatively
recent times. There is an almost complete lack of information on trends, given the absence of
comparative data from previous years. It is noticeable that ecstasy - although it is still very
new on the market compared to other drugs - is already being used to a considerable extent.
In the last 12 months 1.7% of 18-39 year-olds in the western parts and as many as 0.7% of
those in the eastern parts of Germany have used this substance. 3.2% of 18-39 year-olds in
the old Laender and about 1.3% of the subjects in the new Laender have already had
experience with ecstasy (cf. also Table in the appendix). It is striking that the “experience
difference” between the old and the new Laender, which is clearly visible in the case of the
‘old’ drugs such as cocaine, heroin and cannabis, is evidently smaller in the case of ecstasy.
It is true that experiences with ecstasy occur more frequently in the old Laender, but the gap
between old and new Laender has closed quite substantially, particularly among current
users.
Hallucinogens
Almost the only hallucinogenic drug used to an appreciable extent in Germany is LSD. Other
drugs such as mescaline arise only very rarely and are not statistically significant. Lifetime
experience with LSD dropped in 1997 in the western parts down to a prevalence rate of 2.1%
touching again the 1990 level (18-39 age-group). In the new Laender the figure has risen
almost eightfold up to around 0.8%. The frequency of use during the last year is around 0.6%
in the old Laender and 0.7% in the new Laender. The respective figures for 1990 and 1992
were still practically zero. Considering that in 1995 lifetime prevalence of hallucinogens were
still higher than those of ecstasy in the west, one finds inverted figures for 1997. In the new
Laender, it is noticeable that the prevalences for hallucinogen use (lifetime and past 12
months) are almost the same, but higher as in 1995.
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Table 14: Overview of experiences with ecstasy - West and East Germany
Percentage Absolute NumbersWEST
Source
Age-Group
Lifetime
prevalence
12-month-
prevalence
Lifetime
prevalence
12-month-
prevalence
DAS    ’97 12-17 3.0% 3.0% »   127,000 »    127,000
BUND ’97
(Men)
18-59 2.2% 1.2% »   451,000 »    246,000
BUND ’97
(Women)
18-59 1.2% 0.6% »   237,000 »    118,000
BUND ’97 18-39 3.2% 1.7% »   713,000 »    379,000
BUND ’97 18-59 1.7% 0.9% »   684,000 »    362,000
DAS    ’97
BUND ‘97
12-59 1.8% 1.1% »   811,000 »    489,000
Percentage Absolute NumbersEAST
Source
Age-Group
Lifetime
prevalence
12-month-
prevalence
Lifetime
prevalence
12-month-
prevalence
DAS    ’97 12-17 3.0% 2.0% »     36,000 »     24,000
BUND ’97
(Men)
18-59 1.0% 0.5% »     43,000 »     21,000
BUND ’97
(Women)
18-59 0.3% 0.2% »     12,000 »       8,000
BUND ’97 18-39 1.3% 0.7% »     57,000 »     30,700
BUND ’97 18-59 0.7% 0.4% »     58,000 »     33,000
DAS    ’97
BUND ’97
12-59 1.0% 0.6% »     94,000 »     57,000
Source: Drug Affinity Study 1997 (Christiansen & Töppich 1998); Representative Survey 1997 (Kraus &
Bauernfeind 1998)
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Table 15: Overview of experiences with hallucinogens - West and East Germany
Percentage Absolute NumbersWest
Source
Age-Group
Lifetime
prevalence
12-month-
prevalence
Lifetime
prevalence
12-month-
prevalence
DAS    ’97 12-17 1.0% 0.0% »     43,000 0
BUND ’97
(Men)
18-59 2.2% 0.6% »   451,000 »    123,000
BUND ’97
(Women)
18-59 0.9% 0.1% »   177,000 »      20,000
BUND ’97 18-39 2.1% 0.6% »   468,000 »    134,000
BUND ’97 18-59 1.6% 0.4% »   644,000 »    161,000
DAS    ’97
BUND ’97
12-59 1.5% 0.4% »   687,000 »    161,000
Percentage Absolute NumbersEAST
Source
Age-Group
Lifetime
prevalence
12-month-
prevalence
Lifetime
prevalence
12-month-
prevalence
DAS    ’97 12-17 0.0% 0.0% 0 0
BUND ’97
(Men)
18-59 0.8% 0.7% »     34,000 »     30,000
BUND ’97
(Women)
18-59 0.0% 0.0% 0 0
BUND ’97 18-39 0.8% 0.7% »     35,000 »     31,000
BUND ’97 18-59 0.4% 0.4% »     33,000 »     33,000
DAS    ’97
BUND ’97
12-59 0.3% 0.3% »     33,000 »     33,000
Source: Drug Affinity Study 1997 (Christiansen & Töppich 1998); Representative Survey 1997 (Kraus &
Bauernfeind 1998)
Cocaine
In contrast to ecstasy or hallucinogenic drugs, the use of which only rose sharply at the
beginning of the nineties, the group of cocaine users in Germany has shown a very stable
year-on-year growth over more than 10 years. In the last survey in 1997, the percentage of
those having used cocaine during their lifetime in the 18-39 age-group was 2.2% in the West,
while 1.2% reported using it during the last year. These figures increased, compared to the
figures for 1990 (lifetime prevalence in the age-group 12-24: 0.8%). In the East experiences
of cocaine use - in contrast to ecstasy or hallucinogens - are less frequent. In the old
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Laender men are using cocaine far more frequent than women. In new Laender gender
differences are visible for cocaine use during the last 12 months. A relevant use of cocaine is
just to be found in women (0.2%).
Table 16: Overview of experiences with cocaine – West and East Germany
Percentage Absolute NumbersWEST
Source
Age-Group
Lifetime
prevalence
12-month-
prevalence
Lifetime
prevalence
12-month-
prevalence
DAS    ’97 12-17 1.0% 1.0% »     43,000 »      43,000
BUND ’97
(Men)
18-59 2.2% 1.1% »   451,000 »    226,000
BUND ’97
(Women)
18-59 0.8% 0.3% »   158,000 »      59,000
BUND ’97 18-39 2.2% 1.2% »   490,000 »    267,000
BUND ’97 18-59 1.5% 0.7% »   604,000 »    282,000
DAS    ’97
BUND ’97
12-59 1.5% 0.7% »   647,000 »    325,000
Percentage Absolute NumbersEAST
Source
Age-Group
Lifetime
prevalence
12-month-
prevalence
Lifetime prevalence 12-month-
prevalence
DAS    ’97 12-17 0.0% 0.0% 0 0
BUND ’97
(Men)
18-59 0.2% 0.0% »       9,000 »              0
BUND ’97
(Women)
18-59 0.2% 0.2% »       8,000 »       8,000
BUND ’97 18-39 0.4% 0.2% »     18,000 »       9,000
BUND ’97 18-59 0.2% 0.1% »     17,000 »       8,000
DAS    ’97
BUND ’97
12-59 0.2% 0.1% »     17,000 »       8,000
Source: Drug Affinity Study 1997 (Christiansen & Töppich 1998); Representative Survey 1997 (Kraus &
Bauernfeind 1998)
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Heroin
Around 0.6% of the population aged between 18 and 39 in the old Laender and 0.1% in the
new Laender have experiences with heroin during lifetime. The figures for use during the last
12 months are clearly smaller, so that in this case the statistical data should really only be
seen as a rough indication. Moreover, it should be assumed that the figures are subject to a
relatively high degree of inaccuracy, partly as a result of the difficulty in reaching this group in
the context of the usual household surveys. A comparatively large proportion of this group is
automatically out of reach of the usual statistical surveys because of homelessness,
imprisonment or residential therapy, or deliberately does not take part in such surveys. In the
old Laender a relatively large number of ex-users of heroin are found in the age-group above
30 years. However, most experiences are reported in the age-group 25-29 in the West and
18-24 in the East.
Table 17: Overview of experiences with heroin - West and East Germany
Percentage Absolute NumbersWEST
Source
Age-Group
Lifetime
prevalence
12-month-
prevalence
Lifetime
prevalence
12-month-
prevalence
DAS    ’97 12-17 0.0% 0.0% 0 0
BUND ’97 (Men) 18-59 0.6% 0.3% »   123,000 »      62,000
BUND ’97 (Women) 18-59 0.2% 0.0% »     39,000 0
BUND ’97 18-39 0.6% 0.3% »   134,000 »      67,000
BUND ’97 18-59 0.4% 0.2% »   161,000 »      80,000
DAS    ’97
BUND ’97
12-59 0.4% 0.2% »   161,000 »      80,000
Percentage Absolute NumbersEAST
Source
Age-Group
Lifetime
prevalence
12-month-
prevalence
Lifetime
prevalence
12-month-
prevalence
DAS   ’97 12-17 0.0% 0.0% 0 0
BUND ’97 (Men) 18-59 0.0% 0.0% 0 0
BUND ’97 (Women) 18-59 0.1% 0.0% »      4,000 0
BUND ’97 18-39 0.1% 0.0% »     4,000 0
BUND ’97 18-59 0.0% 0.0% 0 0
DAS    ’97
BUND ’97
12-59 0.0% 0.0% 0 0
Source: Drug Affinity Study 1997 (Christiansen & Töppich 1998); Representative Survey 1997 (Kraus &
Bauernfeind 1998)
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Other opiates
In addition to heroin, other opiates are used to a significant extent. These include chiefly
codeine. The evolution in the case of opiates as a whole is in line with the trends described
for heroin.
Table 18: Overview of experiences with other opiates - West Germany
Percentage Absolute NumbersWEST
Source
Age-Group
Lifetime
prevalence
12-month-
prevalence
Lifetime
prevalence
12-month-
prevalence
DAS    ’97 12-17 1) 2) 3) 4)
BUND ’97 (Men) 18-59 0.9% 0.4% »   185,000 »     82,000
BUND ’97 (Women) 18-59 0.5% 0.0% »    99,000 0
BUND ’97 18-39 0.9% 0.4% »   200,000 »      89,000
BUND ’97 18-59 0.7% 0.2% »   282,000 »      80,000
DAS    ’97
BUND ’97
12-59 5) 6) 7) 8)
Source: Drug Affinity Study 1997 (Christiansen & Töppich 1998); Representative Survey 1997 (Kraus &
Bauernfeind 1998)
1)-8) Prevalence rates not known
2.3 Problem drug use
To some extent there are considerable methodical difficulties in assessing the data from
existing survey systems or studies in detail to establish whether they allow conclusions to be
drawn as to the overall spread of problematic or harmful use. In the case of illegal drugs, the
question of where to define the boundary of “problematic” use at first seems simpler. Their
use is almost declared a problem by law. However, if one considers the legal reality and the
everyday situation in Germany at the end of 1990s, one realises that a relatively large
number of young people consume cannabis or ecstasy without any obvious damage being
caused to them or to others at first. The prosecution of possession of cannabis for personal
use has in effect been discontinued in some parts of Germany. On the other hand, there
have been cases of ecstasy-related deaths and a significant number of people with psychotic
symptoms possibly caused in part by excessive cannabis use. Here too it is necessary to
define a boundary if “problematic” use is not simply to be defined on the basis of a formal
legal assessment. In principle, use always becomes problematic for the individual if
· the individual feels it to be so,
· negative physical consequences arise or threaten,
· serious psychological problems arise and / or
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· in particular an addiction develops.
In addition to the inherent methodical difficulties in defining problematic use, there are a
series of specific difficulties affecting statistical surveys in the area of illegal drugs. A series
of investigations have shown that in surveys users of ‘hard drugs’ tend only to report
correctly the use of "soft" drugs such as hashish or LSD, whilst denying the use of heroin, for
example, or understating the frequency of use and the dosage (Johnston 1978). If one bears
in mind that surveys of the use of psychotropic substances enquire into types of behaviour
which in some circumstances lead to prosecution, these effects are not surprising. They also
demonstrate the validity problems affecting investigations of this type. Welz (1987) comes to
the conclusion that representative surveys produce valid statements on experimental use
and lighter forms of multiple or long-term drug use. On the other hand, in particular the group
of so-called “hard users” must be seen as underrepresented. Moreover, in their case the
extent of the problem is “under-reported”. The more detailed the information on the pattern
and details of use, such as quantity, frequency, method of administration etc., the more
difficult it must be in the context of representative samples to portray adequately in particular
that group of people already affected by harmful use, abuse or addiction. Methodological
problems and some studies in the context of the representative survey are published
by Kraus, Bauernfeind & Bühringer (1998). For the reasons given, additional information is
required, particularly in the area of "problematic use". This must above all take into account
the groups of users that are under-represented in the representative studies. Here the most
appropriate data takes the form of treatment statistics describing the use made of medical or
welfare establishments dealing with substance addiction or abuse. This data also makes it
possible to assess the nature of the addiction problem with a high degree of accuracy.
2.3.1  National and locale prevalence estimates of drug use
The described problems with regard to the exact representation of problematic drug use in
the population is the central subject of a report on methods of estimation. It is produced in
1997 by a common working group of the Federal Criminal Police Office, the Epidemiological
Research Group in Berlin, the Institut für Rechtsmedizin (Institute for Legal Medicine) at the
University of Hamburg and the IFT Institute for Therapy Research in Munich on behalf of the
Federal Ministry for Health and the Federal Ministry of the Interior and updates the first report
from 1994 (Bühringer et al. 1997).
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Results of the Report on Methods and Figures about the Extent of the Drug Problem in
Germany (1997)
The report on methods of estimation and estimated figures aims to describe the existing
survey systems, including the methodological bases and sources of error, to estimate the
prevalence of the misuse of “hard” illegal drugs in Germany. The term “hard drugs” is initially
used in this expert report in the everyday sense as shorthand for all illegal substances except
cannabis products5. The report mainly includes a discussion of the findings and description of
a joint estimate based on all the estimating procedures. The following figure shows the re-
spective estimating procedures as well as the groups of references of altogether 8 estima-
tions included in the report. The individual estimating procedures are defined below the table.
Figure 5: Comparison of 8 estimating procedures* and the current estimated
prevalence figures on users of hard drugs
Estimating procedure 1a
296.000 – 322.000
Basis for estimation: users of hard drugs in the population (West and East)
Estimating procedure 2a
224.000 – 276.000
Basis for estimation: users of hard drugs in the population who have become known to the police for
the first time (West and East)
Estimating procedure 1b
81.000 – 122.000
Basis for estimation: frequent users of hard drugs in the population
(West and Westberlin)
Estimating procedure 2b
126.000 – 152.000
Basis for estimation: users of heroin in the population who have become known to
the police for the first time (West and East)
Estimating procedure 3
97.000 – 204.000
Basis for estimation: those who are addicted to hard drugs taken intravenously and
who are undergoing medical treatment as out-patients
 (West and Westberlin)
Estimating procedure 4
81.000 – 129.000
Basis for estimation: users of hard drugs who are undergoing
treatment for addiction (West and East)
Estimating procedure 5
(not possible at present)
Basis for estimation: users of hard drugs who are in emergency
situations
                                                
5 Unlike German jurisdiction (based on the provincial high court’s decision in Karlsruhe on February,
23rd 1986 and the Federal supreme court’s judgement on September, 9th 1996) the Federal Criminal
Police Office currently still counts ecstasy among the group of ‘hard drugs’.
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Estimating procedure 6
80.000 – 112.000
Basis for estimation: use of hard drugs with fatal outcome (West and
East)
Source: Bühringer et al. (1997)
Explanation:
Estimating procedure 1a/b: Representative Survey (1995)
Estimating procedure 2a/b: Federal Criminal Police Office, drugs users, who have
become known to the police for the first time
Estimating procedure 3: Anonymous monitoring of a representative random
sample of doctors in independent practise in Germany
(ANOMO)
Estimating procedure 4: IFT Institute for Therapy Research, EBIS / SEDOS
Estimating procedure 5: Institute for Legal Medicine, Hamburg
Estimating procedure 6: Institute for Legal Medicine, Hamburg
Based on the described results and after a detailed consideration of possible sources of
errors the authors of the report come to the following two common estimations for 1995. In
addition 2.1 million recent cannabis users are estimated, among them 270,000 having
used cannabis at least 20 times during  the last 30 days.
Table 19: Common estimated figures for users of ‘hard’ drugs (amphetamines,
ecstasy, cocaine and opiates)
Taking account of the results from the various estimating procedures and of
assumptions on the risks of underestimates and overestimates associated
with each, the following figures are postulated for 1995 (West and East)6:
1. Wider circle*
Users of hard drugs                                 250,000 to 300,000 people
2. Narrower circle **
Those who take hard drugs frequently
or by a high-risk route 100,000 to 150,000 people
Group 2 is a sub-group of Group 1
Source: Bühringer et al. (1997)
*with drug-use in the last 12 month
**at least 100 x drug-use in the last 12 month and/or i.v. use
                                                
6 Some of the estimation procedures are only valid for the old Laender; but this has nearly no effect
on the accuracy of the estimations for the whole of Germany.
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Assessment of the treatment data at national level
From the number of addicts treated in EBIS participating treatment centres per year,
rehabilitations financed by public pension institutions, the total number of the treatment
centres in Germany and the estimated ratio on consumers in need of treatment who are
reached by the care system the prevalence in the population is projected (Bühringer et al.
1997).
The process of estimation is based on two groups of references:
1) Drug-addicts treated in out-patient facilities: In 951 German out-patient treatment
centres7 consumers of psychotropic substances are treated. In the annual analysis of
1999 EBIS data of 448 centres were considered. In 1999 11,631 of 62,895 admissions
are users of illegal drugs and have illegal substances as main diagnoses (ICD-10: F11,
F14, F15, F16). Based on the assumption, that there is no systematic difference
between the total population of registered addicts treated in EBIS and treatment
admissions, there is a projected number of 19,964 registered clients using illegal drugs
in EBIS participation facilities in 1999.
2) Drug-addicts treated in in-patient facilities: In 1999 8,330 in-patient drug treatments are
financed by public pension insurance institutions (7,164 because of rehabilitation and
about 50% of 2,332 rehabilitations from multiple addictions)8. Approximately 50% of the
patients are referred by an out-patient treatment centre.
By standardising the number of treatment facilities participating in EBIS to the total number of
treatment facilities in Germany the total number of out-patient treated addicts can be
concluded. If one assumes of 951 out-patient treatment facilities in Germany, then a number
of 951 / 448 x 19.964 » 42,379 out-patient treated drug addicts results. As approximately
50% of all 8,330 in-patient drug treatments are referred by out-patient treatment centres
therefore the number of in-patient treatments is considered only to the half. Adding up the
number of inpatient treatments and the projected number of out-patient treatments there is a
total number 42,379 + 4.165 = 46,544 treatments in Germany in 1999.
With assumed 5-20% double counting per year because of parallel or successive treatments
in different treatment centres, altogether 37,235 – 44,217 treated drug-addicts can be
estimated. The ratio of problematic consumers who are reached by the care system is
estimated on 30-40%.
The total number of problematic consumers in the population amounts to (projected):
37,235 ´ 100/40 = 93,088 people (minimal estimation)
44,217 ´ 100/30 = 147,390 people (maximal estimation).
                                                
7 Länderkurzbericht 1999: Alle Bundesländer (BMG 2000)
8 VDR Statistik Rehabilitation 1999, Table 55.00M (VDR 2000)
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One proceeds from the following assumptions:
1. The participating treatment centres are a representative sample of the available
treatment centres in Germany.
2. The ratio of clients who are reached by treatment centres is stable and valid over the
years.
The following methodical problems are in particular:
1. Double counting of persons because of data security reasons and therefore only
estimated, since under normal conditions no identifying combinations of characteristics
can be exchanged.
2. Only the number of treatments, not the exact number of persons are recorded.
3. The information about not participating treatment centres is not complete.
4. The estimation of the ratio of clients that are reached by the treatment system is difficult.
In summary one can say that for the calculation of absolute numbers with this method a set
of parameters only to an estimated extend have some influence on the calculation. Because
of the continuity of data collection, that concerns participating treatment centres and analysis
routines as well as instruments and methods, the comparison of the figures over the years is
valid. This can also be seen in the trends of different indicators.
2.3.2 Problematic drug use on local level
In Germany there are just a few studies available reporting on problematic drug use on a
local level. In the framework of the “Representative Survey on the Use of psychoactive
Substances“ two local surveys on the consumption of legal and illegal drugs were conducted
in the past two years. Both cross-sectional surveys mainly cover substance use in general
population, but it has to be taken into account that fringe groups, heavy drug users and
socially unwanted behaviour are rather underrepresented.
In 1995/96 one representative survey was carried out in the federal capital of Berlin on behalf
of the Senate Administration for School, Youth and Sports (Kraus & Bauernfeind 1998). The
results show that in West Berlin the proportion of the 18-59 year olds, having taken illicit
drugs at least once in their life is more than the double of East Berlin. Differences between
both parts of the city are clearly smaller in 12-months- and 30-days-prevalences. This makes
clear, that the East Berlin level of consumption adopts to the one in West Berlin. Reasons
are to be found in huge social changes in Berlin after the fall of the wall but also in open
frontiers towards the eastern European countries, which are used for production or transport
of illegal drugs in many cases.
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Table 20: Consumption of illegal drugs in Berlin (age-group 18-59 years)
WEST (N = 644) EAST (N = 416)
Illegal Drugs
Men Women Men Women
Lifetime-Prevalence 31.7% 22.5% 15.3% 9.6%
12-Months-Prevalence 15.1% 9.8% 12.8% 3.1%
30-Days-Prevalence 10.8% 6.6% 6.4% 2.3%
Source: Representative Survey 1995/96 (Kraus & Bauernfeind 1998)
In 1997 a local survey was carried out in the framework of the national survey
“Representative Survey on the Use of psychoactive Substances“ (Kraus, Scherer &
Bauernfeind 1998) on behalf of the city of Hamburg. As there has been a separate analysis
in 1990 trends can be analysed over a longer period of time. Lifetime-prevalences for
cannabis remain nearly unchanged as table 21 shows.
Table 21: Consumption of illegal drugs in Hamburg (age-group 15-39 years and 15-17
years)
1990 1997
15-39 Years Lifetime-
Prevalence
12-Months-
Prevalence
Lifetime-
Prevalence
12-Months-
Prevalence
Cannabis 27.9% 9.3% 26.5% 9.8%
Amphetamines 6.9% 0.3% 5.2% 2.1%
LSD 3.9% 0.3% 4.1% 2.3%
Opiates1 3.6% 0.3% 3.4% 2.7%
Cocaine / Crack2 3.3% 1.2% 4.1% 2.7%
15-17 Years Lifetime-
Prevalence
12-Months-
Prevalence
Lifetime-
Prevalence
12-Months-
Prevalence
Cannabis 9.2% 8.4% 21.2% 17.9%
Amphetamines 0.0% 0.0% 5.2% 3.8%
LSD 0.0% 0.0% 1.4% 0.9%
Opiates1 0.8% 0.8% 2.4% 1.9%
Cocaine / Crack2 0.8% 0.8% 1.4% 1.4%
Source: Representative Survey 1997 (Kraus, Scherer & Bauernfeind 1998)
 1 Heroin, Methadone other opiates
 2 Cocaine without Crack in 1990
In 1990 27.9% and in 1997 26.5% of all 15-39 year old respondents used cannabis. In this
age-group lifetime-prevalences of other substances have nearly not been changing. Major
changes can be found in the group of very young drug users. Among 15-17year olds the 12-
month-prevalence of cannabis use has more than doubled from 8.4% (1990) to 17.9%
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(1997). Whereas at the beginning of the 90s there was no ecstasy and LSD use in the last 12
month, it has risen to 3.8% re. 1.4% in 1997. Additionally this survey shows, that
amphetamines are the most widespread drug among teenagers beside cannabis.
2.3.3 Risk behaviour
Intravenous administration of substances under insufficient and unhygienic conditions involve
a large risk for secondary diseases of drug use. Especially the shared use of syringes
contains the considerable risk of transmitting diseases by blood remainders in syringes. Only
limited data on the risk behaviour of drug addicts is available in Germany. In 1997 254 drug
users of the “open drug scene” of Hamburg were asked among other things for there
recent route of drug administration (Homann, Paul, Thiel & Wams 2000). 89% of all
persons asked stated that they had intravenous drug use: 78% reported i.v. heroin
use, 70% i.v. cocaine use, 17% i.v. Benzodiazepine use (multiple responses were
possible). When asked “What kind of drug do you sniff?” 30% reported nasal use of
heroin and/or cocaine. Exclusive heroin use was common among 23%, nasal cocaine
use among 20% use (multiple responses were possible). Smoking of drugs was
especially widespread among young drug users. 49% of all younger than 20 years
were smoking heroin but only 20% of older people asked. Cocaine was smoked by
33% of younger drug users and only by 12% of the elder ones. The study shows that
risky of drug administration are specially evident.
Since 1996 EBIS (i.e. facility based information system for the outpatient treatment of
addicts) is recording the method of administration of drugs; thus only cautious trend analysis
are possible. hand, there was no evidence of a decrease in dangerous injection behaviour.
Current results of EBIS statistics 1999 concerning the mode of administration of drugs
show that half of those treated with a heroin main diagnoses apply the substance
intravenously (about 50%) (Table22). In comparison to previous years there is even a
slight increase in heroin addicted clients with i.v. drug use (1998: 49.0%; 1997: 47.2%).
The basis in numbers is small, but this trend should carefully be monitored in future in any
case. In contrast to heroin there was a tendency in the last 12 months to a less
frequent i.v. use of other opiates (usually codeine or methadone) in comparison to the
two years before (1999: 21.5%; 1998: 22.0%; 1997: 24.5%). Whereas intravenous
application of cocaine has decreased visibly in the last year (1999: 24.3%; 1998:37.8;
1997: 36%), cocaine derivates are still the second most frequent drug to be injected
(27.8%). Table 22 shows, that hypnotics are injected to a lager extent by male drug
users (30%). The i.v. use of cocaine derivates and other hallucinogens is more
common among women.
Data about shared use of syringes is collected by the EBIS-system since 1996. As the
number of cases is still relatively small for several substances, the following table
49
shows results only for heroin and cocaine single diagnoses, which are most frequent.
The results show (Table 23, Figure 6), that a large portion of cocaine and heroin
addicts with i.v. drug use had shared at least once their syringes with other drug
users. In comparison to the year before there was an increasing willingness for a
common use of syringes. In general female drug users do agree more often to share
needles with other users.
Table 22: Single diagnosis and current i.v. drug use
Current i.v. drug useSingle
Diagnoses Men Women Total N
Heroin 50.4% 47.8% 49.8% 3,841
Methadone 9.5% 7.7% 9.0% 873
Codeine 5.2% 4.1% 4.9% 586
Other Opiates 24.0% 12.0% 21.5% 121
Sedatives 10.3% 4.3% 6.1% 98
Hypnotics 30.0% 10.7% 15.8% 38
Cocaine 25.2% 16.2% 24.3% 338
Crack 12.5% 0.0% 11.8% 17
Other Cocaine
Derivates
21.4% 50.0% 27.8% 18
Other Stimulants 9.5% 11.1% 9.8% 132
LSD 5.0% 0.0% 3.8% 26
Other
Hallucinogens
0.0% 25.0% 4.8% 21
Other
psychotropic
Substances
0.0% 0.0% 0.0% 34
Source: EBIS 1999 (Türk & Welsch 2000a)
Table 23: I.v. drug use and “needle-sharing”
Needle Sharing
Men Women TotalSingle
Diagnoses
1998 1999 1998 1999 1998 1999
Heroin 59% 60% 71% 69% 62% 62%
Cocaine 59% 64% 69% 75% 61% 66%
Source: EBIS 1999 (Türk & Welsch 2000a)
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Figure 6: “Needle-sharing” and cocaine or heroin single diagnoses
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Source: EBIS 1999 (Türk & Welsch 2000a)
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3 Health consequences
3.1 Drug treatment demand
In the field of treatment of drug addiction there are two major national statistical
sources: The treatment monitoring systems EBIS and SEDOS. EBIS is a facility based
information system for outpatient treatment centres which is run by the IFT Institute
for Therapy Research since 1980 and which has been held by the EBIS/SEDOS
working group. EBIS registers information on persons, who are cared of in outpatient
counselling or treatment centres because of legal or illegal addictive substances. It is
the most comprehensive routine information system, 448 of 951 centres of this type in
Germany are participating. The last year covered is 1999.
SEDOS (in-patient centre based documentation system) describes data of alcohol and
drug addicts in specialised in-patient treatment centres. The SEDOS information
system has been in existence since 1994 and is also run by the IFT Institute for
Therapy Research. At present 107 in-patient treatment centres are participating. These
are special clinics for drug addicts and/or alcoholics, psychiatric centres and
transitional institutions such as hostels. In 2000 the sixth annual evaluation will be
presented, containing data of 107 in-patient treatment centres and 16,527 people.
Beside these two treatment monitoring systems which are used throughout Germany,
a number of smaller regional information collection systems are used at present, e.g.
in Hamburg and in Schleswig-Holstein. “Horizont” is used as technical basis for a
number of systems.
The statistical committee of the German Council on Addiction Problems (DHS)
ensures the co-ordination of questionnaires of all systems used. An aggregation of
information will be realised on the basis of the German Core Item List, which already
includes the recent draft version of the European Core Items. The implementation of
this synopsis has not been finished yet, an interface of Destas, Horizont and EBIS has
already been defined.
Compared to representative surveys, these statistics have the advantage of including
precisely those groups of "hard users" which are recognisably out of reach of the
representative surveys or cause the results to become distorted. On the other hand,
particularly in the case of EBIS and SEDOS, one has to acknowledge that there are limits on
how representative they are. Both systems cover about 40% of all German treatment
centres. Based of the number of staff the coverage of all out-patient treatment centres in
Germany is about 66%. In this way sufficiently reliable conclusions can be drawn on the
situation of addiction treatment in Germany. Due to the nature of the systems only persons
asking for treatment can be described. This is therefore an appropriate way to supplement
the representative surveys and statistics from the field of treatment, as far as the description
of problematic use of psychoactive substances is concerned. Taken on their own, both
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sources demonstrate typical deficiencies. Recently a study is in progress to prove if EBIS
is representative for all existing outpatient treatment centres.
Characteristics of drug users
Information on clients treated in out-patient counselling and treatment centres shows
that this is not a homogenous group. A breakdown by main diagnosis finds a series of
considerable differences between these groups. Legal problems play an important
role in the group of drug addicts. A considerable proportion of the drug addicts (13%)
treated in out-patient centres are at the beginning of their treatment in prison or on remand
(EBIS 1999). These are about 16% of all male and 2% of all female clients. Figure 7
shows that custodial problems vary considerably between different groups of
diagnoses. With about 55%, the proportion of treated cocaine addicts who are in custody at
the beginning of their treatment, is particularly high. The reasons therefore are not clear.
Either there is more willingness for treatment or there higher prevalences of cocaine users in
custody. Client with major alcohol problems or pharmaceutical addiction are comparatively
less often in custodial sentence or on remand (6% and 7%).
 8.2% of the clients of out-patient treatment centres are foreigners. (EBIS 1999, Türk &
Welsch 2000a). 1.4% are from other European member states, 6.8% from Non-EU
countries, such as former-Yugoslavia, Turkey or from the former Soviet Union. Table 8
shows that the addiction problem among Germans and foreigners varies, whilst in both
groups alcohol is clearly the prime addictive substance. Amongst German clients its
proportion is 78%, amongst foreign clients (EU-citizens and Non-EU-citizens) it is 58% and
clearly lower. The proportion of foreigners treated for opiate addiction is 32% and therefore
more than twice as high as within the group of German clients.
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Figure 7: Alcohol- and drug addicts, in custodial sentence or on remand at the
beginning of their treatment
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Source: EBIS 1999 (Türk & Welsch 2000a)
Figure 8: Main diagnoses by nationality
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Data from the out-patient treatment sector
The following table describes the distribution of the main diagnoses of a total of 15,053
people (old Laender 13,369; new Laender 1,648), who began treatment in 1999 for problems
related to illegal drugs in out-patient psycho-social drug treatment centres9. The main
diagnoses are based on the diagnostic categories from the international classification system
of the WHO (ICD 10) for the classification of disturbances caused by psychotropic
substances (harmful use and addiction). The source of information is the monitoring system
EBIS (Türk & Welsch 2000a).
Table 24: Most common main diagnoses
Main Diagnosis Total Germany East West
Men Women Total Total Total
Opiates 64.6% 65.1% 64.7% 38.2% 68.0%
Cannabis 23.8% 15.7% 22.2% 42.2% 19.7%
Cocaine 8.5% 4.9% 7.7% 9.6% 7.5%
Hypnotics and Sedatives 1.8% 13.3% 4.1% 5.9% 3.9%
Hallucinogens 1.3% 1.1% 1.3% 4.0% 0.9%
Total 100% 100% 100% 100% 100%
Source: EBIS 1999 (Türk & Welsch 2000a)
It is clear that in 1999 drugs containing opiates form the core of problematic drug use. They
represent a total of about 65% of the main diagnoses (Table 24). Problematic drug use at
considerable extent is existing for cocaine (almost 8% of main diagnoses) and
especially for cannabis (22% of main diagnoses). Whereas cannabis is reported more
often as main diagnoses for men (about 24% of main diagnoses) women stand out as
problematic users of hypnotics and sedatives (almost 13% of main diagnoses). From
the year 2000 on Ecstasy can independently be recorded as main diagnoses in EBIS and will
be reported from 2001 on. The tables below show patterns of multiple use among drug-
dependent men and women being cared for or treated in EBIS out-patient centres (EBIS
1999, Türk & Welsch 2000a). Diagnoses are based on harmful use and addiction according
to ICD 10. The results show that among people using opiates, cannabis and especially
cocaine and hallucinogens multiple patterns of use occur to a considerable extent (Table 25,
Table 26). The figures for opiate users must be viewed particularly critically concerning the
use of substitution treatments in Germany. Almost 45% of female and about 51% of male
opiate users also used cocaine to a harmful extent.
                                                
9    Including legal substances (e.g. alcohol and pharmaceuticals), EBIS currently has main
diagnoses for well over 62,051 persons treated (new admissions in 1999).
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Table 25: Patterns of multiple drug use among drug dependent women
Categories of Diagnoses
Categories of
Diagnoses
Alcohol Opioids Cannabis Sedatives
/ Hypnotics
Cocaine Other
Stimulants
Hallucinogens
Alcohol 100.0% 8.3% 8.9% 9.9% 5.8% 2.2% 2.7%
Opioids 36.6% 100.0% 56.9% 33.6% 44.9% 12.2% 18.3%
Cannabis 43.8% 63.2% 100.0% 30.3% 47.5% 19.7% 27.0%
Sedatives /
Hypnotics
61.4% 47.0% 38.2% 100.0% 31.2% 9.8% 15.5%
Cocaine 44.7% 78.6% 74.8% 39.0% 100.0% 22.0% 32.5%
Other
stimulants
42.4% 52.8% 76.5% 30.2% 54.2% 100.0% 37.5%
Hallucinogens 43.3% 66.8% 88.9% 40.6% 67.9% 31.8% 100.0%
Quelle: EBIS 1999 (Türk & Welsch 2000a)
Table 26: Patterns of multiple drug use among drug dependent men
Categories of Diagnoses
Categories of
Diagnoses
Alcohol Opioids Cannabis Sedatives
/ Hypnotics
Cocaine Other
Stimulants
Hallucinogens
Alcohol 100.0% 9.6% 13.1% 5.8% 7.7% 3.2% 4.3%
Opioids 39.3% 100.0% 66.4% 27.7% 50.6% 13.3% 21.4%
Cannabis 46.4% 57.6% 100.0% 22.3% 47.3% 19.6% 28.2%
Sedatives /
Hypnotics
62.2% 72.6% 67.4% 100.0% 54.9% 18.5% 30.0%
Cocaine 46.0% 74.2% 80.0% 30.7% 100.0% 23.8% 35.4%
Other
stimulants
50.1% 51.4% 87.2% 27.4% 62.8% 100.0% 47.0%
Hallucinogens 50.5% 61.3% 93.2% 32.9% 69.4% 34.9% 100.0%
Source: EBIS 1999 (Türk & Welsch 2000a)
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Data from the residential treatment spectrum (SEDOS)
The following table describes the distribution of the main diagnoses of 2,963 people
treated in residential drug treatment centres for problems related to illegal
substances10 (pharmaceuticals included) in 1999. Here too the main diagnoses are based
on the diagnostic categories from the international classification system of the WHO (current
version: ICD 10) for the classification of disorders caused by psychotropic substances
(harmful use and addiction).
Table 27: Most common main diagnoses
Main Diagnoses Men Women Total
Opiates (total) 81,2% 78,9% 81,8%
Cocaine 7,0% 3,9% 6,8%
Stimulants 2,0% 0,9% 1,7%
Sedatives / Hypnotics 2,2% 12,9% 4,7%
Hallucinogens 0,8% 0,6% 0,7%
Cannabis 5,3% 2,5% 4,7%
Other substances 1,5% 1,0% 1,4%
Source: SEDOS 1999 (Türk & Welsch 2000b)
Compared to the out-patient area, where hallucinogens and cannabis already play a more
important role, in the residential area there is an even clearer predominance of drugs
containing opiates (Table 27). As in the year before, with an overall share of more than 82%
of the main diagnoses, they very clearly form the core of problematic drug use here. In
addition, particularly in the cases of cocaine, hypnotics and sedatives, it is evident that their
use frequently gives rise to harmful effects.
3.2 Drug-related mortality
Data on drug-related deaths in Germany is recorded in the individual Laender and then
collected by the Laender Criminal Office and assessed in the drugs case file of the Federal
Criminal Police Office.
The following groups are taken into account when data is collected on drug-related deaths
(BKA 2000a):
· Deaths following unintentional overdose,
· Deaths following health defects (physical decline, HIV or Hepatitis C, weakness of an
organ) caused by long-term drug abuse,
                                                
10 Including legal substances (e.g. alcohol and pharmaceuticals), SEDOS currently covers main diagnoses for
14,632 persons treated.
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· Suicide resulting from despair about the personal circumstances of life or the effects of
withdrawal symptoms (e.g. delusions, heavy physical pain, depression),
· Fatal accidents under the influence of drugs.
In 1999, 1,812 drug-related deaths were registered in Germany. The number of people dying
in connection with the use of drugs has risen in comparison to the year before (+138 cases,
+8.2%). Since the middle of the 80s the annual number of people dying in connection with
the use of drugs has dramatically risen and came to its peak of 2,125 deaths in 1991. In the
years after the number declined again and reached its lowest level since 1990 in 1997
at 1501 drug-related deaths. In the last three years another increase became visible.
The trend in drug-related deaths in the individual Laender varies. With 11.4 drug related-
deaths per 100,000 the Land Bremen has recently got the highest quota nationally,
followed by Hamburg (6.8) and Berlin (6.0). Apart from city states Mannheim (7.7) and
Stuttgart (6.7) are German cities with the highest number of drug-related deaths per
100,000 inhabitants, Düsseldorf with 1.8 drug-related deaths is at the low end of the
scale. In the new federal Laender the number of drug-related deaths varies between 0.1 and
0.2 cases and is therefore still very small. The distribution of gender reveals that there is only
a small portion of women among drug-related deaths, the majority are still men (Figure 9).
Figure 9: Drug-related deaths by gender
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Source: Annual Report on Drugs 1999 (BKA 2000a)
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The mean age of people dying in connection with the use of drugs was 31.5 years in 1999,
43% are younger than 30 years (Figure 10).
Figure 10: Drug-related deaths by age
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Source: Annual Report on Drugs 1999 (BKA 2000a)
59
Between individual Laender there are differences in recording methods and the basis
for assessment. The proportion of drug-related deaths investigated by means of a
post-mortem varies to a considerable extent between the federal Laender. The average
proportion was 62% in 1999. The main cause of the registered deaths in 1999 is
overdosing with heroin alone (30%), or in combination with other drugs (11%). The number
of deaths caused by multiple intoxication with narcotics, alcohol and/or substitutes is rising to
21% (1998: 11.6%; 1997: 8.9%). 3% of all cases are a result of overdosing in connection
with substitutes/medicines , the percentage has fallen in comparison to the previous year
(12.3%). According to the Federal Criminal Office 27 people died in connection with ecstasy
in 1999. In several cases causes of death have been are suicide, long term use or accidents.
In comparison to the previous year the number deaths linked to ecstasy has almost doubled.
Table 28: Drug-related deaths in 1999
Causes of deaths Percentage Absolute1
1. Overdose of:
Heroin 30% 683
Heroin in association with other drugs 11% 253
Cocaine 3% 59
Cocaine in association with other drugs 6% 130
Amphetamines 1% 19
Amphetamines in association with other drugs 0% 11
Ecstasy in association with other drugs 0% 8
Medicines / Substitutes 3% 66
Narcotics in association with Alcohol / Substitutes 21% 484
Other narcotics / unknown 12% 268
2. Suicide 7% 152
3. Chronic damage 6% 127
4. Accident / other 1% 26
5. Total 100.0% 2,286
Source: Annual Report on Drugs 1999 (BKA 2000a)
1) Because of multiple responses the sum of causes of death exceeds the total number of 1.812 drug-related
deaths.
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Drug-related deaths are also recorded by the statistical offices of the federal Laender
and then collected in the general death register of the Federal Statistical Office (StBA).
Records of both sources were compared in an EMCDDA field trial, where the general
death register of the Federal Statistical Office and (StBA) and the Drugs Case Register
of the Federal Criminal Office (BKA) were corresponding closely in numbers. As drug-
related deaths are one of five European Monitoring Centre for Drugs and Drug
Addiction (EMCDDA) key-indicators a national expert group was established in 1999.
Its aim is to adapt German methods of data collection to European standards in order
to make numbers more comparable in future.
Drug-related infectious diseases
As drug-related infectious diseases are one of five EMCDDA key indicators, a national
working group was established for this topic in 2000. As data on infectious diseases
such as HIV, hepatitis B or C and tuberculoses are very scare at the moment, the
working group tries to find out how data from existing routine surveys can be used in
the best way possible. At the same time improvements in getting access to risk
groups for infectious diseases (such as drug using prisoners) will be discussed.
Another task of the group will be to observe the consequences of the planned
amendment of the legal basis and to represent the German situation within relevant
European expert groups. In chapter 14 infectious diseases among drug users will be
examined extensively as special topic.
HIV and AIDS
Drug users are, after homosexuals, the second risk group for HIV infections and AIDS.
Between Federal Laender there is a considerable variation in the number of AIDS
cases. While in the new Laender only few people suffer from AIDS, the number in the
city based Laender Berlin and Hamburg are highest (Table 11).
On the basis of the report from the AIDS centre of the Robert Koch Institute
(http://hiv.rki.de) the proportion of drug addicts amongst new notified Aids cases in
1999 was about 12% in Germany. In Hamburg and Baden-Württemberg its percentage
of 34.6% and 26% was nationally at its highest (Fable 12). Referred to a cumulative
total number of 18,524 AIDS cases in the register the percentage is 14.9%. It has been
possible to slow down substantially the spread of the HI-virus among drug users in
the last years. Prevention measures, campaigns to discourage needle-sharing and
innovations such as substitution and syringe-exchange programmes have clearly had
an effect here.
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Figure 11: AIDS cases in the Federal Laender (rate/mil.), 1999
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With the help of new antiretrovirale substances and quantitative HIV-RNA analysis a
more effective HIV therapy is possible. Drug users can get this treatment at
specialised general practitioners and in hospitals, health insurance covers the
treatment costs. Approximately 15-20% of HAART patients (Highly Activating
Antirectrovirale Treatment) are addicts with intravenous drug use.
Figure 12: Proportion of intravenous drug users (IVDA) among AIDS cases, 1999
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Abbreviations for the various Federal Laender:
BW Baden-Württemberg HE Hesse SN Saxony
BY Bavaria MV Mecklenburg-Western
Pommerania
AN Saxony-Anhalt
BR Berlin NI Lower Saxony SH Schleswig-Holstein
BB Brandenburg NW North Rhine-Westfalia TH Thuringia
HB Bremen RP Rhineland-Palatinate
HH Hamburg SL Saarland
Source: AIDS/HIV Quarterly Report IV 1998 (Robert Koch-Institute AIDS-Research 1999)
Hepatitis B and C
All in all, the health situation is relatively poor, particularly among heroin addicts. This applies
to oral hygiene, infections, parasitic infestations and other problems. The causes are poor
diet, lifestyle and insufficient personal healthcare. Cases of tuberculosis, hepatitis B and
hepatitis C are increasingly common in this group. Recently representative numbers are not
available, but the increasing prevalence rates - mainly of hepatitis C - seem to be alarming.
The annual report 1998 of the Drugs Emergency Service (Drogennotdienst, DND) in
Frankfurt, an institution of the Therapieverbund Jugendberatung und Jugendhilfe e.V.,
reports on the health state of treated clients. The figures reveal a tremendous variety and
severity of diseases among these people (Table 29). Alarming is a portion in this sample of
nearly 97% suffering from hepatitis C. Almost 80% suffer from hepatitis B and 51% from
hepatitis A. In comparison to 1997 and 1996 the high quota of hepatitis C infected is still
rising in this sample whereas it remained rather stable for hepatitis B and hepatitis A.
Table 29: Health state in drug addicts
Health State 31.12.98
(N = 631))
31.12.97
(N=602))
31.12.96
(N=903))
HIV-Infection 27% (17) 28% (17) 20% (18)
AIDS 5% (3) 3% (2) 7% (6)
Hepatitis A 51% (32) 57% (34) 59% (53)
Hepatitis B 79% (50) 80% (48) 80% (72)
Hepatitis C 97% (61) 95% (57) 89% (80)
Source: Jugendberatung und Jugendhilfe (e.V.), 1998
1), 2), 3) Because of multiple responses the sum of individual records may be higher than the total
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Serological testing for hepatitis A, B and C markers was done in 120 i.v. drug users in
inpatient treatment in a study of Holbach, Frösner, Donnerbauer, Dittmeier & Holbach (1998).
Anti-HCV was most prevalent with 66%, hepatitis B markers were found in 48% and hepatitis
A markers in 36% of all cases.
Generally data concerning hepatitis infections among i.v. drug users is still based on single
results. An extensive set of statistics is still missing.
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4 Social and legal correlates and consequences
4.1 Social problems
Social problems such as poor education, unemployment or debts play an important
role in developing a drug-related disorder. Often they result from an addiction in
progress. The treatment monitoring system EBIS gives information on the social
status of clients in out-patient treatment, their situation in life, education, employment
etc. Figure 13 and 14 show that the percentage of men living on their own is low than
the percentage of women. Mostly clients, who are in out-patient counselling or
treatment because of cocaine addiction, live on their own (men: 38%, women: 29%)
whereas clients with a cannabis main diagnoses - an especially young group of clients
- are very often living with other people (men: 79%, women: 83%).
Figure 13: Living situation of male
clients
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Source: EBIS 1999 (Türk & Welsch 2000a)
Figure 14: Living situation of female
clients
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Men and women in out-patient treatment because of cannabis addiction mostly have a
regular job (men:63%, women:60%). On the other hand only 34% of all male and 28%
of all female opiate addicts have a full or part time job. More that half of this croup of
clients is either unemployed or looking for a job (Figure 15, Figure 16).
Debts are a problem which is especially common among opiate and cocaine clients. In
the group of out-patient treated opiate addicts 62% of men and 57% of women have
debts, in the group of cocaine addicts these are 64% of men and 45% of women (Türk
& Welsch 2000a) (Figure 17 and 18). Male cocaine users have especially high debts:
10% have debts more than 50,000 DM. The descriptions given here only refer to drug
users treated in out-patient counselling or treatment.
Figure 15: Job situation of male clients
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Figure 16: Job situation of female clients
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Figure 17: Debts of male clients (in DM)
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Figure 18: Debts of female clients (in DM)
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4.2 Drug offences and drug related crime
Concerning drug offences, the Federal Criminal Police Office (BKA) makes a distinction
between crimes involving offences against the Narcotics Law and cases of direct supply-
related crimes in its statistics. Offences against the Narcotic Law are described by four
different kinds of offences (Figure 34):
· General offences under §29 of the Narcotic Law (offences related to drug use: mainly
possession and purchase),
· illegal traffic and smuggling of drugs under §29 of the Narcotic Law,
· illegal import of a considerable amount of drugs under § 30 of the Narcotic Law
(described by using the term of “more than a negligible amount”)
· other offences against the Narcotic Law.
In 1999 226,563 drug-related offences were registered. As figure 20 shows, 148,650 general
offences (mainly offences related to use) are at 65.6% the biggest portion of all offences. In
66,937 cases (30%) offences were related to illegal trafficking and smuggling. Illegal import
of narcotics of more than negligible amounts were reported in 1999 in 6,334 cases (3%),
other offences against the Narcotic Law have been registered in 4,642 cases (2%).
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Figure 19: Drug-related offences by kind of offence
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Figure 20: Offences against Narcotics Law (1988-1999)
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Crimes related to “direct supply” include all crimes committed to get in possession of drugs,
substitution substances or alternative drugs. 2,992 cases have been registered during the
reporting year, more than half of them were related to forgery of prescriptions (54.6%).
Among use-related offences, cannabis and particularly heroin play a major role (Figure 21).
The significance of cannabis in these statistics is certainly systematically understated, as in
various survey procedures used by the Federal Criminal Police Office the so-called
hierarchic principle applies: in order not to count cases more than once, each case is
classified according to the drug involving the greatest risk. Hence cannabis, which occupies
the last place in this hierarchy, is only recorded if no other substance such as heroin, cocaine
or LSD is involved in the use-related offence. Figure 21 shows, that offences related to
cannabis use have been increasing to a considerable extent in the last three years
(1999: 85,668; 1998: 79,495; 1997: 64,456). Offences related to cocaine use have clearly
been increasing in the previous years, too (1999: 13,810; 1998: 12,835; 1997: 12,167).
Figure 21: Offences related to drug use (1982-1999)
0
10'000
20'000
30'000
40'000
50'000
60'000
70'000
80'000
1982 1984 1986 1988 1990 1992 1994 1996 1998
Heroin
Cocaine
Cannabis
LSD
Amphetamines
Amphetamine derivates
Other
Source: Annual Report on Drugs 1999 (BKA 2000a)
In addition to the total group of offences, the Federal Criminal Police Office also publishes
statistics on those persons who were noticed because of drugs for the first time11. This figure
too has increased markedly since the middle of the eighties. However, developments of
single drugs are different at the moment. In 1999 7,877 persons who have been registered
for heroin use for the first time still hold the largest share of all persons who have been
registered for hard drug use (33.1%), even if their number slightly decreased compared to
last year (1998: 8,659). For amphetamines (1999: 6,143; 1998: 6,654) and cocaine (1999:
                                                
11 In Spring of 1997 the Federal Criminal Police Office changed its requirements of recording:
Persons having a usable amount of drugs with them are counted as first offenders using hard drugs as well and
not only as dealers.
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5,662; 1998: 5,691) numbers were slightly decreasing. Since 1990 annual case numbers for
ecstasy and LSD have rapidly been increasing. For ecstasy a new increase was obvious in
the last year (1999: 3,170; 1998: 2,830), but the number of persons who have been
registered for LSD use for the first time has been decreasing (1999: 738; 1998: 1,090). A
considerable increase of first offenders using hard drugs can be seen in the new Laender
were, compared to 1996 the number is almost three times as high (1999: 2,017; 1998:
1,635; 1997: 1,357; 1996: 770).
Data on verdicts on offences against the Narcotics Act are currently available until 1998.
Accordingly 42,377 offences related to the Narcotics Act out of a total of 554,127 verdicts
(excluding offences related to traffic) have been judged in 1999. As shown in figure 23 most
verdicts related to offences against the Narcotics Act take place among the age group 21-40
years. Respective offences are relatively rare among elder persons.
Figure 22: Persons who have come to the attention of the police for the first time on
account of drugs
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Heroin 6,091 2,254 7,252 8,384 8,501 6,970 7,421 8,771 8,659 7,877
Cocaine 364 567 2,308 3,238 4,307 4,251 3,930 5,144 5,691 5,662
Amphetamines 194 1,586 1,884 2,333 3,119 4,026 5,535 6,654 6,143
Ecstasy 2,371 3,609 3,799 2,830 3,170
LSD 200 168 321 772 1,191 1,356 1,090 738
Source: National Report on Drugs 1999 (BKA 2000a)
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Figure 23: Age distribution of offences against the Narcotic Law among adults
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5 Drug markets
5.1 Availability and supply
In 1999 as in the years before large quantities of narcotics have been seized at the
borders to German neighbour countries. For a big portion of seized substances the
country of departure, origin or transit were investigated by police or customs (BKA
2000a). South East Asia (mainly Afghanistan) was the major source of origin for
heroin, Turkey was the most important way of access. The border to the Czech
Republic is still an important gate of entrance of heroin. Here rather smaller quantities
of heroin seem to be stored from Eastern Europe and then transported to Germany.
The largest quantity of heroin came from the Netherlands. Cocaine was mostly
smuggled from Columbia, Costa Rica and the Netherlands. Germany is in many cases
not only the country of destination but also a transit country. In 1999 39% of all sized
quantities were not determined to remain in Germany. For synthetic drugs
(amphetamines, amphetamines derivates and LSD) as well as for cannabis products
the Netherlands were the main country of origin. In many cases seizures were already
made in the bordering area between Germany and Netherlands.
5.2 Seizures
The number and quantity of drugs seized by police and custom authorities are the
most important indicators for availability and supply of drugs on the illegal drug
market. Seizures do not only reflect the number and quantity of imported and
distributed drugs but also priorities and strategies in the field of law enforcement as
well as personal and logistic resources of police and custom authorities. The number
of seized drugs may vary considerably as a consequence of a few seizures of large
quantities. In order to better judge random effects the number of seizures should also
be taken into account. Until the reporting year 1996 numbers of seizures have not
separately been reported in the annual report of the German Federal Criminal Police. Due to
this the number of offences related to illicit traffic and smuggling or import of considerable
amounts of illicit drugs served as a reference figure. Since 1997 the annual report of the
German Federal Criminal Police gives information on numbers of seizures which is
presented in for figure 25 last year’s period.
In 1999 about 73,300 offences involved with illegal traffic and smuggling and import of
considerable amounts of illegal drugs have been registered in Germany. Still offences
involved with cannabis (1999: 33,300; 1998: 30,368) represent the majority of all registered
cases. Heroin (1999: 17,421, 1998: 18;192), cocaine (1999: 11;689, 1998: 10;556),
amphetamines and derivates (1999: 7;770; 1998: 7;008), LSD (1999: 526; 1998: 632) and
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other substances (1999: 2,560; 1998: 2,238) complete the picture of drug related offences
(Figure 24). From mid of the eighties till 1992 the offences related to heroin have more
than tripled, then they were stable for several years and are even decreasing at the
moment. Especially in cannabis offences there is a continuously increasing trend
since the middle of the 90s, which has been increasing also in the reporting year. The
respective numbers for cocaine are six times as high as in the eighties and were also
increasing in the reporting year. Offences involved with traffic, smuggling or import of
considerable amounts of amphetamines have also increased. Offences related to LSD
have reduced by half compared to 1997.
In 1999 the total amount of hard drugs (heroin, cocaine, amphetamines, ecstasy and
LSD) seized was rising considerably. A relatively continuous growth is observed over the
years in the quantities seized, particularly in the case of amphetamines (Table 29). On the
other hand, seizures of cannabis and cocaine in the last five years have been subject to
extraordinary fluctuations and are therefore difficult to interpret.
Figure 24: Trafficking, smuggling and illegal import (1982-1999)
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Table 30: Seizures (Quantity) 1991 - 1999
Heroin
(Kg)
Cocaine
(Kg)
Cannabis
(Kg)
LSD
(Trips)
Amphetamines
(Kg)
Ecstasy
(Tablets)
1991 1,595 964 12,344 13,887 88
1992 1,438 1,332 12,166 29,571 105
1993 1,095 1,051 11,353 23,442 117 77,922
1994 1,590 767 25,693 29,627 120 239,051
1995 933 1,846 14,245 71,069 138 380,858
1996 898 1,373 9,355 67,082 160 692,397
1997 722 1,721 11,495 78,430 234 694,281
1998 686 1,133 21,007 32,250 310 419,329
1999 796 1,979 19,909 22,965 360 1,470,507
Source: Annual Report on Drugs 1999 (BKA 2000a)
Amounts of seized LSD decreased considerably during last year, the amounts of seized
ecstasy units have increased dramatically in the last year. One will have to wait for
upcoming year’s developments before trend statements will be drawn. Quantities of seized
heroin decreased continuously during the last years which may reflect this substance’s
decreasing importance on the market. In the last year a slight increase was visible again
for the first time, but the total number of seizures has not changed much. About 60%
of all drug seizures were cannabis products or plants. The number of seizures
including cannabis products decreased in the last year (1999: 30,433; 1998: 31,241).
Figure 25 also shows a decreasing number of seizures for heroin (1999: 7,748; 1998:
8,387), amphetamines (1999: 3,811; 1998: 4,079) and LSD (1999: 434; 1998: 561). These
developments are the same for drug-related offences (Figure 21). There was also a
small decrease in the number of cocaine seizures if compared to the year before
(1999: 5,491; 1998: 5,532).
Figure 25: Number of drug seizures in Germany
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Source: Annual Report on Drugs 1999 (BKA 2000a)
 
 The situation of supply with illegal drugs is also demonstrated by the trend in procurability of
drugs. Since 1990, the Representative Survey has asked whether those questioned consider
they are able to procure illegal drugs within 24 hours. Particularly large differences arise
between those with experience of drugs and those without experience of drugs. Among
people without experience of drugs a clear increase in procurability has been evident since
1990. In the last representative survey (Kraus & Bauernfeind 1998) the figures for West
Germany have almost doubled if compared to 1990. This is a critical development as drugs
are getting more available to users without any drug experience. In the new Laender drugs
are clearly not procurable to the same extent as in the old, although the figures have risen
more sharply here in the last few years.
 
5.3 Price and purity of seized drugs
 A further indicator of the illegal drug market is provided by changes in drug prices and in the
purity of the drugs. Since 1975, the Federal Criminal Police Office has established an
average price for different drugs on the basis of seizures. A distinction is drawn between
small quantities of several grams and quantities of 1 kilogram and over. The former tend to
show the price paid by the user, while the latter reflect the costs of relevance to the drug
dealer. The drug prices thus ascertained can only be interpreted as approximate values,
particularly since the sometimes very great differences in purity between the drugs are not
taken into account when the price is ascertained. There is the further difficulty that the
individual seizures on which the price is based are not genuine “random samples” of drug
purchases, so that random effects may alter the figures substantially. The latest information
available is from 1999. For some time, the Federal Criminal Police Office has ascertained not
only the prices but the purity of the various drugs on the market. In 1999 analyses of the
purity and content of active substances are based on about 16,000 samples resulting from
seizures. All the values should be interpreted only as rough guidelines, as marked random
effects may arise, chiefly from the very great differences in purity between the various drug
seizures.
Cannabis
 As a result of the increased availability and supply of hashish (cf. above), the price, which in
1984 had risen to its highest level of DM 18 (9,2 Euro) per gram, has fallen to around DM 11
(5,6 Euro). For small quantities it is around two and a half times as high as for quantities in
kilograms. Systematic investigations of the content of active substances in hashish are done
by the BKA systematically since 1993 and has been enlarged since then. The comparability
between recent results and figures from earlier years is therefore limited. A
comparison between the purity of recent samples and those from 1997 and 1998 show
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an increase in mean percentage of THC. 66% of 3,793 samples in 1999 showed a
proportion of tetrahydrocannabinol (THC) between 5 to 11%. 15,5% of all samples
showed a lower proportion of active substance, 18,5% have had a higher one. Taking
into consideration the large number of samples this may indicate a further increase of
highly potential cannabis on the market.
 
Cocaine
 In the case of cocaine prices also have clearly fallen since the middle of the eighties. An
average of around DM 125 (63,9 Euro) per gram was paid in 1999. The prices for quantities
over one kilo, which as a rule are seized from dealers, are around 73 DM (37,3 Euro). 1999
2,682 cocaine samples were analysed by the laboratories of the Land criminal offices.
 More than 64% of them had between 20% and 70% cocaine base. Nearly one third of
the samples contained more than 70% of the pure substance. There could be a
correlation between an increase in purity and a change of patterns of drug use.
 
Figure 26: Prices for hashish per gram
for small and large amounts
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Figure 27:THC content of Cannabis
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Figure 28: Prices for cocaine per gram
for small and large amounts
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Figure 29: Cocaine base content of
cocaine
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Heroin
Since 1975, the price of heroin had been subject to relatively sharp fluctuations. From an
average price of around 315 DM (about 161,1 Euro) per gram (1980) for quantities below
one kilogram, by the middle of the eighties it had almost doubled. This coincided with a
period of stable or even falling numbers of drug addicts. The rapid decline in heroin prices up
to 1990, which led to a price below DM 150 (about 76,7 Euro) per gram, occurred at the
same time as a very sharp rise in the number of users and drug-related deaths. The ongoing
–slowed down- decrease of prices between 1990 - 1999 (85,5 DM; 43,7 Euro) is faced with
a stable or decreasing number of users. The average content of diacetylmorphine reflects the
purity of the heroin samples and the active substance content in the drug on the market. In
spite of falling prices and evidently greater quantities of heroin on the market, the average
content clearly decreased from 1985 till 1998 but was slightly rising in 1999. 4,172 heroin
samples were analysed in the laboratories of the Land criminal police offices. 76% had
a diacetylmorphine content of less than 20%. 24% of all samples analysed had a
content of 20% to 90%.
77
Figure 30: Prices for cocaine per gram
for small and large amounts
0
50
100
150
200
250
300
350
1975 1980 1985 1990 1995 2000
DM
small large
DM 1975 1985 1990 1995 1999
Small 220 315 175 128 85,5
Large 80 175 75 52 42,7
Source: BKA (2000)
Figure 31: Diacetylmorphine content in
heroin samples
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6 Trends per drug
6.1 Cannabis
In Germany cannabis is the most frequently consumed illegal drug. According to the latest
representative population survey cannabis has been used during the last year by 4.5% of the
population in West Germany respectively by 2.3% in East Germany (Kraus & Bauernfeind
1998). Higher prevalence rates can be found among young adults: Among 21-24 year old
persons in West Germany the prevalence rate is 14.7% and among 21-25 year old persons
in East Germany 13%.
Figure 32: Trends in out-patient counselling and treatment: Cannabis
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Total 2,350 3,002 4,749 5,564 7,066 7,806 +10.5%
West 2,339 2,974 4,625 5,342 6,663 7,090 +6.4%
East 11 28 124 222 403 713 +76.9%
Men 1,910 2,456 3,883 4,642 5,861 6,545 +11.7%
Women 440 546 866 922 1,205 1,261 +4.6%
Main diagnosis 1,028 1,368 1,696 1,977 2,623 3,343 +27.4%
Source: EBIS 1999 (Türk & Welsch 2000a)
Amongst drug users treated in out-patient treatment facilities cannabis was the main
reason for treatment in 22% (last year: 18%) (Türk & Welsch 2000a). With this cannabis
is in position two of all illegal substances. Among drug users treated in inpatient
treatment facilities the proportion of persons treated for cannabis is 4,7% (last year:
3.3%) (Türk & Welsch 2000b). The “typical” client treated mainly for cannabis is
relatively young and treated for the first time. His circumstances of living are quite
stable and he is situated in an extended period of education or training that allows
some “safe place” to live. In Germany most drug related offences are connected with
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cannabis (1999: 54%). Having a closer look at the kind of offence which is mainly involved, it
can be observed that in 1999 about 66% of all offences are related to “use” (Statistics of
the German Federal Criminal Police; Polizeiliche Kriminalstatistik 1999).
6.2 Synthetic drugs (amphetamines, ecstasy, LSD)
About 2% of all persons aged between 18 and 39 years in West Germany and less than 1%
of the respective age group in East Germany have consumed amphetamines at least once in
their life (Kraus & Bauernfeind 1998). Respective figures for last year’s prevalence are 0.9%
and 0.6% and with this nearly divided by half. Compared to 1990 the figures related to actual
consumption show an increase. Having a look at lifetime prevalence slight increases can be
observed in East Germany whereas the figures in West Germany slightly decreased between
1990 and 1997. However, the recent number of seizures of amphetamines and
metamphetamines shows a slight decrease in the last year (1999: 3,811; 1998: 4,079;
1997: 3,571). Also the number of persons who have been registered by the police
because of amphetamines for the first time decreased in the last year (1999: 6,143;
1998: 6,654; 1997: 5,535). In contrast the quantity seized increased. Further
developments have to be observed.
On the German drug market ecstasy plays an important role since the beginning of the
nineties. The last representative population survey carried out in 1997 showed that ecstasy-
despite the fact that it has not such a long history on the German market compared to other
drugs- is consumed by a considerable amount of persons. Young persons use the drug most
frequently. Among 18-24 year old persons lifetime prevalence is 6% making ecstasy to the
number two of drugs in favour of young users right behind cannabis. This picture is
confirmed by the drug affinity study of 1997. According to this study 5% of 12-25 year old
youngsters in West Germany and 4% of the respective age group in East Germany report
experiences with ecstasy. In West Germany ecstasy is on position two on the list of preferred
illegal drugs among youth in 1997. The study shows, that ecstasy use is mainly influenced by
friends and not by frequency of visits of techno-events or duration of these visits.
In the field of the police numbers are rapidly increasing for ecstasy after a decrease in
the year before. The number of seizures clearly increased last year (1999: 2,883; 1998:
1,986; 1997: 2,368), as well as the number of persons who have come to the attention
of the police for the first time because of ecstasy (1999: 3.,710; 1998: 2,830; 1997:
3,799). The number of clients in out-patient counselling or treatment with a primary
ecstasy related problem rose about 15,8% in 1999 (Türk & Welsch 1999a).
According to the results of the latest population survey LSD is nearly the only hallucinogen
drug that is used in Germany (Kraus & Bauernfeind 1998). Other drugs like e.g. mescaline
do not play a significant role. In 1997 the number of persons in West Germany (age group
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18-39 years) who made experiences with LSD at least once in their life decreased to the
level of 1990 (2.1%). In East Germany lifetime prevalence of LSD use nearly multiplied by
eight and actually reached a level of 0.8%. Whereas lifetime prevalence of hallucinogen use
in West Germany in 1995 was even higher than the respective figure for ecstasy the overall
picture was vice versa in 1997. The number of LSD seizures made by police has been
decreasing since four years (1999: 434; 1998: 561; 1997: 727; 1996: 822).
Figure 33: Trends in out-patient counselling and treatment: Ecstasy and related
substances
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Total 1,300 1,379 2,754 3,430 4,033 4,412 +9.4%
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East 13 30 100 204 333 557 +67.3%
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Source: EBIS 1999 (Türk & Welsch 2000a)
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6.3 Opiates
About 0.6% of the total population between 18 and 39 years in West Germany and 0.1% of
the respective age group in East Germany made experiences with heroin at least once in
their life (Kraus & Bauernfeind 1998). Last year’s prevalence rates are much lower.
Methadone has been used by 0.2% of the West German population at least once in their life
and by 0.1% during the last year. 0.7% of all West German inhabitants and 0.2% of the East
German population consumed other opiates like codeine or dihydrocodeine at least once in
their life. Statistical figures resulting from population surveys are assumed to under-estimate
the true prevalence rates due to difficulties of reaching the target population. Therefore these
figures may only be used as rough estimates. Despite the fact that heroin use is not widely
distributed among the total population it still is the main reason for treatment demand.
Figure 34: Trends in out-patient counselling and treatment: Opiates
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Total 7,502 8,266 9,827 10,517 11,928 12,001 +0.6%
West 7,469 8,216 9,704 10,339 11,569 11,300 -2.3%
East 33 50 123 178 359 694 +93.3%
Men 5,724 6,288 7,459 8,248 9,223 9,496 +3.0%
Women 1,778 1,978 2,368 2,269 2,705 2,505 -7.4%
Main diagnosis 6,526 7,717 8,558 7,954 9,417 9,742 +3.5%
Source: EBIS 1999 (Türk & Welsch 2000a)
About 9,700 main diagnosis were made for this group in 1999, 3.5% more than the year
before. The number of single diagnosis doubled in the new Laender but is still low.
Almost half of heroin users treated were injecting the drug (Türk & Welsch 2000a).
About 30% of drug-related deaths registered by the police in 1999 were caused by a
heroin overdose. In another 11% heroin were the cause of death in association with
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other drugs. The number of heroin seizures registered by the police in Germany
decreases (1999: 7,748; 1998: 8,387; 1997: 9,509). With the total number of 7,877
individuals, heroin users still represent the biggest group among hard drug users
registered by the police or custom authorities for the first time (33.1%). However their
total number decreased slightly compared to the year before (1998: 8,659). Taking into
account all sources available they indicate a stable situation of heroin related
problems since about 1992. The increase in treated heroin users can partly be
explained by the fact that the target clients are better reached especially because of
an extension of substitution programmes.
6.4 Cocaine
The percentage of persons who made experiences with cocaine at least once in their life is
2.2% among 18-39 year old persons in West Germany (Kraus & Bauernfeind 1998).
Compared to 1990 results these figures increased (lifetime prevalence of 12-24 year old
population of 0.8%). In East Germany experiences with cocaine can hardly be found.
Compared to ecstasy or hallucinogens for which figures rapidly increased at the beginning of
the nineties, a continuous and stable increase in numbers of cocaine users is observed since
more than 10 years. The misuse of or addiction to cocaine is the third most main
diagnosis to be found in out-patient treatment. Here the percentage of cocaine main
diagnosis is 7% (Türk & Welsch 2000a), in inpatient treatment it is about the same
(Türk & Welsch 2000b). The number of cocaine main diagnoses has more than
doubles since 1994. There are six times more single diagnoses than main diagnoses
which means that cocaine is mostly used as a secondary drug. It is used in
combination with opiates and increasingly in combination with other substances, too.
In the number of cocaine seizures only minimal differences can be found in 1999 in
comparison to the year before. It was slightly decreasing (1999: 5,491; 1998: 5,532;
1997: 5,482; 1996: 5,532), whereas the quantity of seizures has reached its highest
level since 1990. The number of persons who have been registered by the police for
cocaine use for the first time decreased (1999: 5,491; 1998: 5,691; 1997: 5,144). In total
figures on use, treatment and law enforcement indicate a increasing importance of
cocaine.
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Figure 35: Trends in out-patient counselling and treatment: Cocaine
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Total 2,062 2,496 4,105 4,851 5,781 5,982 3.50%
West 2,050 2,478 4,043 4,745 5,545 5,475 -1.30%
East 12 18 62 106 236 503 113.10%
Men 1,665 2,028 3,240 3,960 4,640 4,929 6.20%
Women 397 468 865 891 1,141 1,053 -7.70%
Main diagnosis 481 714 863 830 1,037 1,167 12.50%
Quelle: EBIS 1999 (Türk & Welsch 2000a)
6.5 Pharmaceuticals
Misuse and abuse of pharmaceuticals are difficult to detect by general population surveys. It
is possible to ask for frequencies of use but valid statements on daily doses or indications
can not be obtained. According to the latest representative survey dated from 1997 nearly
twice as much women (19.5%) than men (11.5%) reported to have used pharmaceuticals
with psychoactive effects (e.g. analgesics, sleeping drugs, sedatives, stimulants, laxatives or
appetite suppressants) at least once per week during the last four weeks (Kraus &
Bauernfeind 1998). Among these analgesics are by far the most frequently consumed
substances (West: 10.9%, East: 11.5%), followed by sedatives (West: 3%, East: 3.3%) and
sleeping drugs (West: 2.4%, East: 3.3%). EBIS also records clients in out-patient
counselling or treatment primarily because of sedatives and hypnotics. In 1999 about
621 persons received such a main diagnosis (Türk & Welsch 2000a). As single
diagnoses pharmaceuticals are mentioned in 4,237 cases - what is a higher frequency.
This underlines that abuse of or addiction to pharmaceuticals are increasing but also
that those substances are usually used beside other drugs. This fits to the
observation that multiple drug use and addiction to more than one substance become
more and more frequent.
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6.6 Multiple use (including alcohol)
Considerable proportions of polyvalent patterns of use can especially be found among
addicted women and men who use alcohol, opiates, cannabis and mainly cocaine and
hallucinogens. Especially figures of opiate users have to be seen as critical regarding to
substitution treatment in Germany. More than 44% of those female and 51% of the
respective male persons additionally use cocaine in a harmful way. Harmful use or
addiction to alcohol can also frequently be found among clients with a heroin main
diagnosis. 39% of men and 37% of women with an opiate diagnosis have an alcohol
diagnosis, too (Türk & Welsch 2000a).
6.7 Solvents
In Germany volatile inhalants are not used very frequently. The representative population
survey of 1997 (Kraus & Bauernfeind 1998) shows, that 0.7% of the West German adult
population used volatile inhalants at least once in their life, during the last year only 0.2% did
so. Most experiences with volatile inhalants are reported by the group of 21-24 years old
persons. Among this group 2.4% used the substances at least once in their life, 1.1% did so
during the last 12 months. In out-patient counselling or treatment centres solvents do nearly
not exist as main diagnosis as single diagnosis they are prevalent among 0,3% of all treated
men and women (Türk & Welsch 2000a).
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7 Discussion
7.1 Consistency between indicators
Most indicators show a continuous direction since several years. Especially persons being
registered by the police for drug issues for the first time and treatment data reflect very
similar trends. Compared to police data the higher increase of opiate users in the treatment
area during the last 2 years may reflect that persons are better reached by treatment offers.
The considerable increase in methadone treatments may be the reason for this. Other
indicators, partly based on very limited samples, seem to be influenced by many factors
beside overall prevalence of drug use:
Ø The decrease of heroin prices since the middle of the 80ies goes in line with an
increase in the number of heroin users noticed by the police for the first time until
1992. Procurability and prevalences of heroin use were decreasing afterwards.
Ø In comparison to intravenous heroin use oral heroin use is clearly increasing
which could be explained by low prices.
7.2 Implications for policy and interventions
Especially the increase of ecstasy use caused considerable public debates and sorrows.
Special prevention projects have been launched especially addressed to visitors of rave
parties and fans of techno music. Data that are collected at the moment, may contribute to
get more insight into the problem’s extend, certain patterns of use and to gain possible
options to improve prevention activities. Meanwhile methadone based substitution which had
been discussed intensively before being implemented in Germany, became a normal part of
the overall treatment spectrum. In the framework of planned heroin prescription studies also
effects on drug markets and regional load concerning criminality will be researched.
7.3 Methodological limitations and data quality
Whereas figures describing the consumption of “soft” drugs among the general population
and their partial groups are relatively valid and statistical reliable, data describing the hard
core of heroin users are limited concerning numbers and quality. The police, having access
to this group, is only able to provide an absolute minimum of data (age, gender, drug,
location of arrest). Information coming from treatment centres are also limited in their
meaningfulness, due to the fact that not all persons affected use these offers. However, a
satisfying quality of overall statements is enabled by cross-validating data coming from
different sources.
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PART III DEMAND REDUCTION INTERVENTIONS
8 Strategies in Demand Reduction at National Level
8.1 Major strategies and activities
Developments at the federal level
The subject “demand reduction” is under the responsibility of different sectors of
politics and administration. At federal level at the first place the Federal Ministry for
Health (Bundesministerium für Gesundheit, BMG) and - within its sphere of business -
the Federal Centre for Health Education (Bundeszentrale für gesundheitliche
Aufklärung, BZgA) are working on this topics. Besides taking initiatives they are
playing a mayor role as co-ordinators of preventive activities in Germany. The Federal
Ministry for Health (BMG), the Federal Ministry of the Interior (Bundesministeriums
des Innerern, BMI) and the Federal Ministry of Justice (Bundesministerium der Justiz
BMJ) in agreement with the Federal Laender define the legal basis, which is relevant
also for prevention work. The Federal Criminal Office (Bundeskriminalamt, BKA), a
sub-ordinate organisation to the Ministry of the Interior - besides repressive measures
against drug offences - also conducts activities for education and prevention. A
special department for “criminal prevention and public relations” has been created to
support the preventive activities of the Laender police organisations. These measures
point to a broader self concept of the police in Germany.
New developments at Land and municipality level
Crucial input in relation to measures and activities for demand reduction also comes
from the Federal Laender. The drug commissioners and the prevention
commissioners of the Federal Laender play an important role in this respect. Within
the respective work-groups they ensure the information exchange between Federal
government and Laender. In nearly all Federal Laender task forces or work-groups on
prevention are offering expert collaboration and an institutional framework for
common decision-making and planning including representatives of the authorities.
Many Laender within these co-ordination groups have developed Land programmes or
global concepts for addiction prophylactics and prevention, which serve as a basis for
action for the collaboration with associations, projects, institutions and organisers
responsible for prevention measures in order to extend addiction prevention. In
addition within the Federal Laender there are inter-ministerial work-groups to better
co-ordinate measures at Land level. Usually the Ministry for Social Affairs, the Ministry
of the Interior including the Land Criminal Office, the Ministries for Culture and Sports
and the Ministry for Justice are part of theses groups.
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Most prevention takes place at to the municipality or local level. Within these projects
children and adolescents are contacted via opinion leaders directly at their place of
living. These persons frequently come from the departments health and social affairs,
education, youth help and interior. However, compared to the big number of activities
and measures, still a big proportion of all the activities is done by the staff of centres
for drug treatment and psychosocial counselling. One can feel, that the engagement
for the development of common guidelines and quality criteria for this work has
increased. This leads to an increasing care about co-ordination of actors at
municipality and Land level and at the same time a higher weight is given to quality
insurance, evaluation and further development of concepts.
8.2 Approaches and new developments
The Federal drug commissioner launched the Drug and Addiction Report 1999 in
March 2000. Addiction prevention is underlined in this text as leading topic of the drug
policy. The new convened Commission for Drugs and Addiction has been asked to
develop a new prevention concept for the Ministry for Health, which at the moment
follows a strategy of education, primary and secondary prevention. The differentiation
between legal and illegal substances is getting less and less relevant in the field of
prevention, the potential harm of tobacco and alcohol becomes part of information
and prevention campaigns.
Franzkowiak and Sabo (1999) analysed more than 100 publications from the journal
“Prävention” (Prevention) from 1978 to 1997 in relation to the development of lead
concepts and focus in the field of “drugs”. The study mentions the following trends:
1. Recent lead concepts are a as much as possible drug free lifestyle or the use of
substances without causing health related harm
2. As alternative to drug use “life skills” are focussed upon, i.e. strengthening direct
responsibility, social competence and ability for conflicts. In this respect more and
more concepts have been developed for specific target groups:
Ø Gender specific addiction prevention
Ø Work with adolescents and young adults in social problem situations
Ø education and developmental support for migrants, evacuates
Ø and others, which are sensible to cultural background
The strategies of “risk escort” and “risk competence” are thought to reach youths and
young adults with drug experiences. Besides offering help they should transmit safety
rules for risk minimisation. The strategy of risk competence includes several
components:
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Ø critical awareness of  drug consequences and addiction risks on the basis of
information
Ø the development of personal rules for use, which should help to minimise personal
risk and harmful consequences as far as possible
Ø soberness on the spot for selected settings, situations and developmental stages
(e.g. pregnancy, at work)
Ø “Ritualisierte Formen” of non harmful use of psychotropic and addictive
substances (“rules for intoxication")
Ø freedom and strength of decision for long term option of use between abstinence
and controlled use
Drug addiction in Germany insurance law is seen as a disease with psychic, social
and somatic factors. This is similar to the concept of a disease as the WHO
International Classification System (ICD9) describes it. At Federal level a broad
system of addiction care for treatment and support is funded, which should fulfil the
needs of the addict individual. The enlargement and differentiation of treatment offers
started in the beginning of the 90s as a consequence of the HIV epidemics. Besides
the drug free inpatient treatment system low threshold social and health related
services were developed in out-patient drug care. Also today help to survive and harm
reduction measures are judged as especially necessary because of the again
increasing number of drug related deaths and the bad health conditions of many drug
addicts (e.g. through infectious diseases like hepatitis or tuberculosis as well as
psychiatric co-morbidity). The aim of harm minimisation is also reflected in the
revision of the Narcotic Law (BtMG-ÄndG) which came info force 1st of April 2000. The
law provides a clear legal situation for so called “drug consumption rooms” and
extends the possibilities for the government to regulate the prescription of
substitution substances. These prescription regulations are worked out at the
moment. This law also is the basis for the installation of a central reporting system for
patients under substitution, which is thought to fight multiple prescriptions though
different doctors as well as the increased availability of methadone on the black
market.
Co-operation, co-ordination and networking at the moment are very prominent in the
development of demand redaction. Through a better division of work, e.g. between
youth help and drug help  double work should be avoided and efficacy in total
increased. Whereas until some years ago drug help tried to develop own services for
example in the field of work, medical care etc. at the moment increasingly support
from the normal help system is searched for, as one can see.
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Approaches and new developments at federal level
Within demand reduction at Federal level at the moment those concepts are
prominent, which are striving to better reach drug users, who are (at the moment) not
willing to participate in a drug-free or methadone substitution treatment. The focus of
health policy  is especially on a model project of heroin supported treatment, which is
accompanied by scientific evaluation. It includes heroin substitution for long term,
heavily addicted opiate users. It will be studied, if and how it is possible to stabilise
and to motivate these clients for further treatment. The project start is scheduled for
beginning of 2001.
Approaches and new developments at Laender level
In order to be able to give an overview on demand reduction in the 16 Federal Laender,
the DBDD asked the Land drug commissioners for information. Some measures,
which are important from a strategic point of view or the result of new strategies are
taken from the reports of the respective ministries and introduced here as examples.
Bayern
Specific concepts to motivate “therapy resistant” drug addicts for treatment at the
moment are developed in a research project supported by the Land of Bavaria. In a
first step the question on factors is raised, why a drug addict is not accepting
treatment and if they would come into therapeutic contact through new motivating
concepts of motivation.
In the Augsburg region a model project is conducted at the moment with
accompanying scientific evaluation. It studies, if central parameters of quality of
therapeutic services can be improved - including a reduction of drug related deaths -
by better co-operation between all organisations involved (e.g. facilities for addiction
care, practitioners, police, justice, emergency care). At the same time an analysis is
done on all drug related deaths in Bavaria. The collection of background information
on the time period before the drug related death should give some indication of
possible causes which would offer a starting point for new measures within addiction
care.
Berlin
During the last years the network of low threshold services has been considerably
extended. By positioning buses at the meeting places of the drug scene, syringe
exchange schemes, medical help and hepatitis test and vaccination on the spot have
been done. Within the project “drug emergency prophylactics” social work has be
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done which follows the client up and addicts have been referred to counselling and
further services at a focal hospital, where especially high numbers of drug addicts
were entering admitted. Another pilot project, which is continued on Land budgets is
the study on “Prevention of drug related emergencies and deaths through
strengthening self help”. In this project staff from  prisons and drug treatment
facilities as well as drug addicts are trained in first aid measures for drug related
emergencies. Drug addicts specially qualified are handed over the antidote naloxone,
which they can use in case of emergencies. Syringe exchange in prisons is studied in
a model project as part of a global concept including amongst others accompanying
measures of medical help and social work, external aids and drug counselling and
help to stop drug use. An expertise on situation and problems of the open drug
scenes in Berlin will be available already this year.
Mecklenburg-Vorpommern
In Rostock the model project “Sprechstunde on designer drugs” has been started at
the end of 1998. Counselling, medical and psychological examination and treatment
as well as social-pedagogic help is offered to youth drug users, who are still in an
experimental phase. This is done by a multiple disciplinary team in an out-patient
setting. The model project has started in autumn 1998, it will continue for three years
with the option of an one-year-prolongation. It is funded by the Federal Ministry for
Health, the Mecklenburg-Vorpommern Ministry of Social Affairs and the municipality
of the Hansestadt Rostock. Accompanying scientific evaluation  of the model project
is fully covered by the Federal Ministry for Health. The aim is to develop strategies for
early treatment, abstinence and solutions at an earlier point of time and to strengthen
the youths and children within their situation of life.
Rheinland-Pfalz
The project “prevention and early intervention for children from problem families with
addiction problems” has been finished in 1999 resulting in a four part training course
“children of addicts - recognise and help”. In the model project “addiction prevention
within kindergartens” ways to support life competencies have been tested and
documented. This should motivate Male and female kindergarten teacher and
specialists in addiction to establish addiction prevention. The “Mondorf” group
(Saarland, Luxembourg, Lothringen, the German speaking population in Belgium and
Rheinland-Pfalz) within the framework of its trans-national work as well as the Upper
Rhine Conference have conducted different measures of addiction prevention. For
example, a cross border youth project and a seminar on “intercultural health
promotion and migration” have been done. End of 1999 help offered to heavily
indebted addicted people has been improved. Debts are nor rare amongst the clientele
of counselling centres. At five counselling centres for addiction and drugs counselling
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for debtors have been set up in accordance with the new law on insolvency. Individual
counselling as well as further education and the development of co-operation
structures for special staff is offered.
Saarland
“Therapy - now” is offered to drug addicts willing to drop out since 1998. They get the
chance to do detoxification and after that therapy directly and without bureaucratic
hurdles. Similar programmes have been done in the past among others in Northrhine-
Westphalia and Bavaria. At the beginning of 2001 a survey on drug use is planned to
be done as part of the cross border collaboration of the above mentioned “Mondorf
group” work in their area.
Schleswig-Holstein
Since 1994 all over the Land Schleswig-Holstein the project “school of glass” is done
for addiction prevention close to schools. A questionnaire is used to make visible
specific patterns and motives for use, but also stresses, health impairments and
communication disorders for pupils of a school. Measures of health promotion and
addiction prevention can be targeted to the specific problem profile and used within
lessons. The Landesstelle gegen die Suchtgefahren (Land Office against drug
problems) as well as the co-ordination unit for school addiction prevention are holders
of the project. Since 1998 “school of glass” is applied also in Brandenburg and
Mecklenburg-Vorpommern.
Demand reduction and socio-cultural background
About 8,3% of all clients treated in out-patient centres for counselling and treatment
are foreigners. 1,5% come from European neighbour countries, 6,9% from non EU
countries like former Yugoslavia, Turkey of former Soviet Union (EBIS 1999). Until now
addiction care is mostly unable to offer services to addict foreigners, which
sufficiently take into account cultural, social and religious background. Some staff is
working in low threshold services, counselling centres and out-patient and in-patient
treatment which has the respective lingual competence of ethnic background.
Developments in public opinion
Public opinion on persons with HIV and AIDS in Germany can be described as little
stigmatising and excluding this group. This is shown by a representative repeated
survey “Aids in public awareness 1999”, which has been published by the Federal
Centre for Health Education (Bundeszentrale für gesundheitliche Aufklärung, BZgA) in
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April 2000 (Christiansen & Töppich 2000). While In 1995, before education campaigns
started, 36% of the subjects supported the idea to isolate people suffering from Aids,
this have been only 4% in 1999. The same study, however, shows, that Aids within the
media is perceived to a lesser extent. While in 1993 in West Germany 83% got
informed about Aids through TV spots, brochures, advertisements and information
events, this was true only for 47% in 1999. There has also been a reduction in
interpersonal communication on HIV and Aids. While 1999 50% reported about
conversations  on these topics, in 1999 it was only 14%. Safety behaviour within the
population is still at a high level also for population sub-groups at higher risk of
infection like singles below 45 years. 61% in this group, for example, had a condom
with them when they were asked.
Special events during the reporting period
"Schools, Internet & Non-smoking" is an internet competition for female and male
pupils from 6th grade on, which is conducted until May 2001 at German and British
schools. Under the competition motto “give a better image to non smoking” pupils are
asked to produce web pages, which show in an original way how non smoking can
attract youths. Also elements from activities and projects to support non-smoking
within schools can be described. The competition is aiming at creative ways to use
computer and internet in connection with health related topics. The project is run by
IFT Munich, IFT Nord and TACADE Manchester and  supported from EU budgets.
Information dissemination for experts on demand reduction
Regular publication of a “newsletter” is an adequate, efficient and far reaching
instrument for information purposes for experts and institutions in the areas of
prevention, treatment, research, politics and statistics. The German Council on
Addiction problems (Deutsche Hauptstelle gegen die Suchtgefahren, DHS) is the
umbrella organisation of 22 mostly non governmental member organisations. They are
holding more than 1.000 counselling centres and 4.500 self help groups as well as 160
specialised clinics, all psychiatric clinics and other institution in drug treatment and
prevention. The DHS informs through a newsletter published every quarter on recent
news from their committees and work groups. New projects on demand reduction are
introduced and results from seminars, meetings and conferences are described in a
conclusive way. Also new articles and book publications are introduced.
The German Reference Point for the EMCDDA (Deutsche Referenzstelle für die
Europäische Beobachtungsstelle für Drogen und Drogensucht, DBDD) also informs
their co-operation partners through a regular newsletter on its focal point activities as
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well as new developments at national and international level. The website
(www.dbdd.de) has been launched recently as a platform for information on
epidemiological data, new developments and DBDD activities. Many relevant
institutions from the fields of politics, research, prevention and therapy are linked via
hyperlinks.
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9 Intervention Areas
In Chapter 9 a variety of approaches and new developments in demand reduction is
described structured by the fields of primary and secondary prevention as well as
treatment and after-care.
9.1 Primary prevention
9.1.1 Infancy and family
As primary prevention strategies are in the focus of addiction prevention now especially
children – already before they start going to school – are in the centre of planning measures.
Given the age group such measures are not targeted towards information on specific
addictive substances or drug education but they teach general health promoting behaviour
as well as the development of mental “strength“. Those projects, which are implemented in
kindergarten and basic education in the first place today are part of the standard offer of
prevention practitioners. Here it can be referred to an expert report by Kämmerer (1996)
induced by the by the BZgA which evaluated existing material on addiction prevention in pre-
school age. This paper provides an detailed overview of the field. As a recent example of
activities in this area, the joint project of drug prevention units in Hamburg entitled ‘Strong
Childhood - Strong Life’ is introduced here. The project run over two years and became
evaluated in 1998. It is aimed mainly at parents and male or female educators in 8 day
nurseries. The modules of the project consisted of information events, further vocational
training, aids of organisation and intensive care in practical work.
Another innovative concept for addiction prevention in the pre-school-age the Working Group
for Health Education in Hesse (HAGE) started at the end of 1996 and was supported by
the BZgA. This demonstration project was planned to go on for 5 years and consists of three
linked project modules (information, encouragement, psychomotoric). While the module
information gives well-known information about drug prevention to parents and educators,
the so called encouragement training for educators (supervision) and a psychomotoric
conceptualised motion programme for the children at the kindergarten are new concepts in
addiction prevention. Psychomotoric elements offer the children free, joyful and playful
incentives and experiences necessary for maturing. Experiences of body, material and of
social character are relevant. In 1999 the evaluation was finished.
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When children shall be taught a life style which supports their psychological and physic
health, the family if central importance. It is generally agreed that the family is of central
influence in teaching children a way of life which promotes their mental and physical health.
Despite this agreement upon the overriding role of the family in the development of specific
behaviours of the children, there have been only few documented addiction-prevention
activities aimed at German families until the early nineties (Künzel-Böhmer 1993). This
changed fundamentally in the last years. A main focus on primary preventive activities in the
family can be found at national level and in all federal Laender. As an example the
brochure series for parents ‘We can do a lot to prevent that children become addicted’ of the
BZgA is mentioned, published in 1994. This brochure deals with the situation of children from
early childhood until puberty (part one), deals in particular with the phase of puberty (part
two) and offers comprehensive support and hints for families (part three). In 1997 another
part was added with the title “talking about drugs”. Here parents are given information and
recommendations on the form of dialogue with adolescents.
In the field of family and adult education measures aiming at families as target group have
been tested within the last two years. In 1999 a thorough documentation concerning the joint
project of catholic, Lutheran and not confessionally bound organisations engaged in family
and adult education was published (BZgA Schriftenreihe Vol. 7: Starke Kinder brauchen
starke Eltern, 1999). All of the activities and projects concerning early childhood and
prevention in families are supported by the broad mass-media campaign of the BZgA for the
prevention of addiction and drugs “Make Children Strong”. This campaign serves as a
“communication umbrella” under which numerous local initiatives can unfold or to which they
can be linked to.
9.1.2 School programmes
In Germany, preventive programmes in schools on the basis of the Laender’ s supreme
power have to be organised by each Land on its own. This makes a conclusive description
and evaluation of preventive activities at schools quite a difficult undertaking for all Germany.
The majority of all activities should be found for the treatment of subjects related to drugs,
addiction etc. within the classes. These topics have already been included in the curricula of
all types of school. During the last years the BZgA has developed cross Laender training
materials for different age groups, which have been approved by the Land Ministries of
Cultural Affairs and Education.
In 1998, a new media-package (educational film and accompanying booklet, teacher’ s aid
for class, flyer) on the subject of ecstasy was introduced nation wide. Moreover, an
intervention programme to detect addiction at an early stage (Step by Step) was offered to
teachers on CD-ROM for the first time. The compact disk is an aid to teachers dealing with
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conspicuous students and has been developed as a means of orientation for teachers for
taking action in early detection of addiction (secondary prevention). On the basis of this
model some institutes for teacher further education in the Federal Laender in 1999 started to
use the programme “Step by Step“ on a broad scale within this training.
At Laender level working material, training curricula and print media are developed at
a large scale. They are aiming directly at teachers to help them deal with children and,
teenagers in relation to drugs (e.g. Mecklenburg-Vorpommern, Bremen). In 2000 the
BZgA has prepared a market overview on teaching material for addiction prevention in
schools.
The implementation of so-called ’projection weeks’ as a special form of organisation of
classes offers further chances of experiences. The involvement of non-school units (such as
drugs counselling, medical doctors, the police) is facilitated, too.
Till now it is still an exception if a so called prevention programme is conducted, but during
the last years different models have been developed. Here programmes to support non-
smoking have a longer tradition (e.g. class 2000). New programmes, for example the Lions-
Quest-programme for pupils and the modified quest programme ‘growing up’ (Teachers`
manual 1997) as well as the ALF programme developed by IFT Munich a making different
addictive substances the subject (e.g. alcohol, tobacco etc.) and focus on life skills approach.
While the effectively of the programme is well evaluated, a broad application of them is still
missing. Other elements of addiction prevention at school are teachers’ classes for
qualification and further education, which are offered by continuation institutions for teachers,
which belong the Laender. Some of the Laender, (e.g. NRW, NS and others) have developed
extensive concepts and manuals for this purpose. Besides working-groups for addiction
commissioners and drug counselling teachers also training for counselling and further
education are offered (so called school internal advanced training for teachers) which can be
targeted to a change of the total social climate at school. Besides these offers of advanced
training and continued education which have been initiated by school authorities, other
organisations offer workshops, seminars and meetings for teachers as well, especially done
by experts for addiction prevention. Prevention activities, which come from the pupils
themselves, are still big exceptions. Though the concept of “peer-education” has increased in
importance also in addiction prevention, events at school are still very rare. The European
non-smoking-competition campaign “be smart-don't start” will be supported in the
term of 2000/2001 for the 4th time by the European Commission in the framework of the
action plan “Europe against cancer”. This time the project will be carried out in all
schools of about 10 federal Laender. In addition a few regions from four more federal
Laender will participate.
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9.1.3 Youth programmes outside schools
Many youth programmes outside Schools take place in community or church youth
organisations, youth centres or sports clubs. Often, youth programmes of this type are also
initiated by counselling centres of various funding bodies and associations, and by
information and co-ordination centres, whose work comes under the heading of addiction,
addiction therapy and prevention. Youth programmes outside schools are oriented towards
leisure time, unlike those in schools. Young people are free to participate in the programme.
The activities are so varied in their range and ambitions as to defy comparison. They range
from simple leisure activities, discussions and cultural events to fully-developed hands-on
educational concepts. The increasing use of PCs and internet in youth work is a new trend.
They are not only applied for information retrieval but they become an interactive discussion
and information forum for peers when chat-rooms and newsgroups are set up for (AJS-
Forum 1999).
In the year 2000 an interactive computer program for the training of opinion formers in
youth programmes outside school is developed in the framework of a German,
Austrian, Liechtenstein and Swiss co-operation. The fundamental idea is that
symptoms, which indicate that a pupil, trainee or employee has got a drug problem,
are often not realised. Frequently the reasons are a lack of knowledge on  symptoms
or the wish to treat the person affected gently. Often much time passes until
counselling centres are contacted. In this context the interactive computer program
helps to give information on early indications of drug problems among teenagers and
refer to specific interventions.
Preventive work for young people is essentially holistic in orientation, with 'learning by doing';
experiences are passed on directly (Hillman 1989). Formally, there are regular routine
meetings (such as group evenings) and specific activities which go beyond the usual range
of experience (such as project work). As gender specific aspects have gained more interest
during the last years also increasingly projects especially for boys and girls have been
conceptualised. There are some prevention projects explicitly and exclusively targeting
at girls, e.g. the project “Girl play Theatre” in Hesse. In Northrhine-Westphalia there
was a conference on “risk behaviour of girls”. A comprehensive activity, which reaches
children and youth by the means of their sport club, is the common initiative of the BZgA and
the big sport associations the German Athletic Association, the German Football
Association DFB, the German Sports Association and the German Gymnastic
Association DTB running since 1994. The campaign aims first of all on qualifying
measures for youth trainers of sport clubs, whose attention should be drawn to the addiction
problem and in their function as opinion-formers they should raise awareness for the
problems of addiction and drugs and promote addiction preventive behaviour within the area
of sports clubs. In 2000 about 2500 new opinion formers working with children and
99
teenagers in there associations were contacted in about 100 work-shops in 13 federal
Laender. In the framework of the “Make Children Strong “ tour sports, games and
competition events were used to get in tough with trainers and parents. In about 31
events almost 750,000 visitors could be reached in 2000. Also the “Join-In-Action” of the
BZgA, which was carried out with a competition between clubs aims at transporting the
message “Make Children Strong” into the clubs. To find access to the prevention of
addiction via sports was also successful in different federal Laender. An example is
the project group LA OLA of the Land Association against the Addictions of Baden.
There are many links between this initiative and the BZgA project as well as the association
‘life live’ on the contents side. In this way club sports has increasingly become an relevant
action field for the prevention of addictions.
In March 2000 the BZgA was in charge of a conference on “addiction prevention in
sports clubs” in Potsdam. More than 210 persons from sports associations, sports
clubs, prevention units, politics, teaching and research were participating. Subject of
the event were for example “criteria for the quality of drug preventive work and
structures in sports clubs” or “drug use and sports club's rituals and culture”. A
summary of all subjects and results of the conference was published as a brochure by
the BZgA.
Many initiatives take notice of ecstasy. They address different target groups and
communicate either “safer use” (e.g. Eve and Rave) or “clean messages” e.g. in the Mind
Zone project (Kröger, Künzel, Bühringer, Tauscher & Walden 1997). For 2001 the BZgA
also plans an internet project aiming at teenagers and adolescents due to the fact that
members of the techno party scene prefer this modern means of communication.
Apart from the ecstasy topic in the reporting period there has been an increase of new
concepts to address alcohol abuse as a topic to the young target groups. One model for this
could be the leisure time project of the Hamburg Office for Addiction Prevention, which was
conducted under the heading “mobile but safe” by order of the German Traffic Watch and the
BZgA (Büro für Suchtprävention 1998). Experiences from this project were laid down in a
work book and an video documentation, which was made available to others for information
and imitation.
9.1.4 Community programmes
Interventions in this area can be classified phenomenologically into two groups (Künzel-
Böhmer 1993): 1. programmes with the specific aim of preventing addiction and 2.
comprehensive health promotion programmes aiming at the encouragement of a healthy
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lifestyle and environment, and thus striving towards (non-specific) beneficial effects including
the avoidance of drug use. The youth programmes described above, whether school-based
or not, are also part of the community-based preventive activities.
In Germany, community activities which are specifically drug-related include many (large-
scale) events under a drug-free banner (“anti-drugs discos”, rave parties with a “no-drugs”
motto). In almost every German city centres such as drug-free cafes and similar leisure
facilities are now in existence. At a local level isolated attempts are being made to influence
alcohol consumption in the young by lowering the prices of non-alcoholic beverages in the
pubs. In Germany there is a legal duty to sell one non-alcoholic beverage for equal prize as
the cheapest alcoholic beverage at same quantity (BGBL I S. 34586). The Federal Criminal
Police Office (BKA) runs a project data bank for criminal prevention ("Infopool
Prävention") which integrates among other things the field of “drugs and addiction”.
Many police departments are doing drug prevention, usually combined with the
dissemination of information on illegal drugs and drug-related delinquency, the organisation
of anti-addiction days or weeks, and organising anti-drugs discos. The target groups are
generally younger people, particularly schoolchildren, but also parents, teachers, and other
opinion-formers. By adapting the model project "women (regular) tables” from
Switzerland the BZgA supported a district approach to acquire and qualify new
honorary opinion formers. The projects copies the concept of the “Tupperware”
marketing strategy. Hostesses invite especially trained honorary opinion formers who
lead discussions about general questions on education and give on a low threshold
information on drug prevention for children in every day's life. A process evaluation of
the project is made by the University of Kiel.
9.1.5 Telephone help lines
An information telephone help line for addition prevention is available at the BZgA as
national number for drug-related questions. It is an offer which covers different
subjects and can be reached by a nation-wide telephone number.
Additionally it was tried to organise a unified national number for drug counselling
centres in order to provide secondary prevention 24 hours a day. The number "19237"
can only be reached in Berlin and Nürnberg. A more widespread dissemination failed
until now because most of the drugs counselling centres are not able to offer access
for a minimum of 12 hours daily which was a standard asked for. Unified telephone
help lines at regional level are established in different cities all over Germany, for
example in Munich, Cologne, Düsseldorf, Frankfurt, Berlin and Bremen. These are
regional initiatives which gave up national standards and make individual offers.
These are mainly general information on drug use, misuse and addiction, in a few
cases these telephone help lines are a part of a counselling and care concept. It has to
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be taken into account that of course each drug counselling centre can be reached by
telephone and contacts are often established via phone. Statistical data on telephone
calls for help do not exist at national level. The Berlin drug emergency service
(Drogennotdienst), for example, has presented a set of statistics in 1996 which
showed about 8000 calls per year. About half of them were received outside regular
working hours of drug counselling centres. Telephone help lines apart from normal
counselling services are partially done on honorary basis. In general counsellors at
the telephone get a special training in counselling and conversation and are
supervised.
9.1.6 Mass media campaigns
The mass-media campaigns in Germany are centred on the wide-ranging multimedia
campaign on preventing drugs and addiction, which is operated by the Federal Centre for
Health Education and is made up of a variety of elements. The most important mass-media
elements in the campaign "Make Children Strong" (Kinder stark machen) are several
advertising themes, TV and cinema-spots as well as a travelling exhibition. An evaluation
study of the advertising campaign 'Make Children Strong' showed at the beginnings of the
90ies mainly positive results. For example, the advertising campaign aroused the interest of
another 3 million people, approximately, in the topic of addiction and drugs (Denis et al.
1994). In 1998, after a two year intermission, beside new advertising themes also new TV
spots were produced and its publication continued in 1999. The campaign “No power to
drugs“, which was funded from national budgets was stopped end of 1998. At a poster
advertising activity of the German Sports Association (DSB) and the BZgA the
Fachverband für Außenwerbung (FAW) offered advertising area all through the
country for free.
Concerning the topic “alcohol” the BZgA developed a campaign called “Responsible
Alcohol Use Sets a Limit”. A central element of the campaign is a brochure with tips
and information for a responsible use of alcohol. Also at the Land level there are still
regional focused actions similar to campaigns. For example in Nordrhein-Westfalen since a
couple of years a Land campaign is conducted with regionally organised addiction weeks
under the slogan "addiction always has a history". Other Laender like Schleswig-Holstein
("Once its enough"), Hamburg ("we act before addiction emerges") or Baden-Württemberg
are joining in with posters, TV spots and advertisements to make addiction prevention a topic
of discussion. Bayern and Thüringen have set new accents in 1997 with mass
communications on misuse of alcohol. On the basis of these Laender campaigns in 1999
discussions between the Federal Laender and the Federal Centre for Health Education were
started with the aim to build a common umbrella for mass communication in alcohol
prevention in Germany. In 2000 this lead to some first common activities.
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9.1.7 Internet
With an increasing dissemination and change of daily forms of communication by so-
called “new media” - especially by computer, Email, mobile phones and internet – also
the possibilities of creating and transmitting demand reduction interventions have
grown and changed.
In the field of drug-related care, especially in counselling and treatment centres as
well as in institutions of prevention electronic media play an important role. About
40% of German citizens have access to this medium at the moment, 30% are really
using it (Gruner und Jahr Media- Service: On Screen Band I, Hamburg 2000). It is quite
certain that male individuals with a higher level of education are more than
proportionally using this medium. Systematic improvement in access to and the use
of this medium is strived for by Ministers for Education and the Art and industry
through a program called “Schools to the Net”. Meanwhile 13,000 schools got access
to the net; until the end of 2001 all schools should be connected. Further initiatives,
for example co-operations with the economy aim at a better supply of schools with
needed hardware. There are no systematic and quantitative information on the
institutions´ and associations´ access to the internet. As in the last years technical
facilities have been improved in most centres and the use of computers has been
largely introduced it is estimated that about 30% of all 1,200 addiction and drug
counselling centres registered by the DHS are already represented in the internet.
A random examination of some centres which are represented in the internet showed
that web-sites mainly serve as means of presentation for their work and services as
well as for a tool of information research (e.g. internal search engines, archives,
downloads, collection of links). For interactive contact (E-mail, chat) with clients it is
used less often. However besides information on addiction and drugs there are also
self administered tests which help to evaluate the personal profile of addiction and
respective counselling services. There is large variation in the design of web-sites as
well as in professional quality and recency of information. Small and creative clubs
and self-help groups often have an excellent presentation with high recency of
information and an amazing professional level in the layout of their web-site. The web-
sites of some associations or federal institutions are clearly less attractive. In the web
smaller and larger, public and private, professional and non professional providers
are equally available. There is a much better chance for small initiatives - such as self
help groups or clubs - for public perception. On the other hand there is more
competition for large associations or institutions concerning visibility in public. For
the user it becomes more difficult to evaluate quality and seriousness of the
information provided. If the big efforts are examined which have been made by
commercial enterprises in the last years to establish adequate presence in the web
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considerably increasing resources for this kind of media have to be taken into
account in the next years for organisations in the field of prevention and therapy.
The German Reference Centre for the European Monitoring Centre for Drugs and Drug
Addiction (DBDD) informs its partners by means of a regular distributed newsletter
about focal point activities and new developments on national and international level.
The new established website (www.dbdd.de) is a platform for information
epidemiological data, new developments and the work of the DBDD. Many relevant
institutions from the field of politics, research, prevention and treatment are
connected by hyperlink.
Concerning content and subjects which are communicated via internet in the
framework of drugs and addiction there is an enormous variety which makes it
difficult to keep a general overview. The internet reflects all positions of drug policy
which are also existing in society. Not at least the large variety of offers available in
the web make a systematic collection of links necessary to give more orientation for
seaching information sources. An internet guide is still missing which summarises
and updates the best sites availabe on a certain topic. Also the question of quality
control is important as the user can hardly evaluate the information of a largely
growing number if sites.
The internet gives all providers the opportunity to bring selected contents and
subjects to the public. Many organisations use the medium as an electronic annual
report to show own offers, projects and services. Others use its communicative
possibilities as a new way of interpersonal communication with the target group. At
national level a project has been developed at the BZgA with the aim of getting a direct
contacts by the internet to teenagers at the risk of drug use. Besides the presentation
of information and prevention activities of youth groups and classes direct
counselling should be provided. Local counselling centres (for example in Frankfurt)
also try and test personal counselling via internet. Examples of prevention units
(Präventionsfachstellen) which are using the internet as a communication platform
can be found at www.ginko-ev.de.
9.2 Reduction of drug related harm
9.2.1 Outreach work
Outreach work targets at a low-threshold support of people without requiring a drug
free personal state. By means of these approaches the drug help system is connected
with the reality of drug users. Street-work brings the problems of the drug scene into
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the drug help system and improves the acceptance of professional care by drug
users. Target are to get more and better contacts to drug abusing and drug addicted
persons as well as to intensify support and changes of clients. The targets turn to
persons who stay at public streets or places, sometimes because they are homeless
and cannot make use of care services at all or only to a small extent. Additionally
there is an approach in law politics to destroy open drug scenes if possible and to
send people to specific help centres.
First outreach work was an element of youth help before it was also adapted in drug
help. In general it is oriented towards the open drug scene and is done by
professionals. Approaches of outreach work for example in families or self-help
groups are rare. Major tasks of outreach work are to get in contact with people, to
establish stable relationships, to give social support (care in emergency) crisis
intervention and counselling. Tasks are also care in institutions and the
representation of interests and public relations work.
Recent results of research in this fields are not existing in Germany. From 1987 to
1990 the model project "outreach work for long-term drug addicts" was conducted on
behalf of the Federal Ministry for Health. 907 persons in 17 centres were contacted,
more than half of them in the framework of the main activity "outreach work". A result
of the study was that easier contact to clients could be made by means of outreach
work and a better link to care institutions.
Specific training for professionals in outreach work is not available. Only in Nürnberg
a training for professionals in "accepting drug work" is provided every two or three
years.
9.2.2 Low threshold services
Low threshold services are interventions reaching for harm minimisation. In the last
10 years they were introduced for users of illegal drugs in Germany. They are either
part of drug counselling or treatment centres or an institution of its own. Contact
shops offer food, sanitation facilities, needle exchange, problem oriented counselling
and arrangement of further medical and psycho-social help. In some big cities there
are also places to sleep for homeless drug addicts. Medical care often provided is also
very important. Low threshold services are exclusively provided by facilities of non
profit organisations. In some cities (Berlin, Frankfurt, Hamburg, Munich) regional low
threshold services of several organisations are co-operating. Since the Narcotics Act
was changed it is possible to set up drug consumption rooms for drug addicts in
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which they can use their drugs under hygienic conditions. Certain standards and
guidelines of Land authorities have to be followed. On a total there is only little
research outcome existing on this matter until now.
Target groups of low threshold services are acute drug users. Social contacts are
often missing and there are deficits in housing, education, work, income as well as
physical, social and mental damage as a consequence of long and intensive misuse of
or addition to narcotics. Major aims are to safe life, prevent physical damage, save
social structures of affected people and to maintain and improve physical and mental
health. Based on 1998 numbers there are about 75 facilities providing low threshold
services and about 15 facilities offering places to sleep for drug addicts in Germany.
Low threshold services are a part of the tasks done by the network of drug help
services and are offered by professionals in the framework of their duties.
9.2.3  Prevention of infectious diseases
Measures to prevent infectious diseases such as HIV, hepatitis B and C or
tuberculoses are offered in Germany by low threshold contact services or services for
crisis intervention. Also projects or centres targeting to groups at risk from drugs or
experimenting with drugs often offer services to prevent infectious diseases. Needle
exchange, free condoms and counselling are standard offers made.
Sterile syringes can be bought cheaply in pharmacies. If drug users don’t have money,
the pharmacy is obliged to deliver cost free sterile syringes to them. They can also be
handed out or exchanged at syringe machines or at syringe exchange services of the
AIDS and drug help services. In some German cities general mobile needle exchange
services for intravenous drug users are existing, in Hamburg for example there is a
DROB-INN bus nearby the railway station. Also for the prevention of hepatitis in Germany
measures to prevent infections are offered to drug addicts and persons at risk. Since 1996
for example in Berlin the association Mobilfix/Fixpunkt e.V. conducts hepatitis
education and vaccination for drug users. A “hepatitis mobile" is situated close to a
meeting point of the drug scene. Target groups for hepatitis A and B vaccinations as
well as for counselling are i.v. drug users and clients with a high risk to start i.v. drug
use (e.g. inhalers and smoker of heroin and cocaine). The website www.belgonet.de
has addresses of more than 100 counselling and contact places in over 80 German
cities. The offer is often used as shows the drug emergency service L24 in Munich. In
1999 almost 60,000 new syringes were taken: 29,000 were bought and almost 31.000
were changed.
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The German AIDS-Help give "safer-use" education on risks of i.v. drug use on their
homepage (www.aidshilfe.de/html/service/drogen/spritzen.htm). Different types of
syringes and needles are examined as well as risks of virus, bacteria and mushrooms
in needle and drug sharing, dangers when inserting a needle and emergency
situations. Condoms to prevent sexually transmitted diseases are easy to get for the
group of drug addicts. At local level they are often distributed for free in the
framework of low threshold services. For a small amount of money they are available
in pharmacies, supermarkets or at condom machines in bars or discotheques.
Anonymous AIDS testing was supported by the Federal Ministry for Health for a long
period of time. In many German health centres free HIV testing including additional
counselling is possible. Whereas the "PCR" test makes genetic material of HIV already
visible after two or three days HIV antibodies can only be proofed after about three
months. First the "ELISA" test is used. If the results are positive a further antibody
test is used the so-called "Western-Blot". It can prove antibodies o HIV-1, HIV-2 and
subtypes. Since 1999 HIV tests are part of a medical benefits catalogue of the public
health insurance. The health insurance scheme pay for the tests if there are symptoms
for a HIV-infection. Should the test be made without any of these symptoms it has to
be paid by the tested himself.
Beside these services there are special activities to prevent infectious diseases. For
example INDRO e.V. offers in co-operation with the city of Münster special safer use
material in Russian language for migrants. In a two year model project interventions
for the prevention of infectious diseases were established in two prisons of Lower
Saxony (Meyenberg et al 1999). In Hamburg the first drug consumption room for
female drug users was opened.
9.3 Treatment
9.3.1 Treatment and health care at national level
For addicts who want to cope with their addiction with professional support there is
much help to get out of drug use and there are many therapeutic services available.
According to recent state of knowledge treatment is split into four fundamental
stages:
Ø phase of contact,
Ø phase of detoxification and withdrawal,
Ø phase of rehabilitation,
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Ø phase of further treatment and after care.
This concept plans intensive counselling at a drug counselling or treatment centre at
the beginning of the treatment. There medical, mental and social diagnoses and
anamneses have to be made. Centred around an agreement between professionals
and clients about the help this leads ideally to an individual help plan. All offers of
treatment and health care which are available at regional level are taken into
consideration to select the best interventions. In this context "case management" is
getting more importance. A major goal of the phase of contact is the motivation for
treatment.
In the phase of detoxification and withdrawal the "qualified withdrawal" is increasingly
preferred by professionals. A multi-professional team works already in the stage of
detoxification on different aspects of addiction. Part of this intensive medical, psycho-
social and therapeutical care are informational and motivational units for group
therapy. They help to continue the motivational work from  the stage of contact during
detoxification. The phase of detoxification and withdrawal can take two to six weeks
depending on each single case. In Germany it is mainly done in inpatient treatment
centres.
During the phase of rehabilitation the abstinence which was reached by detoxification
should be stabilised and addiction should be finished in the long term. Rehabilitation
can be out-patient, partial inpatient or inpatient. For drug addicts an average
rehabilitation of six months is planned. Inpatient rehabilitation is usually done in
special clinics, therapeutical communities or specialised units of psychiatric
hospitals. There are special inpatient services for women, parents and children,
minors or migrants. Individual or group therapeutical offers, work therapy, sports and
creative offers are in the centre of treatment.
Besides offers described in paragraph 9.5 the phase of further treatment and after
care refers in drug addiction treatment mainly to the phase of adaptation. In this phase
individual therapeutical applications are reduced in order to improve the orientation
towards integration, work and society which are outside of treatment.
One of the main standards in drug addiction treatment is the co-operation of different
professions from social work/pedagogic, psychology and medicine. Holders of
centres or the Federal Laender or communities are responsible for quality
management and professional supervision of out-patient services. For detoxification
and withdrawal the respective funding authorities have the responsibility. Important
treatment offers are also described in the field of substitution (see 9.4.2.).
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Addiction treatment is aiming at a drug free life, but in professional discussion a
hierarchy of goals developed which allows different steps on this way. At least in the
contact phase it is necessary for clients to control their drug use in order to be able to
participate actively. Withdrawal treatment is only offered drug free but drug relapses
are increasingly used to work out individual problems and not lead to discharge.
In Germany drug help reaches a high percentage of addicts and has a focus on
substitution. There are more than 300 specialised drug treatment and counselling
centres, more than 1,600 slots for detoxification and about 4,900 for withdrawal
treatment (Länderkurzbericht 1999). Further counselling centres are available for drug
related and other problems. About 1,000 out-patient rehabilitations are granted each
year but about 20% of them are not started.
Services to get out of drug use and therapy are offered by an associated system of
services, most of the institutions are non-profit holders. There is a further level of
networking at the Federal Laender. It contains the connection of public health
institutions with local doctors.
Services to help stopping drug use and therapy are mainly funded by public budgets.
It has to be taken into consideration that about one third of the costs in out-patient
centres have to be paid by the organisations´ holders themselves. With the exception
of out-patient therapeutic treatment out-patient drug care is paid to a large extent by
Laender and communities on a voluntary basis. There is no legal demand for this
support. Institutions have to accept annual funding, too. Public health insurances are
responsible for the phase of detoxification and withdrawal. Public pension insurances
are in the competence of rehabilitations, which is funding medical rehabilitation to re-
establish the ability to work. Public pension insurances determine method, scope and
duration of treatment. For further treatment and after care there is no legal basis for
funding except in certain cases. Holders of institutions depend on individual models
of funding.
9.3.2 Substitution and maintenance programmes
Until the beginning of the eighties it was only in isolated cases possible to use substitution
substances for the treatment of drug addicts in Germany. General practitioners did not
participate in the treatment of drug addiction apart from emergency cases, secondary
diseases and the prescription of substitution substances from time to time. Since about 1985,
however, this group was included first through prescription of legal substitutes of opiates
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(e.g. codeine and Dihydrocodeine). Since the amendment of the Narcotics Law (BtmG) and
the adaptation of decree on the prescription of narcotics (BtmVV) in 1992 this group was very
much involved in addiction treatment through methadone substitution. Since the beginning of
1998 drug addicts in Germany exceptionally can be treated with codeine and dihydrocodeine
as a substitute in specific medical cases. The Third Amendment of the Narcotic Law (3.
BtMG-ÄndG) passed on 28th of February helps now to regulate substitution more
detailed by means of decrees. It also includes a register for substituted clients. The
aim is to combat multiple prescriptions by several doctors as well as an increasing
availability of methadone on the black market. The so-called "central substitution
register" will be established at the Federal Institute for Drugs and Medical Devices
(BfArM). A decree - which is still missing - has to regulate all details, i.e. which
substances have to be registered, how often do they have to be reported and how data
should to be processed.
As this is paid by the health insurance in principle, there exist additional regulations from the
national committee of the Medical doctors and the health insurance which define the
prerequisites for the funding of substitution (AUB regulations, latest changes in June 1999).
The regulation is based on a differentiated determination of indication which allows to settle
accounts with the health insurance only for certain indications. If substitution is paid for by
Land programmes or private prescriptions of General practitioners are used, the AUB
regulations do no apply. Beside the general practitioners in Germany especially in the cities
(e.g. Berlin, Frankfurt, Hanover, Köln) substitution ambulatories and other specialised
facilities are existing. They are embedded in the regional therapeutic service. Within the
ambulatories medical doctors, psychologists and social workers are working closely together
implementing a substitution concept. Compared to substitution offered within a doctor’s office
some structural and therapeutic advances are given, especially in relation to psychosocial
aspects of treatment.
There is a general agreement between experts, that substitution has to be linked to
psychosocial care and treatment. This is seen as an integrative part of this specific treatment
offer. Also AUB regulations and the regulations of the BtMVV require accompanying
psychosocial care. The costs of psychosocial care are not accepted as minimum social
security benefit because substitution treatment is not seen as a causal therapy of drug
addiction. Therefore substitution treatment in reality also takes place without psychosocial
support of clients. Substitution treatment within the compound system of drug care is building
a bridge to health and psychosocial stabilisation, but also towards the acceptance of  further
help to get away from the drug scene and the drug binding on mid or long term. It increases
access to groups of clients, who had no contact to the help system till then or who had
broken contact long before and in this way improves survival during phases of acute drug
addiction. In parallel the health status of the long term addicts is stabilised and somatic
damages as a consequence of heroin use are avoided. Important aims are also the
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protection of the social situation of the person through measures to preserve the flat, the job
and the support of family structures as well as parallel activities to avoid social disintegration.
As substitution also makes longer phases of abstinence possible it can help the drug addicts
to get insight into his basic disease and to accept his need for treatment. This should be
followed by out-patient, semi-inpatient or in-patient interventions.
The number of clients under substitution in Germany cannot be derived directly as adequate
documentation systems are missing. The Central Institute of Panel Doctors (ZI) in 1998 has
reported about 20,900 patients treated with methadone (census) paid by public pension
insurances. The results of a new study will be available from the beginning of 2001
onwards. Total estimates on the basis of levomethadone, methadone and dihydrocodeine
delivered through public pharmacies are more than twice as high (Bühringer & Künzel 1997).
9.4 After-care and re-integration
9.4.1 Organisation and access
In Germany after-care and re-integration are both financed only to a small extent by
Laender, communities or holders of social security. Funding is not based on the
Social Law. This is the reason why there are about 150 mainly non profit holders of
organisations with a large variety of after-care and re-integration services depending
on regional necessities and circumstances. Re-integration offers have developed at a
large scale during the last years. They are no longer the last link in the chain of
treatment but have to be offered in each phase of the treatment process. That means
that services have to be available and accessible for drug users, substituted persons,
during and after medical rehabilitation and as well after the stage of contact.
Given the fact that about 80% of drug addicts are unemployed, about 50% don't have
any professional training, about 60 to 70% have no sufficient school education and
about 20% do not have stable housing there are diverse areas of responsibilities. It
has to be taken into consideration that the development of drug addiction was often
accompanied by school or job failure, therefore qualification in this specific area is
absolutely necessary in treatment of drug addiction. Facing about 60,000 treated drug
addicts per year at least 30,000 offers in the field of re-integration should be available.
In fact existing services in the field of occupation/qualification can reach about 1,500
persons, in the field of education about 300 persons, in the field of housing about
2,000 persons and in the field of culture (theatre, music, arts etc.) about 200 persons
at best.
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9.4.2 Education and training
Viewing deficits of drug addicts in the job situation, long time of unemployment during
their professional career, a lack in school education and the missing of job training
education and training are major factors in their re-integration. In some places there
are school projects where b- and c-levels can be made. Further projects in which job
training can be started are widely available. There is a close co-operation with trade
and industry which makes special institutions of the drug help system often not
necessary. Training is offered to learn key qualifications such as endurance, power of
concentration, sense of responsibility, critical faculty. Among those are school and
job interventions which meet the demands of the labour market,  for example
application training, interventions for qualification, job and occupational projects as
well as practical training in business of the normal labour market. It is not possible to
quantify those interventions. In the field of occupational re-integration day structuring
interventions are especially important. Work and useful occupation help drug addicts
to structure their day. Those interventions give new possibilities to start a
professional and social re-integration. To be confronted with everyday's reality
improves social competence, establishes social relationships and leads to an
independent way of life without any help. Means of day structuring are for example
work therapy, occupational therapy and work and occupation projects.
9.4.3 Employment
Work and occupation projects are part of the drug help system. They offer diverse
possibilities to get gradually used to work and work processes up to full employment.
After those projects the chance of affected persons to get re-integrated into the labour
market or to get further reaching training or re-education becomes more realistic. As
work and occupation projects cannot be done by generic drug care services they have
become an independent field of professional work within the drug help system. Drug
care holds a large variety of enterprises and interventions but exclusively on regional
level.
9.4.4 Housing
Accompanied housing is the major intervention of social re-integration. It is a
superordinate term for different forms of support for housing in drug care. It aims at
stabilising, orientation and crisis intervention after inpatient treatment. Substituted
and abstinent people still needing support can be offered accompanied housing.
People in accompanied housing need regular but not permanent help of professionals.
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9.5 Interventions in the criminal justice system
The prosecution statistics of the Federal Statistical Office (Statistisches Bundesamt,
StBA) shows that about 11% of all offences 21 to 30 year old men were prosecuted for
in 1998 were offences against the Narcotic Law (Federal Statistical Office). In prisons
drug-related problems are according to existing estimates even more frequent. As part
of a multi centre field study in seven European countries the percentage of i.v. drug
users was estimated 40% in a Cologne prison (Weilandt & Rotily 1998). Küfner, Beloch,
Scharfenberg & Türk (2000) evaluated counselling offered by externals to prison inmates
with addiction or at risk of addiction. In this study the heads of 33 bavarian prisons estimated,
that from all prisoners with addiction problems one third shows drug problems while
tow thirds have an alcohol problem. Often there are problems of withdrawal among
inmates addicted to drugs as well as multiple addiction or a coexisting mental illness.
The risk to get infectious diseases such as HIV, Hepatitis B or C or tuberculosis is
increasing when sterile syringes are not available and therefore drug and needles are
shared. Drug trafficking within the prisons has become a very critical problems by now for all
concerned and is far more brutal. In general personal resources in prisons are limited.
Therefore special counselling through outside organisations has since become a common
form of drug services in the penal institutions. The appropriate workers are based at various
drug treatment centres in the relevant regions, and the aim of their work is generally the
building up bridges to the outside therapeutic services in accordance with section 35ff
Narcotics Act. During the period of imprisonment they offer psychosocial support. The follow-
up services after outtake are extremely important, particularly in view of the fact that some
drug addicts do not make their first contact with the support system until they go to prison.
Since the beginning of the 1990s methadone substitution has become established in the
prisons. This was initially recognised as a procedure for those already on substitution before
entering prison, and has since partly been extended to drug addicts who have not taken
substitutes earlier. From 1996 to 1998 a model project was carried out in Lower Saxony
prisons. Prevention oriented information and training was given to drug addicted inmates,
additionally they had the possibility to exchange syringes. A final report of the model
project is already available (Meyenberg, Stöver, Jacob & Pospeschill 1999).
In 1998 a European conference to "prisons and drugs" was taking place. Drug free
treatment, substitution, needle-exchange programs and peer support in prisons were
part of the professional discussion. The necessity of training and events providing
information on drugs and drug-related health problems for prison staff and inmates
was considered especially important. At the University of Oldenburg a manual with
modules for such a training is worked out: It should inform on treatment and services
for drug addicted prisoners of drug help, on infectious diseases as well as on risk
minimising interventions.
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9.6 Specific targets and settings
9.6.1 Self-help groups
Within the field of drug help in Germany there is a variety of self help groups. As only a small
number of them have united to national associations or are belonging to Narcotics
Anonymous no information can be given about the number of groups and participants.
“Release” groups which started as self-help groups today are mainly working professionally.
Big holders of self-help are still “Synanon” (Berlin and Schmerzwitz), “Elrond” (Bremen and
Osnabrück), “Suchthilfe Fleckenbühl” (Cölbe) and “Almedro” (Berlin). Within AIDS help the
self-help groups have united into „JES“ (Junkies, Ex-Users, Persons under substitution).
Often self-help groups are also built up with professional guidance through drug help
facilities. Recently there is an increasing interest of health policy in self-help which is also
fostered by financial limitations of the public budgets.
9.6.2 Gender-specific issues
The orientation of many of the programmes, measures or systems described earlier takes
account of specifically gender-related aspects not as much as it would be asked for. For this
reason in Germany a group of about 15 facilities has been set up, which offer services
exclusively for women mostly following feministic concepts. An important starting point for
these facilities is the situation, that women in mixed facilities - where they most often are
under represented - cannot sufficiently tackle their specific experiences from their drug
history. Offers specially targeted towards women also can be found in in-patient treatment
facilities. Almost every city also has special counselling services for girls who are addicts or
at risk of addiction (such as the Kajal project from Hamburg). Recently, special services have
also come into being for drug-addicted female prostitutes, in the low-threshold field and close
to the drugs scene. Besides many psychosocial services and practical assistance for
everyday living (needle exchange, issue of condoms, etc.) these centres also offer specific
overnight projects in recognition of the fact that most prostitutes work into the morning hours
and therefore need different sleeping times from those offered in normal emergency
accommodation. Many of these specialised centres mentioned are also actively engaged
beside psycho-social counselling in the framework of opinion-formers activities and to this
end advise and support educators, teachers and social worker in their work with women and
girls who are addicts or at risk of becoming addicted. Also in the area of prevention many of
the programmes, measures and activities described above are considering gender-specific
aspects. So-called "prostitute projects" exist for example in Berlin (Hydra e.V.) and in
Bochum (Madonna e.V.). The homepage of the self-help project HWG in Frankfurt
educates prostitutes in cocaine and crack use and gives information on health risks
and safer use.
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9.6.3 Children of drug users
A not inconsiderable proportion of addicts have children of their own to care for, both in the
phase of active addiction and after treatment has ended. These children often find it difficult
to lead a normal childhood. Their everyday life lacks the basic essentials and the necessary
stability in their material and emotional environment. Moreover, in their own milieu they are at
special risk of being stigmatised and disadvantaged. Frequently, there is the threat that the
children are brought up by strangers, outside their own family. With such a background, it is
necessary to construct a special support system for these children and their parents.
Nationally, there are only very few special services in out-patient care. In in-patient  care
there are about 20 treatment facilities which take in children together with their drug addicted
parents. Some of them, e.g. in Ingenheim (Therapiezentrum Villa Maria), Lüneburg
(Therapeutische Gemeinschaft Wilschenbruch) or Obersulm (Therapiezentrum Friedrichshof)
have developed special facilities for children, which take care of the support of the children
within the normal system (kindergarten, school). Some of these facilities are acknowledged
by the law on children and youth welfare (Kinder- und Jugendhilfegesetzt KJHG). The
funding of the childrens´ stay is still not adequately solved.
9.6.4 Parents of drug users
Counselling and help for parents of drug users is the responsibility of the out-patient
counselling and treatment centres in the first place. About one out of 10 interventions of
these facilities is targeted towards relatives. Self-help groups of parents (Elternkreise) have
united into national associations of parent groups (“Bundesverband der Elternkreise“,
“Elternkreisen für akzeptierende Drogenarbeit“). These groups are often supported by
professional facilities. In these self-help groups the main stress is on exchanging
experiences and giving support in coping with the children's drug addiction. In some cases,
more formally organised relatives' groups (such as registered associations) grow out of the
self-help initiatives, which also look outwards through their own services of individual
counselling, group services, crisis interventions, public relations and information and take
influence on drug policy respectively.
9.6.5 Ethnic minorities
During the last two to three years problems associated with drugs and addiction
among foreign citizens became more and more a topic of interest in Germany. Yet
distinctions have to be made between different groups of immigrants. Since the 1950s
so called foreign workers came to Germany mainly from countries of Southern
Europe. Some families already live here for three generations, younger family
members were born and grown up in Germany. Other children of foreign workers grew
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up in their home country and came here later in the framework of the principle of
allowing families to be united. According to estimates of the DHS approximately 3.7
million emigrants from Eastern and Southern European countries have been taken up
from mid of the 1950s to mid of the 1990s. Today most of the late emigrants come
from republics of the former Soviet Union. Over and above that there are refugees (e.g.
from former Yugoslavia) and persons seeking asylum (e.g. from Africa or Kurds from
Turkey).
Despite the fact that the group of migrants is very heterogeneous, for many foreigners
immigration is associated with similar problems of integration: Farewell from family
members and friends in the country of origin, language difficulties, unemployment,
crowded living conditions, social isolation, partly wrong expectations concerning the
new life in Germany. Especially young foreigners often have additional problems in
school or education and suffer from a lack of perspectives and idols. Increasing
consumption of alcohol, drugs or legal medicines may be an attempt, to cope with
severe problems of migration. A survey carried out by the umbrella organisation of
chartities of the Land of Baden-Württemberg among their associations came to the
result, that services specialised in migrats estimated approximately 15 percent of their
clients to be addicts. This is five times as much as the average of the general
population (Landesstelle gegen die Suchtgefahren Baden-Württemberg 1997).
In Nürnberg "mudra", a social and rehabilitation service for drug addicts, offers a
special treatment service for clients from the Middle Eastern area. Employees who are
native Turkish and German speakers have an understanding of therapy with a special
acknowledgement to this cultural background: The menus are orientated towards the
Middle Eastern cooking, Islamic feasts are celebrated and Turkish newspapers are
available. Recently an increase of drug users among Russian immigrants with a
German ethnical background can be observed. These emigrants, who are partly very
young, often form subgroups outside the public drug scene and can hardly be
reached by standard help offers.
In 1999 the two years pilot project "Outreaching, community-based, psycho-social
company/ care of drug users from Russia with a German ethnical background“
("Aufsuchende, stadtteilorientierte, psychosoziale Begleitung/Betreuung von
russlanddeutschen Drogenkonsumenten") has been launched in Münster. It is funded
by the City of Münster and carried out by Indro e.V. It aims at finding access to
Russian drug users with a German ethnical background, improvement of their psycho-
social and health situation and improving their integration into the existing help
system. Measures taken have been production and dissemination of information
material concerning safer-use in Russian language. Employees who are able to speak
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Russian offer psycho-social support and assist in arranging detoxification,
substitution treatment and therapy.
Currently in Belgium, Germany and Italy the pilot project "Race - Drugs - Europe" is
carried out, dealing with the inclusion of so called "visible minorities“ in drug care and
drug policy. The project is co-ordinated by the University of Middlesex, the European
city-network "European Cities on Drug Policy" (ECDP) is the German responsible. In a
first pilot phase a qualitative analysis and evaluation of the work of specialised drug
services in Germany, Belgium and Italy have been conducted. These three countries
have been chosen because visible minorities of considerable large size live in the
respective countries. The German focus of interest was the city of Frankfurt as a
community with a very high percentage of foreigners. Making use of interviews carried
out with employees of drug services as well as with clients profiles of treatment
centres and needs of clients were identified. So called "Action Points for Change"
have been developed to assist drug treatment services in conceptualising new
integrative approaches and to test whether by this the offer for certain minorities can
be improved. In the framework of a further project dealing with social exclusion of
minorities on behalf of the European Monitoring Centre for Drugs and Drug Addiction
(EMCDDA) information concerning social exclusion of ethnic minorities in the drug
area in the 15 EU Member States are currently collected and evaluated. So far the
impression emerges that information is very rare in most of the EU Member States.
10 Quality assurance
10.1 Quality assurance procedures
By a revised version of the Code of Social Law V quality assurance became a legal
basis of therapeutic and preventive work in the whole field of medicine. The demand
for realising health benefits at minimal costs lead to several requirements and
developments also in the field of drug prevention and treatment. Some of them are
specific for this area, others concern this as well as other areas of work dealing with
psychic problems.
In the field of treatment
Among treatment centres especially inpatient treatment centres are comprehensively
integrated into programmes of quality assurance which have been initialised by
pension and health insurances. Because these bodies responsible fund the majority of
treatments they define the standards in fact. Among others this includes surveys
among patients concerning their satisfaction, an examination of the clinic’s concept
and its equipment and the standard realisation of treatment. Quality circles consisting
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of therapists of comparable treatment centres are established for supervision and the
handling is examined in single cases. Recently similar models are also discussed in
the field of prevention, currently a reader dealing with quality assurance in health
promotion and prevention is under preparation on behalf of the Federal Centre for
Health Education (FCHE; BZgA). Clustering of clinics which are comparable in clients
and aims should also enable benchmarking. During the last years many clinics
underwent certification procedures concerning quality assurance (ISO 9000f, EFQM
etc.).
Services to become abstinent from drugs and therapy are comprehensively
documented by respective clinics. At federal level several different monitoring
systems based on "core items sets“ as defined by the German Council on Addiction
Problems ensure comparable statistics. However, it is still difficult to pool these data
because there is no obligation for documentation. Due to this the national report is
nearly exclusively based on one single system (EBIS). All existing monitoring systems
restricted themselves to statistical data collection. Documentation of the course of
treatment, which describe help offers and allow more detailed analyses and
statements, are under development and will only gradually be accepted due to the
demanding and more comprehensive system. Also follow-up studies are only carried
out unsystematically and not exhaustively. Due to this the data availability is still
unsatisfying.
In the field of prevention
Due to the federal structure and the subsidiary principle in the German health system
it can not be spoken about unified formal requirements or criteria for quality
assurance of measures for demand reduction despite some efforts in the field of
prevention have been made. Moreover there is a variety of concepts, methods and
instruments which are used here. For example the Federal Centre for Health Education
(FCHE; BZgA) bases its planing, realisation and evaluation of efficacy and effectively
of its work on results of representative surveys among the general population,
scientific projects dealing with special topics and evaluation studies. To support
exchange of information and experience between science and practice the FCHE
organises national and international conferences. Over and above that it holds a
brochure, in which studies, expertises and results of expert conferences are
published. Basis of the way the Federal Centre for Health Education (FCHE) sees
quality assurance is the concept of continuous improvement of work processes and
results and by this of efficacy and effectivity of drug prevention. In this concept
evaluation as an instrument of quality assurance plays an important role (see Fachheft
8: "Evaluation - ein Instrument zur Qualitätssicherung in der Gesundheitsförderung").
Also on Laender level several measures exist in this context (publications about
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quality management, quality circles, etc.). However, big differences with regard to
available resources can be found.
Starting point of the process of quality assurance is the planning of new or evaluation
and further development of existing measures and campaigns based on actual
scientific knowledge. This knowledge is developed through e.g. literature expertise,
scientific conferences and representative surveys. Beside a youth survey which is
conducted regularly ("Drug Affinity Study") especially the "Representative Survey on
the Use of psychoactive Substances of adults in Germany" carried out by the Institute
for Therapy Research (IFT) on behalf of the Federal Ministry for Health is a central
source of information. But also studies focusing on local level as in the Land Bayern
(Wittchen et al. 1998) or in Nordrhein-Westfalia (Hurrelmann et al. 1998) are important
information resources. Over and above that regular scientific analyses of important
questions concerning drug prevention take place in the framework of the brochure
"Forschung und Praxis der Gesundheitsförderung“ ("Science and practice of health
promotion“) held by the Federal Centre for Health Education (FCHE), e.g. dealing with
topics like "Geschlechtsbezogene Suchtprävention“ ("Gender-related drug
prevention“), "Prävention durch Angst? Stand der Furchtappellforschung“
("Prevention by fear? State of the art of fear-oriented research“) (Volume 2 and 4,
1998) or "Schutz oder Risiko? Familienumwelten im Spiegel der Kommunikation
zwischen Eltern und ihren Kindern“ ("Prevention or risk? Environment of families in
the mirror of communication between parents and their children“) (Volume 11, 2000).
Results of this planning phase is a concept, that lays down, how which aims measures
should be reached in which target group by making use of which instruments or. This
concept is the central basis for planning the evaluation.
The next step is to identify already available instruments. Overviews on markets allow
to identify already existing media and activities (e.g. "Printmedien über illegale
Drogen"; "Printmedia about illegal drugs“) and it can be tested, if these instruments
can be taken over. Central and new media should be evaluated in pretest before they
are regularly used, because only this allows to identify, whether they may become
effective with regard to the conceptualisation. Currently the Federal Centre for Health
Education (FCHE) develops semi standardised instruments to allow systematic
comparisons ("benchmarking") between different media (e.g. advertisements, spots in
TV or cinemas). To examine, if the target group of drug prevention is really reached by
these measures, i.e. if requirements for preventive effects are given, if they are
functional and if different effects exist, further evaluation studies are needed.
Depending on intervention strategy and setting different strategies are needed. On the
one hand the Federal Centre for Health Education (FCHE) makes use of regular and
representative surveys to observe indicators for the judgement of intervention effects.
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On the other hand setting-oriented evaluation studies are conducted (e.g. concerning
further education dealing with "drug prevention“ for sports club trainers).
Results of evaluation studies are conveyed to political decision makers, co-operation
partners and the public. Fast feed-back of results to experts involved in planning and
practice of drug prevention is of special interest. By this these results can
immediately be used in drug prevention ("continuous improvement“).
10.2  Evaluation
In the field of treatment
In the framework of routine quality assurance treatment is continuously observed by
funding agencies. Beside these smaller or larger evaluation studies dealing with
certain methods or groups of persons are conducted. Regularly this takes place in the
framework of pilot projects. Regular follow-up studies can only be found in single
clinics, in the out-patient setting such studies are very rare. Programmes and systems
for treatment documentation partly include respective modules, partly these modules
are under development.
In the field of prevention
At the beginning of the 90s (see Künzel-Böhmer 1993, Denis et al. 1994) the number of
evaluated preventive measures in Germany increased considerably. In particular, the
school programme of the special research area 227 (“Prevention and Intervention in
Childhood and Youth”, Hurrelmann), and similar projects from the University of Leipzig
(Petermann) and the IFT are scientifically supported by comprehensive progress evaluation,
which can be expected to provide data on the effects of the various methods of intervention.
There are also some empirically-based intermediate findings on the efficacy of individual
nursery school programmes (see project HAGE). There is also some work on assessing the
area of information-based preventive measures. Aspects of the campaign "Kinder stark
machen“ ("Make Children Strong“) have already been evaluated at different times,
resulting in a more positive state of knowledge in this area.
In 1998 the Institute for Therapy Research (IFT) developed the Manual for the
Evaluation of Measures dealing with Addiction Prevention ("Handbuch für die
Evaluation von Maßnahmen zur Suchtprävention“) on behalf of the EMCDDA.
Additionally several expert meetings and workshops on evaluation and quality control and
quality management took place during the reporting period. At the end of 1997 in the
Laender a ongoing process was started to develop concepts and instruments for evaluation
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purposes, which are expected medium-term to guide practical work and to offer detailed
information for policy makers.
Documentation of demand reduction measures is non-uniform. In the field of services
for drug addicts the facility-based documentation systems EBIS (out-patient treatment
centres) and SEDOS (inpatient treatment centres) are used since several years. In
both systems information about the respective treatment facility like type of centre
and offers, structure of employees and data about the clients in the areas case
history, socio-demographic information and diagnoses are registered. Additional
regional systems based on the computer programme HORIZONT are used e.g. in
Schleswig-Holstein and Nordrhein-Westfalen. The common basis is defined in the
"German Core Item Set“ (Deutscher Kerndatensatz). In the area of prevention several
documentation systems are currently under development or already used by several
agencies. Following the federal structure of the German health system this
development takes place on level of the individual Laender. By means of an initiative the
“Badischer Landesverband gegen die Suchtgefahren (BVL)” for example developed a
prevention documentation system for its members, which should also be able to control the
quality of activities. Similar efforts were made in other Federal Laender as well (Nordrhein-
Westfalen, Rheinland-Pfalz etc.). For purposes of information and experience exchange
a national working-group has been established in 2000. The Federal Criminal Police
Office (BKA) holds a project database for the area of criminal prevention ("Infopool
Prävention") which among others also includes the topics "drugs/ addiction“. The
process of improved documentation of prevention practice and quality ensurance
oriented evaluation, is backed up on national level by the establishment of the
EDDRA-programme which is located in the German Focal Point and run by the Federal
Centre for Health Education (FCHE).
The already mentioned secondary analysis of specific criteria of effective drug
prevention by Künzel-Böhmer et al. (1993) resp. Denis (1994) which became directive
for many drug preventive activities in Germany and served as basis for the Federal
Centre for Health Education (FCHE) campaign "Make Children Strong" ("Kinder stark
machen“) may serve as an example for making use of evaluation results when
planning, initialising and conducting measures for drug demand reduction. An
important results was, that especially long-term oriented programmes running for
several years are much more effective than single short-time activities. The
programme should centre around development of behaviour skills and the promotion
of attitudes against drug misuse instead of pure information exchange. There are also
integrated programmes, which are independent from age and consist of substance-
specific as well as substance-unspecific parts. Prevention measures should begin as
early as possible in the life of children and youngsters. The main emphasis should be
put on strengthening and promotion of life skills. Following these results an expert
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conference wastaking place dealing with further conceptual development of the
Federal Centre for Health Education (FCHE) drug prevention campaigns.
In general, the situation of research into preventive intervention has improved. However,
despite promising developments on the part of many responsible bodies it has to be
acknowledged that further support is needed. As already mentioned, the Federal Centre
for Health Education (FCHE) considers evaluation primarily to be an instrument for
quality assurance aiming at improvement of efficacy and effectivity of drug
prevention.
10.3 Research
A recent overview on the most import focuses of research including planned budget is not
available from the main organisations which support research at the national level. The
research project “Addiction” of the Federal Ministry for Education and Research (BMBF) is
finished at the end of the year 1999. It will be continued in 2001 targeting towards topics of
the improvement of services.
Currently among others the following research projects take place: A multi centre
study dealing with appetising effects of cannabis extracts among anorexia/cachexia in
an advanced tumour stadium is under preparation at the European Institute for
Oncology and Immunology Research (Europäisches Institut für onkologische und
immunologische Forschung) in Berlin (http://www.eifoi.de) since four years. Since
November 1999 the study is running in nine university clinics (Bonn, Berlin, Bern,
Halle, Darmstadt, Regensburg and St. Gallen). In altogether 30 centres (inter alia in
Austria and the Netherlands) 445 patients shall be recruited during a 18 months
period. The study design controls for placebo effects, it is double-blind and
randomised. For 12 weeks patients receive 2,5 mg Delta-9-Tetrahyydrocannabinol
twice a day, a standardised natural cannabis extract resp. placebo. Because
cannabinoides come under the narcotic law, the Federal Opium Agency grants an
exception for each individual client. Appetite, sickness, bodyweight, mood,
immunology parameters and side-effects are controlled in regular intervals. A final
analysis is expected at the end of 2001.
Use of active substances of cannabis is currently tested among patients with cardio-
vascular diseases. The science project is funded by the German Research Association
(Deutsche Forschungsgesellschaft).
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A large project on heroin prescription is expected to start in 2001. It is funded by the
federal government and will be carried out in several cities of Germany. Currently the
second phase of surveying the project is finished.
The mentioned studies are only a small selection of running projects, which seem to
be of special interest in this area.
10.4 Training for professionals
In the field of treatment
Depending on the respective occupational group different offers of further training are
made for medical and non-medical therapists of drug addicts after their basic
education is finished. In the area of medical education some specific drug related
topics have recently been included in the regular curriculum. Beside this several
offers for further training are made by professional associations of different
occupational groups. Some of these offers are requirements for carrying out
substitution measures. Since its 10th amendment the narcotic law contains clear
statements concerning required qualifications of professionals working in substitution
treatment.
In the field of prevention
By a growing role of quality assurance and quality promotion in the field of demand
reduction measures the need of respectively qualified experts is growing. Existing
education and training offers mainly differ concerning the specification of taught
contents (specific in the trade vs. universal) and target groups. Consultancy agencies
e.g. offer training seminars and further education dealing with general aspects of
quality promotion, referring to the economy as well as the non—profit field. An
important reference point in most of these trainings is the world-wide standard ISO
9000 f. The definition of quality as it is related to this standard ("Quality is what fits the
requirements“) is universal and not restricted to certain areas. In the university field
several trainings exist (psychology, social sciences, economy) containing lessons
dealing with "quality assurance“.
The Federal Centre for Health Education (FCHE) runs a training course with the title
"Introduction in Quality Promotion“, aiming at professionals working in the area of
health promotion and prevention. Beside an overview on used strategies of quality
promotion mainly the connection to ones own work should be stressed. In the
framework of a pilot project funded by the Federal Centre for Health Education (FCHE)
a concept of quality circles that has been proved good in out-patient medical
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treatment has been tested in several areas of health promotion. This project has had
the aim, to develop requirements for a general implementation of the concept.
With the introduction of the EDDRA programme in Germany qualification of
responsibles for project upholders of measures in the field of documentation and
quality assurance should be reached. Beside giving advice of how to enter data into
the EDDRA questionnaire the Federal Centre for Health Education (FCHE), which is
responsible for the project within the German Focal Point, information seminars are
offered dealing with "Documentation of Projects and Quality Assurance like for
instance the European information system EDDRA“. The overall picture of the training
field is heterogeneous. The common denominator of all offers is the basic idea of
continuous improvement of quality (working structures, contents and/ or processes)
by using the principles of "feed-back“ and "change“ resp. "assimilation“.
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11 Conclusions: future trends
The main approach of how to deal with drug problems, did not change. By combining
preventive, therapeutic and repressive measures drug use should be avoided as good
as possible, its consequences should be minimised. The main focus aims at help and
support, however, law enforcement is still important. The main point of emphasis in
political activities points out that existing help offers - e.g. leading to heroin
prescription for certain sub-groups - should be supplemented. To improve the
effectivity of public funding the co-operation between drug field and standard systems
of public help (e.g. youth-oriented help, help for unemployed) is further developed and
supported. Concerning all psychoactive substances a rational point of view which is
also based on medical and epidemiological findings becomes more and more evident,
weighing between risks and benefits of individual substances.
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PART IV KEY ISSUES
12 Drug Strategies in European Union Member States
12.1 National policies and strategies
In 1998 governmental responsibilities passed from a christian-liberal to a
socialdemocratic-green coalition. In this framework the office of the Federal
Government's Drug Commissioner was moved to the Ministry for Health which was in
line with the new government’s concept to give more weight to prevention, psycho-
social and medical care for drug addicts compared to law enforcement. this can also
be seen in the actions taken in the area of addiction and drugs by the Federal
government.
The 1999 report on drugs and addictions, which was published by the Drug
Commissioner of the Federal Government is focussing on several aspects
1. Prevention
Preventive measures are focussed on the use of illegal psychotropic substances, but
should increasingly cover misuse of alcohol and tobacco in future. “Health
promotion” and “strengthening of life skills” are in the focus of activities targeted
primarily towards children, adolescents and young adults.
2. Further development of services, especially for target groups not reached until
now
A differentiated system of addiction care should offer each addict individualised help
on the basis of his psychological, physical and social situation. Access should be as
easy as possible, the services for the drug addict should cover the whole range from
help for dropout to low threshold offers aiming at harm reduction and help to survive.
Gaps are seen especially in the field of low threshold activities, where for example
heroin addicts are not reached sufficiently by the service provided including
substitution.
3. Quality insurance
The Federal government aims to strengthen addiction care oriented towards efficiency
and quality. This should secure high quality services in all areas of help and support
despite the increasing financial pressure.
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In December 1999 a new Commission on Drugs and Addiction was convened by the
Ministry for Health. The group is composed from 14 experts from psychology,
medicine, social science and law, a representative from the persons concerned  and a
journalist. A central task for this group is to collaborate on the development of a new
national drug action plan. The national strategy, which at the moment is merely visible
in the focus of work and single projects will become according to the plan more
formalised in near future.
12.2 Application of national strategies and policies
The application of the described political aims and strategies can be seen in funding
as well as in the focus of work in legal and other aspects of drug problems.
ad 1: Prevention
The Commission for Drugs and Addiction, composed by the new Federal Government
of exerts from different areas of research and practice was asked as one of its first
tasks to help developing an innovative concept for prevention. The group in this way
is expected to deliver an important input  for the implementation of the political aims
in the coming years.
ad 2: Further development of help provided
In Germany there is already a rather differentiated offer of services for drug addicts
and drug users. The increase in substitution treatment in the 90s has considerably
enlarged low threshold services offered. In the meanwhile also a legal framework for
the installation of rooms for drug use has been installed and legal problems around
syringe exchange have been solved.
A special focus of work for the coming years will be those heroin addicts which are
not yet reached by substitution treatment offers. The planned study on heroin
prescription is on one hand planned as a medicament trial which is the precondition to
licence heroin as a medicament. On the other side a number of preconditions have
been formulated to evaluate the effect of this service offer on the health, psychological
and social situation of the subjects as well as its effects on the drug scene in the
participating cities.
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ad 3: Quality insurance
The government considers past procedures and the concepts for help as successful
in principle. However, in some instances critical developments became visible.
Reacting to that, for example the intensity of control as well as the expert support in
substitution treatment has been increased. On one side more specific qualification
has been supported for medical doctors doing substitution treatment. On the other
side in future double prescription of substances will be avoided through the
installation of a substitution register. A considerable grey area of codeine substitution
was targeted by a change in the regulations for the prescription of these substances
which in future allows this type of substitution only for special cases.
12.3 Evaluation of national strategies
The new strategy is a complex set of changes compared to the former German drug
policy. It is a bundle of administrative and legal activities as well as a chance in focus
in contents and funding for prevention and treatment. Given this complexity it is very
difficult to do an in depth evaluation of national strategies, but evaluation takes place
for each single action. The national heroin project is accompanied - as for this type of
study standard - by an international group of experts.
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13 Cocaine and crack
13.1 Different patterns and user groups
Since more the 10 years the number of cocaine users has been increasing steadily in
Germany. In the representative population survey in 1997 in the age-group 18-39 the
rate for life-time users is 2.2% for the West (Figure 36), for last years drug use is 1.2%
(Figure 37). This means a considerable increase compared to 1990. In the East
experiences with cocaine use are more rare. Males are more frequently users of
cocaine compared to females.
Figure 36: Cocaine use during lifetime (age-group 18-39 years)
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Source: Representative Survey 1997 (Kraus & Bauernfeind 1998)
Figure 37: Cocaine use during the last year (age-group 18-39 years)
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The most recent national figures on cocaine experiences available are from the year
1997. On the basis of these figures it can be estimated that around 650,000 persons in
the old and 17,000 persons in the new Laender have made some experiences with
cocaine during their lifetime. For the last 12 months the respective figures are 325,000
and 8,000. A number of facts let assume that in the meanwhile the situation in East
has become more similar to the old Laender (Table 31). Given the method of data
collection it has to be assumed that real figures are well above that numbers, as it is
difficult to reach critical groups through surveys. are reached only. It also has to be
assumed that not all experiences are reported.
Table 31: Overview on cocaine experiences - West and East Germany
Percentage Absolute numbersWEST
Source
Age-group
Life time
prevalence
12-months
prevalence
Life time
prevalence
12-months-
prevalence
DAS    ’97 12-17 1.0% 1.0% »     43,000 »      43,000
BUND ’97 (male) 18-59 2.2% 1.1% »   451,000 »    226,000
BUND ’97 (female) 18-59 0.8% 0.3% »   158,000 »      59,000
BUND ’97 18-39 2.2% 1.2% »   490,000 »    267,000
BUND ’97 18-59 1.5% 0.7% »   604,000 »    282,000
DAS    ’97
BUND ’97
12-59 1.5% 0.7% »   647,000 »    325,000
Percentage Absolute numbersEast
Source
Age-group
Life time
prevalence
12-months
prevalence
Life time
prevalence
12-months-
prevalence
DAS    ’97 12-17 0.0% 0.0% 0 0
BUND ’97 (male) 18-59 0.2% 0.0% »       9,000 »              0
BUND ’97 (female) 18-59 0.2% 0.2% »       8,000 »       8,000
BUND ’97 18-39 0.4% 0.2% »     18,000 »       9,000
BUND ’97 18-59 0.2% 0.1% »     17,000 »       8,000
DAS    ’97
BUND ’97
12-59 0.2% 0.1% »     17,000 »       8,000
Source: Drug Affinity Study 1997 (Christiansen & Töppich 1998); Representative Survey 1997 (Kraus &
Bauernfeind 1998)
The comparison makes clear, that only about half of the persons with cocaine
experiences are recent users (Figure 38 and 39)
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Figure 38: Experiences with cocaine in the age-group 18-59 years (West)
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Figure 39: Experiences with cocaine in the age-group 18-59 years (East)
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A study from the year 1998 (Perkonigg, Lieb & Wittchen 1998) reports life time
prevalence for a metropolitan areas (Munich). The figures ware considerable above
the results of the Repräsentativerhebung, which is partly reflecting regional
characteristics, partly differences in the age structure of the sample. The question on
the frequency of use shows, that more than half of the males and females with
experiences with cocaine have taken this less than 5 times.
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Figure 40: Lifetime prevalence for cocaine use in a metropolitan area
(age-group 14-24 years)
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Parallel to the development of case numbers within the population surveys also the
number of persons with first offences against drug laws increased continuously for
cocaine from 1985 until 1998. From 1998 to 1999 the numbers remained nearly
unchanged. Also here the increase concerns males in the first place (Figure 41).
Figure 41: Drug-related offences: Cocaine users first notified by the police
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The changes in purity for cocaine seizures taken between 1998 and 1999 show that
today more substance is on the market which allows non i.v. use given the amount of
active substance. Future will show, if especially smoking of cocaine will become more
widespread in Germany through this factor during the coming years (Figure 42).
Figure 42: Distribution of purity for cocaine
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13.2 Problems and needs for services
The number of treatment cases in out-patient drug care on the basis of ICD10
diagnoses are available since 1980. Harmful or dependent use of cocaine in 1999 has
been the third main diagnosis by  frequency with a percentage of 7% (Türk & Welsch
2000a).
There are about 6 times as much single diagnoses than main diagnoses, which means
that most clients use cocaine as a secondary drug. It is frequently used with opiates,
increasingly also with other substances. In the framework of an increasing adjustment
of the new Laender in relation to the old ones a massive increase in cases can be seen
there. The caseload has about doubled there annually during the last years. The
number of main diagnoses about cocaine has more than doubled since 1994. In these
cases cocaine is the primary cause of treatment. This increase concerns mostly males
(Figure 43).
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Figure 43: Developments in cocaine treatment (1994-1999)
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Single diagnoses 1994 1995 1996 1997 1998 1999 changes
1999 vs. 1998
Total 2,062 2,496 4,105 4,851 5,781 5,982 3.50%
West 2,050 2,478 4,043 4,745 5,545 5,475 -1.30%
East 12 18 62 106 236 503 113.10%
Males 1,665 2,028 3,240 3,960 4,640 4,929 6.20%
Females 397 468 865 891 1,141 1,053 -7.70%
Main diagnoses 481 714 863 830 1,037 1,167 12.50%
Source: EBIS 1999 (Türk & Welsch 2000a)
In 1999 about 12% of all prison inmates in out-patient treatment monitored by EBIS
were cocaine addicts (N = 7,641). After opiates and alcohol (47% resp. 38%) cocaine
comes on place three in frequency within the prisons. On the other side, cocaine
problems are especially addressed by prison inmates. Half of the male, but only 8% of
the female clients with primary cocaine problems are in prison at the beginning of
their treatment.
The number of cases with a crack related diagnosis in Germany is still low, but has
increased during a couple of years considerably. In out-patient care is has about
doubled from 1996 to 1998 (Table 32). This group of persons can be judged as
especially problematic on the basis of low school education, high unemployment and
bad income situation.
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Figure 44: Cocaine clients of out-patient treatment centres in prison
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Table 32: Single diagnoses of crack for persons in out-patient treatment
Crack diagnoses 1996 1997 1998 1999
Total 205 316 410 415
Male 171 258 341 356
Female 34 58 69 59
Source: EBIS 1998 (Simon & Palazzetti 1999); EBIS 1999 (Türk & Welsch 2000a)
13.3 Intervention projects
During the last years in several places in Germany special services for clients with a
primary cocaine related problem have been developed. As one example Kokon in
Berlin can be mentioned. Other projects are targeting very special groups like female
prostitutes with cocaine problems aiming at information and harm minimisation.
Special offers of out-patient treatment try to preserve the social setting of the cocaine
dependent which usually is a stable one. Different from in-patient treatment this does
interrupt neither employment nor social or family relationships. A considerable
proportion of treatment of cocaine problems is assumed to take place in the field of
private medical doctors and therapists - given the social and economic situation of the
clients. On this matter no additional information is available.
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14 Infectious diseases
14.1 Prevalence and incidence of HCV, HBV and HIV among drug users
In the following text several indicators should give an indication of the prevalence of
infectious diseases amongst the group of drug users: results from laboratory test,
out-patient care, studies on drug users in prisons and autopsies of drug related
deaths through forensic institutes.
The AIDS-centre of the Robert Koch Institute in Berlin (Federal Centre for Infectious
Diseases) is publishing data on i.v. (opiate) users on confirmed HIV antibody tests in
regular periods. On the basis of the regulation on laboratories all labs in the Federal
Republic of Germany are obliged since 1987 to notify these tests anonymously to the
AIDS-centre at the Robert Koch Institute. These notifications include information on
age, sex, place of living and way of infection transmission. In addition in the AIDS
case register epidemiological data on diagnosed cases of AIDS are collected in an
anonymised form on the basis of voluntary information from treating practitioners. A
regular update of the epidemiological data can be downloaded via internet
(http://www.rki.de/INFEKT/AIDS_STD/AZ.HTM).
The information system of the Robert Koch Institute shows, that the number of
confirmed HIV anti body test has declined each year since 1993 starting with 2,417 to
1,688 in 1999. Between Federal Laender there is a considerable variation in the
number of AIDS cases. While in the new Laender only few people suffer from AIDS, the
number in the city based Laender Berlin and Hamburg are highest (Table 45). I.v. drug
users come as second risk group for HIV infection and AIDS after homosexual males.
The proportion of drug users with intravenous modes of application amongst first
diagnoses has been rather stable between 12.1% (1994) and 9.9% (1996). In 1999
10.9% of all HIV first diagnoses (i.e. 184 out of 1,688 cases) showed intravenous drug
use as infection risk.
On the basis of the report from the AIDS centre of the Robert Koch Institute
(http://hiv.rki.de) the proportion of drug addicts amongst new notified Aids cases in
1999 was about 12% in Germany. In Hamburg and Baden-Württemberg its percentage
of 34.6% and 26% was nationally at its highest.
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Figure 45: Aids-Cases in the Federal Laender (per 1 Mio. population), 1999
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Figure 46: Proportion of intravenous drug addicts (IVDA) amongst AIDS cases, 1999
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Data on HIV amongst drug addicts in out-patient centres for counselling and treatment
are available through EBIS (Türk & Welsch 2000a). In 1999 448 facilities all over
Germany have collected information on HIV-status and tests for a total of 5,805
clients. Around 55% of these clients until then had never undergone a HIV test, in
39.1% of the cases the result was negative, 2.1% positive. 3.1% of the clients were
tested with unknown result. Figure 47 shows the percentage of HIV positive clients for
different main diagnoses. 5.7% of all females and 3.3% of all males, which are in out-
patient counselling and treatment because of illegal drugs and where a test result is
known, are HIV positive. The percentage for females is highest for main diagnoses
related to cocaine or cannabis (6.7%), for males for opiates (3.8%).
Figure 47: HIV-infection among clients in out-patient care
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Since 2000 in EBIS also collects data on hepatitis B and C, results will be available in
2001. As in EBIS data on infectious diseases are based on voluntary information from
the clients and not on test results it is very likely that the real prevalence of the
disease is underestimated (underreporting).
In some Federal Laender within the prisons an AIDS test is done on a routine basis as
part of the medical examination at intake if the prisoner agrees. In other Laender the
test is only done on the inmate’s request. Tests for hepatitis are rather rare, but take
place on regional level. So in Hamburg test rates in prisons 80-90%. For statistical
purposes these data are not available, however.
During the last years several studies have been conducted on HIV/AIDS and hepatitis
in prisons. So in 1998 the results of a multi centre European study have been
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published (Weilandt & Rotily 1998). In this study, which took place in France,
Germany, Italy, Portugal, Spain, Sweden and Belgium, HIV and HCV prevalence were
assessed by saliva testing. The prevalence for HIV amongst i.v. drug using inmates in
German prisons was 1.4% (N = 143), for non i.v. drug users 0.4% (N = 284). The
prevalence of hepatitis C for i.v. drug users was 14.4%, but only 0.4% for non i.v. drug
users. The prevalence in German prisons were, however, considerably lower than in
other European prisons, were HIV prevalence reached 28% and HCV prevalence 64%
for i.v. drug users)
Data on infectious diseases amongst  drug users also come from autopsies made by
the forensic institutes. In some regions, for example in Hamburg, Frankfurt and
Munich HIV tests are done as routine part of the autopsy, hepatitis b tests only in
Hamburg. The autopsy rate varies between Laender from 18% to 100% (BKA 2000) and
was 62% on the average in 1999. As the Federal Criminal Office (BKA) reports, in 1999
from 1,812 drug related dead 56 had a HIV infection (BKA 2000a)
Also treatment statistics from pension insurance (VDR) as well as the general hospital
statistics are collecting information on infectious diseases, but they cannot
distinguish between drug users and non users.
14.2 Determinants and consequences
Hepatitis B, C and HIV are infectious diseases, which often emerge at drug users as a
consequence of intravenous application of substances. The common use of needles
and syringes (“needle sharing”) or the sharing of drugs by use of a syringe (“drug
sharing”) involve a considerable risk to transmit viruses and bacteria via blood
remaining at the needle. Also unhygienic conditions during injection, e.g. through
spoiled spoons, used filters or flat water are sources of pathogenic agents - tattoos
and piercing are frequently applied in some groups of the drug addicts. Here unclean,
non sterile tools also can be a risk for the transmission of infections.
Different sources report on risky patterns of drug use. In EBIS, for example, common
use of injecting materials is asked for. Figure 48 shows, that 75% of female cocaine
addicts and 69% of the female heroin addicts in out-patient care share needles and
syringes with others. “Needle sharing” is amongst them is more widespread than
amongst male clients, where 64% of cocaine and 60% of heroine addicts share
injection instruments. As this information is only available for about one quarter of all
drug addicted clients, interpretation is limited in quality (Türk & Welsch 2000a).
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Figure 48: "Needle sharing" among clients in out-patient care
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In the multi centre study on European prisons (see above) inmates with and without
i.v. use were asked about behaviour relevant for infections, e.g. tattooing and piercing
(Weilandt & Rotily 1998). Results show, that tattooing and piercing is done frequently
within the prisons. In Germany 38% of the subjects with and 16% without i.v. drug use
said, that they let apply a new tattoo during their time in prison. 13% of inmates with
i.v. drug use and 4% without got a piercing and have been not very aware of risks
around infections diseases also in this case.
14.3 New developments and uptake of prevention / harm reduction
In order to prevent infectious diseases at drug addicts, preventive measures are taken
by different actors. In nearly all bigger cities in Germany low threshold facilities and
AIDS help exist, which distribute syringes and also condoms, inform about infection
risks and measures of “safer use”. Hepatitis B and C vaccinations are done by
General Practitioners and they are cost free for drug addicts. During the last years
there have been efforts to improve prevention of infectious diseases for special client
groups. In some German prisons pilot projects were conducted (e.g. in Lower Saxony,
Hamburg, Berlin and Lübeck). They aimed at an improvement of infection
prophylactics by distribution of sterile one-way syringes to drug addicts as well as
training offers to inmates and prison staff (e.g. Meyenberg et al. 1999)
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AIDS tests can be done by General Practitioners, counselling centres of the German
Aids help and health authorities. If somatic symptoms are given, which make an HIV
infection likely, the test is cost-free for the client and is paid by the health insurance.
In all other cases, the client has to pay for the test. Before and after each test
counselling takes place, independent from the result. Out-patient HIV therapy is done
by specialised hospitals and General Practitioners financed by the health insurance.
To increase compliance and retention rate of drug addicted HIV infected clients there
are special programmes, which for example have reduced the number of medicament
intakes to twice per day (e.g. University of Frankfurt a.M.).
In April 2000 an international workshop took place at the Robert Koch Institute in
Berlin to discuss recent developments and new strategies and measures in the fight
against AIDS. Topics were amongst others the collection of reliable data on the spread
of HIV and its consequences, preventive measures, quality of services and medical
treatment. The workshop was organised by the UN AIDS collaboration centre and
financially supported by the Federal Ministry for Health. Participants were
representatives from 22 countries as well as from international organisations
(UNAIDS, WHO UNICEF).
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ANNEX I
DRUG MONITORING SYSTEMS AND
SOURCES OF INFORMATION
Table 33: National studies on drug use
Subject: Central Questions: Coverage:
Consumption surveys Prevalence, incidence, patterns of
use, consequences of drug use,
attitudes, groups of low / high risk
(National /
Regional)
Representative survey
(IFT)
Prevalence, patterns of use and
attitudes in the general population (18-
59 years)
National
Drug Affinity Study
(Federal Centre for Health
Education FCHE))
Prevalence, patterns of use and
attitudes among young people (12-25
years)
National
Mikrozensus (Federal
Statistical Office; StBA)
Use and abuse of tobacco in the general
population (16 up to more than 64 years)
National
National health survey
(Gesundheitssurvey)
(Robert-Koch-Institut)
Attitudes to alcohol, tobacco and soft
drugs and their use in the general
population (18 to 79 years)
National
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Table 34: National sources of information in the field of clinical epidemiology and
health care
Subject: Central questions: Coverage:
Clinical epidemiology /
health care
Prevalence of problematic
drug use, social, medical and
psychological diagnoses,
treatment statistics (treatment
demands, outcome)
(National / Regional)
EBIS (IFT) Monitoring systems for out-
patient treatment centres
National / Regional
SEDOS (IFT) Monitoring systems for in-patient
treatment centres
National
DESTAS Specific monitoring system for
treatment centres, held by a
specific treatment organisation
National
BADO-Hamburg Regional registration system for
treatment centres
Regional
General hospital statistics
(Federal Statistical Office;
StBA)
Inquiry about all ICD-9
diagnoses in hospitals,
prevention and rehabilitation
centres
National
Treatment statistics of
pension insurance schemes
(Federation of German
Pension Insurance
Institutions, VDR)
Type and number of
rehabilitations for adults financed
by pension insurance
National
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Table 35: National sources of information in the field of diseases as a result of drug
use
Subject: Central questions: Coverage:
Secondary diseases in drug
users
· HIV and AIDS related to
intravenous drug use
· Diseases as a result of
drug use
(National / Regional)
AIDS case register (Robert-
Koch-Institut)
Number of notified AIDS
cases related to intravenous
drug use
National / Regional
HIV notifications
(Robert-Koch-Institut)
Number of notified HIV
infections related to
intravenous drug use
National / Regional
Treatment statistics from
pension insurance schemes
(Federation of German
Pension Insurance
Institutions, VDR)
Diseases as a result of drug
use coded following ICD-9
National / Regional
General hospital statistics
(Federal Statistical Office)
ICD-9 diagnoses of
secondary diseases for drug
users in hospitals and
institution for social care and
rehabilitation
National
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Table 36: Drug-related sources of information of the Federal Criminal Police Office
 
Subject: Central questions: Coverage:
Police data · First offenders
· Drug users
· Seizures
· illicit traffic
· Smuggling
· Characteristics of
drugs appearing on
the drug market (price,
purity)
(National / Regional)
Drugs case file (Falldatei
Rauschgift FDR)
Drug related deaths, drug
users who are registered for
the first time, offender in the
field of illicit traffic,
smuggling and possession
National / Regional
Police' s crime statistics
(Polizeiliche Kriminalstatistik
PKS)
Seizures, illicit traffic and
smuggling, price and purity
National / Regional
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Table 37: National judicial sources of information in the field of drug use and drug
users
Subject: Central questions: Coverage:
Judicial statistics · Data on the penal system
· Convictions related to
drugs
· Accidents related to drug
influence
· Withdrawal of driving
licenses
National / Regional
Penal statistics (Federal
Statistical Office, StBA)
Demographic and
criminological
characteristics of prisoners
National
Prosecution statistics
(Federal Statistical Office,
StBA)
Convictions related to drugs National
Statistics on withdrawal of
driving licenses (Federal
Traffic Office, Kraftfahrt
Bundesamt)
Withdrawal of driving
licenses stratified by
detailed reasons and
Laender
National / Regional
146
Table 38: Sources of information in the field of primary prevention
Subject: Central questions: Coverage:
Primary prevention · Groups at risk
· patterns of use, attitudes to
drugs and drug use
· Organisation and guidance
· kind and number of
activities carried out
· 
National / Regional
Representative survey (IFT) Groups at risk, patterns of use,
attitudes to drugs and drug use
in general population
National / Regional
Drug Affinity Study (Federal
Centre for Health Education
FCHE)
Groups at risk, patterns of use,
attitudes to drugs and drug use
among youth
National
Questioning of Laender
prevention commissioners
(Federal Centre for Health
Education, FCHE)
Overview on guidance and
organisation of prevention
Activities, information about
outstanding activities and
campaigns, distribution of
financial sources, staff,
structural information
National / Regional
EBIS (IFT) Type of activities, target
groups, number of persons
reached, duration
National / Regional
Infopool-Prävention (Federal
Criminal Police Office, BKA)
Documentation of protagonists,
models and projects of crime
and drug prevention
National / Regional
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Table 39: Sources of information in the field of counselling and treatment of drug
users
Subject: Central questions: Reports:
Treatment of drug addicts
and harm reduction activities
· Treatment of problematic drug use
· Activities aiming at reintegration into
working life and rehabilitation
· Activities aiming at reduction of risk
behaviour
· Register of treatment institutions
· Register of therapy and treatment
concepts
National/
Regional
EBIS / SEDOS (IFT) Characteristics of treatment institutions
and clients, documentation of course of
treatment and treatment outcome
National /
Regional
EBIS-(B)asishilfen / DWA
(EBIS version for institutions
caring for homeless people and
persons who committed criminal
offences)
Characteristics of treatment institutions
and clients in the area of institutions caring
for homeless people and persons who
committed criminal offences
National /
Regional
Treatment statistics of pension
insurance schemes (Federation
of German Pension Insurance
Institutions, VDR)
Activities aiming at reintegration into
working life and rehabilitation, social
stability and relapse prevention
National
Statistics of treatment
institutions (German Council on
Addiction Problems, DHS)
Register of treatment institutions and
treatment concepts
National
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Table 40: Sources of information in the field of harm reduction activities (reduction of
risk behaviour and follow-up diseases of drug use)
Subject: Central questions: Coverage:
Data on reduction of risk
behaviour and follow-up
diseases of drug use
· Substitution
· Avoidance of diseases as a
result of drug use
National /
Regional
Regulations and control of the
prescription of L-Polamidon
(BtMVV / AUB)
Concept of prescription and
results
National /
Regional
Number of methadone based
substitution treatments
(panel doctors)
Substitution treatments National /
Regional
Statistics on prescription of
methadone (Federal Institute for
Drugs and Medical Devices
BfArM)
Allocation of Levomethadon- and
methadone to public pharmacies
(100% coverage)
National
EBIS (IFT) Substitution treatments National /
Regional
Statistics on low threshold
activities (e.g. syringe exchange
to reduce risk behaviour)
Statistics on Laender level (partly) Regional
149
Table 41: Sources of information in the field of drug policy and drug legislation
Subject: Central questions: Coverage:
Programmes in the field
of policy / judicial data
Legal measures,
programmes of political
authorities related to
drugs
   (National / Regional)
Federal law gazette
(Bundesgesetzblatt)
Announcement of new laws
or changes of laws (e.g.
German Narcotics Act)
National
Programmes of the Federal
and Laender governments
to fight against drug related
problems
Wording of programmes,
data on organisation and
evaluation of specific
programmes and campaigns
National / Regional
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Table 42: Documentation centres
Subject: Central questions: Coverage:
Drug-related
documentation centres
Scientific literature and
databases
(National / Regional)
German Institute for Medical
Documentation and
Information (Deutsches
Institut für medizinische
Information und
Dokumentation; DIMDI)
Bibliographical information
on scientific literature
national and international
databases
National
Institute for Public Health in
North-Rhine Westphalia
LOEDG (previously IDIS)
Smaller (specialised)
documentation centres,
reports and publications on
the subject of legal and
illegal drugs
National
Archive and Documentation
Centre for Drugs Literature
(ARCHIDO) of the Institute
for Drug Research at the
University of Bremen
Smaller (specialised)
documentation centres,
such as the which allows
computer-assisted searches
of the literature, reports and
publications on the subject
of legal and illegal drugs
National
Centre for Psychological
Documentation and
Information (ZIPID)
Smaller (specialised)
documentation centres,
such as the which allows
computer-assisted searches
of the literature
National
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ANNEX II TABLES
Consumption of illegal drugs (Tables 43 - 59)
Table 43: Lifetime-, 12-months- and 30-days-prevalence; West-Germany
Geschlecht Altersgruppen
Gesamt Männer Frauen 18-20 21-24 25-29 30-39 40-49 50-59
Lebenszeit 6380 3209 3171 573 521 539 1712 1419 1616
Cannabis 13.4 (855) 16.2 10.6 20.6 27.8 20.7 17.3 9.3 3.3
Amphetamine 1.8 (113) 2.5 1.0 3.4 2.0 2.8 2.1 2.2 0.1
Ecstasy 1.7 (110) 2.2 1.2 4.6 6.6 3.8 1.6 0.2 --
LSD, Mescalin o. ä. 1.6 (99) 2.2 0.9 1.6 1.9 3.2 1.9 2.0 0.1
Heroin 0.4 (27) 0.6 0.2 0.3 0.8 0.9 0.6 0.5 --
Methadon 0.2 (10) 0.2 0.1 -- -- 0.3 0.2 0.3 --
Andere Opiate 0.7 (45) 0.9 0.5 0.6 0.6 0.8 1.1 0.8 0.2
Kokain 1.5 (96) 2.2 0.8 1.5 2.7 2.7 2.1 1.6 0.0
Crack 0.1 (9) 0.2 0.1 0.4 0.2 0.2 0.2 0.1 --
Andere Drogen als
Cannabis
4.5 (284) 5.9 3.0 8.2 10.3 6.8 5.2 3.6 0.4
Illegale Drogen1 14.2 (906) 17.1 11.3 23.2 31.0 21.1 18.1 9.6 3.3
Schnüffelstoffe 0.7 (45) 0.9 0.5 1.6 2.4 0.9 0.5 0.5 0.1
12-Monate Gesamt Männer Frauen 18-20 21-24 25-29 30-39 40-49 50-59
Cannabis 4.5 (285) 5.9 3.0 11.9 14.7 7.9 4.4 1.3 0.3
Amphetamine 0.5 (30) 0.9 0.1 2.5 1.3 1.0 0.2 -- --
Ecstasy 0.9 (58) 1.2 0.6 3.2 3.2 1.7 0.7 0.1 --
LSD, Mescalin o. ä. 0.4 (23) 0.6 0.1 1.6 0.9 0.5 0.2 0.3 --
Heroin 0.2 (11) 0.3 0.0 0.3 -- 0.8 0.3 -- --
Methadon 0.1 (5) 0.2 0.0 -- -- 0.3 0.2 -- --
Andere Opiate 0.2 (13) 0.4 -- 0.4 0.4 0.8 0.2 0.1 --
Kokain 0.7 (44) 1.1 0.3 1.4 2.4 1.6 0.6 0.3 --
Crack 0.1 (3) 0.1 -- -- 0.1 -- 0.1 0.1 --
Andere Drogen als
Cannabis
1.7 (106) 2.5 0.8 6.3 5.6 2.3 1.2 0.6 --
Illegale Drogen1 4.9 (310) 6.4 3.3 13.8 16.3 8.1 4.7 1.3 0.3
Schnüffelstoffe 0.2 (12) 0.3 0.1 0.7 1.1 -- 0.1 -- --
30-Tage Gesamt Männer Frauen 18-20 21-24 25-29 30-39 40-49 50-59
Cannabis 3.0 (192) 4.0 2.0 8.4 10.2 5.3 2.6 0.9 0.3
Amphetamine 0.2 (12) 0.4 0.0 0.7 0.5 0.6 0.2 -- --
Ecstasy 0.3 (19) 0.4 0.2 1.3 1.2 0.4 0.2 -- --
LSD, Mescalin o. ä. 0.0 (3) 0.1 0.0 0.3 -- 0.0 0.0 0.0 --
Heroin 0.1 (6) 0.2 -- -- -- 0.8 0.1 -- --
Methadon 0.0 (3) 0.1 0.0 -- -- 0.3 0.1 -- --
Andere Opiate 0.1 (7) 0.2 -- -- -- 0.8 0.2 -- --
Kokain 0.3 (21) 0.5 0.2 0.4 0.6 1.0 0.4 0.2 --
Crack 0.0 (1) 0.0 -- -- -- -- 0.0 -- --
Andere Drogen als
Cannabis
0.8 (53) 1.2 0.4 2.4 2.3 1.9 0.8 0.3 --
Illegale Drogen1 3.3 (212) 4.5 2.2 9.2 12.0 5.7 2.9 0.9 0.3
Schnüffelstoffe 0.1 (3) 0.1 -- -- 0.5 -- 0.0 -- --
1 Mindestens eine illegale Droge
Source: Representative Survey 1997 (Kraus & Bauernfeind 1998)
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Table 44: Lifetime-, 12-months- and 30-days-prevalence; East-Germany
Geschlecht Altersgruppen
Gesamt Männer Frauen 18-20 21-24 25-29 30-39 40-49 50-59
Lebenszeit 1620 810 810 175 118 112 439 357 419
Cannabis 4.2 (68) 4.7 3.6 11.3 12.9 16.4 2.8 0.4 0.2
Amphetamine 0.5 (9) 1.0 0.1 2.2 1.0 0.8 0.5 0.1 --
Ecstasy 0.7 (11) 1.0 0.3 2.3 2.6 2.4 0.2 -- --
LSD, Mescalin o. ä. 0.4 (7) 0.8 -- 2.5 -- 1.4 0.2 -- --
Heroin 0.0 (0) -- 0.1 -- 0.4 -- -- -- --
Methadon -- -- -- -- -- -- -- -- -- --
Andere Opiate 0.2 (4) 0.4 -- 1.9 -- 0.2 -- -- --
Kokain 0.2 (4) 0.2 0.2 -- 1.7 0.7 0.2 0.1 --
Crack 0.1 (2) 0.2 -- 1.1 -- -- -- -- --
Andere Drogen als
Cannabis
1.3 (22) 2.0 0.7 4.8 5.8 3.1 0.5 0.2 --
Illegale Drogen1 4.8 (78) 5.6 4.0 13.4 15.8 17.2 3.0 0.6 0.2
Schnüffelstoffe 0.0 (0) 0.0 0.0 -- -- 0.1 -- 0.0 --
12-Monate Gesamt Männer Frauen 18-20 21-24 25-29 30-39 40-49 50-59
Cannabis 2.3 (38) 3.2 1.5 7.9 5.4 13.0 0.8 -- --
Amphetamine 0.3 (5) 0.6 -- 2.2 -- -- 0.2 -- --
Ecstasy 0.4 (6) 0.5 0.2 2.3 -- 1.4 0.2 -- --
LSD, Mescalin o. ä. 0.4 (6) 0.7 -- 2.5 -- 0.7 0.2 -- --
Heroin 0.0 (0) -- 0.0 -- 0.1 -- -- -- --
Methadon -- -- -- -- -- -- -- -- -- --
Andere Opiate 0.2 (3) 0.4 -- 1.9 -- -- -- -- --
Kokain 0.1 (2) -- 0.2 -- 1.7 -- -- -- --
Crack 0.1 (2) 0.2 -- 1.1 -- -- -- -- --
Andere Drogen als
Cannabis
0.8 (14) 1.2 0.5 4.8 1.8 2.1 0.2 -- --
Illegale Drogen1 2.7 (43) 3.6 1.7 10.0 5.4 14.0 0.8 -- --
Schnüffelstoffe -- -- -- -- -- -- -- -- -- --
30-Tage Gesamt Männer Frauen 18-20 21-24 25-29 30-39 40-49 50-59
Cannabis 1.7 (28) 2.8 0.6 6.6 3.5 10.7 -- -- --
Amphetamine 0.2 (3) 0.4 -- 1.9 -- -- -- -- --
Ecstasy 0.1 (2) 0.3 -- 1.2 -- -- -- -- --
LSD, Mescalin o. ä. -- -- -- -- -- -- -- -- -- --
Heroin -- -- -- -- -- -- -- -- -- --
Methadon -- -- -- -- -- -- -- -- -- --
Andere Opiate -- -- -- -- -- -- -- -- -- --
Kokain -- -- -- -- -- -- -- -- -- --
Crack 0.1 (2) 0.2 -- 1.1 -- -- -- -- --
Andere Drogen als
Cannabis
0.3 (5) 0.7 -- 3.1 -- -- -- -- --
Illegale Drogen1 1.8 (30) 3.0 0.6 7.8 3.5 10.7 -- -- --
Schnüffelstoffe -- -- -- -- -- -- -- -- -- --
1 Mindestens eine illegale Droge
Source: Representative Survey 1997 (Kraus & Bauernfeind 1998)
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Table 45: Lifetime- and 12-months-frequence; West-Germany
Gesamt Frequenz
Lebenszeit N k. A. 1x 2-5x 6-9x 10-19x 20-59x 60-99x 100-199x >=200x
Cannabis 855 -- 23.7 27.2 7.7 10.2 10.3 4.8 4.9 11.2
Amphetamine 113 0.7 19.9 23.3 23.5 16.7 6.9 1.3 1.1 6.6
Ecstasy 110 0.8 20.2 39.4 9.4 8.4 8.7 5.4 6.6 1.1
LSD 99 -- 38.9 18.4 15.0 16.1 8.2 2.0 -- 1.3
Heroin 27 7.8 13.7 6.1 10.2 11.0 4.5 2.2 44.5 7.8
Methadon 10 8.4 -- -- 8.8 -- 37.5 -- 8.6 36.7
Andere Opiate 45 -- 34.0 29.9 13.1 5.4 2.8 5.5 -- 9.2
Kokain 96 8.3 17.9 23.2 12.5 15.6 12.8 1.3 2.7 5.7
Crack 9 -- 53.0 6.5 -- 6.3 18.1 -- -- 16.1
Schnüffelstoffe 45 1.8 23.4 41.9 7.2 10.6 7.8 -- 7.3 --
12-Monate N k. A. 1x 2-5x 6-9x 10-19x 20-59x 60-99x 100-199x >=200x
Cannabis 258 0.7 17.1 23.0 7.4 15.1 14.0 5.5 8.0 9.2
Amphetamine 30 -- 13.8 39.2 28.4 1.9 14.2 -- -- 2.4
Ecstasy 58 2.2 24.1 42.5 9.9 6.5 10.7 3.5 -- 0.6
LSD 23 2.9 30.8 61.0 2.8 2.5 -- -- -- --
Heroin 11 33.9 -- 6.2 -- -- 8.0 -- -- 51.9
Methadon 5 -- -- 15.7 -- 15.1 15.3 -- -- 53.9
Andere Opiate 13 -- 40.9 3.9 6.0 -- 18.8 4.4 -- 26.1
Kokain 44 17.5 4.3 31.4 14.3 13.3 6.3 3.9 7.1 1.9
Crack 3 -- 9.5 25.8 -- 40.1 -- 24.5 -- --
Schnüffelstoffe 12 -- 51.5 14.6 6.9 -- 27.1 -- -- --
 Source: Representative Survey 1997 (Kraus & Bauernfeind 1998)
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Table 46: Lifetime- and 12-months-frequence; East-Germany
Gesamt Frequenz
Lebenszeit N k. A. 1x 2-5x 6-9x 10-19x 20-59x 60-99x 100-199x >=200x
Cannabis 68 0.5 17.3 35.9 25.2 4.8 4.7 6.0 4.0 1.6
Amphetamine 9 -- 18.1 -- 15.9 47.2 18.8 -- -- --
Ecstasy 11 -- 65.7 9.2 7.3 -- -- 17.8 -- --
LSD 7 -- 19.8 49.3 22.6 8.4 -- -- -- --
Heroin 0 -- 100.0 -- -- -- -- -- -- --
Methadon -- -- -- -- -- -- -- -- -- --
Andere Opiate 4 -- 7.4 -- 92.6 -- -- -- -- --
Kokain 4 -- 52.2 47.8 -- -- -- -- -- --
Crack 2 -- -- -- -- -- 100.0 -- -- --
Schnüffelstoffe 0 -- -- 50.7 49.3 -- -- -- -- --
12-Monate N k. A. 1x 2-5x 6-9x 10-19x 20-59x 60-99x 100-199x >=200x
Cannabis 38 -- 26.1 46.1 2.0 5.8 2.6 17.4 -- --
Amphetamine 5 -- 71.3 16.5 -- 12.1 -- -- -- --
Ecstasy 6 -- 46.1 24.2 29.7 -- -- -- -- --
LSD 6 -- 64.6 25.8 -- 9.6 -- -- -- --
Heroin 0 -- 100.0 -- -- -- -- -- -- --
Methadon -- -- -- -- -- -- -- -- -- --
Andere Opiate 3 -- -- 100.0 -- -- -- -- -- --
Kokain 2 -- 100.0 -- -- -- -- -- -- --
Crack 2 -- -- 100.0 -- -- -- -- -- --
Schnüffelstoffe -- -- -- -- -- -- -- -- -- --
Source: Representative Survey 1997 (Kraus & Bauernfeind 1998)
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Table 47: 30-days-frequence; West- and East-Germany
Gesamt Konsumtage
Westdeutschland N k. A. 1 2-5 6-9 10-19 20-30
Cannabis 192 1.7 23.5 37.2 3.7 16.0 17.9
Amphetamine 12 -- 35.7 27.0 26.6 4.7 6.0
Ecstasy 19 15.2 28.1 35.8 19.0 -- 1.9
LSD 3 -- 5.6 63.3 -- 5.7 25.4
Heroin 6 -- -- 13.7 -- 39.1 47.2
Methadon 3 -- -- -- -- -- 100.0
Andere Opiate 7 10.8 -- -- -- 41.9 47.3
Kokain 21 -- 32.6 45.1 -- 7.4 14.9
Crack 1 -- -- -- -- 100.0 --
Schnüffelstoffe 3 -- -- 100.0 -- -- --
Ostdeutschland N k. A. 1 2-5 6-9 10-19 20-30
Cannabis 28 1.8 29.6 23.7 -- 25.6 19.2
Amphetamine 3 100.
0
-- -- -- -- --
Ecstasy 2 -- 7.4 -- 92.6 -- --
LSD -- -- -- -- -- -- --
Heroin -- -- -- -- -- -- --
Methadon -- -- -- -- -- -- --
Andere Opiate -- -- -- -- -- -- --
Kokain -- -- -- -- -- -- --
Crack 2 -- -- -- 100.0 -- --
Schnüffelstoffe -- -- -- -- -- -- --
Source: Representative Survey 1997 (Kraus & Bauernfeind 1998)
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Out-patient treatment, Germany
Table 48: Main diagnosis
Betreuungsgrund Alter in Jahren Gesamt
-14 15 - 17 18 - 19 20 - 24 25 - 29 30 - 39 40 - 49 50 - 59 60 - Mittelwert Abs. %
eigene Symptomatik  0,5%  2,0%  3,4%  10,6%  10,8%  30,3%  27,2%  11,8%  3,3% 36,8 55119 95,1%
davon HD Alkohol  0,3%  0,4%  0,8%  3,8%  6,4%  32,0%  35,6%  16,2%  4,5% 40,8 36687 63,3%
davon HD Opiate  0,4%  2,0%  6,0%  27,5%  25,2%  30,7%  7,4%  0,7%  0,1% 28,2 7748 13,4%
 davon HD Cannabis  1,4%  19,8%  22,8%  31,2%  11,5%  10,1%  2,4%  0,5%  0,2% 22,3 2859 4,9%
M davon HD Sedativa/Hypnotika   0,5%  1,4%  8,3%  13,0%  31,5%  26,4%  13,4%  5,6% 39,1 216 0,4%
Ä davon HD Kokain  0,1%  1,7%  4,4%  23,3%  25,4%  36,4%  7,4%  1,2%  0,1% 29,1 1016 1,8%
N davon HD Halluzinogene  0,6%  8,2%  21,5%  46,2%  14,6%  6,3%  2,5%   21,1 158 0,3%
N davon HD Eßstörungen  2,1%  9,7%  5,5%  8,3%  10,3%  26,2%  24,1%  9,0%  4,8% 34,7 145 0,3%
E davon HD path. Spielverhalten  0,7%  0,5%  1,9%  12,2%  21,5%  41,4%  14,8%  5,2%  1,7% 33,3 1078 1,9%
R davon ohne Hauptdiagnose  1,7%  2,5%  5,2%  16,2%  14,6%  28,2%  21,2%  8,2%  2,2% 33,8 4389 7,6%
Familienangehörige  4,1%  2,5%  1,5%  4,1%  3,8%  18,2%  33,8%  19,9%  12,2% 43,0 1083 1,9%
Sonstige Gründe  2,7%  4,1%  3,3%  10,2%  9,4%  27,8%  26,1%  12,3%  4,1% 36,7 1753 3,0%
Alle Abs. 377 1190 1952 6058 6178 17404 15833 6933 2030 36,9 57955 100%
% 0,7% 2,1% 3,4% 10,5% 10,7% 30,0% 27,3% 12,0% 3,5% 100% 
eigene Symptomatik  1,0%  3,9%  4,0%  8,2%  7,4%  28,0%  27,9%  14,5%  5,1% 38,4 16769 74,4%
davon HD Alkohol  0,4%  0,5%  0,5%  1,5%  3,7%  28,7%  37,2%  20,3%  7,2% 43,7 10311 45,7%
davon HD Opiate  0,6%  6,1%  9,1%  24,7%  19,4%  32,3%  6,5%  1,2%  0,2% 27,8 1988 8,8%
 davon HD Cannabis  5,0%  31,5%  20,4%  21,7%  7,3%  10,6%  2,7%  0,2%  0,6% 21,4 480 2,1%
F davon HD Sedativa/Hypnotika  0,7%  1,7%  1,5%  4,9%  5,4%  27,4%  34,8%  16,5%  6,9% 41,5 405 1,8%
R davon HD Kokain  0,7%  6,7%  12,7%  26,0%  16,0%  30,0%  7,3%  0,7%  26,8 150 0,7%
A davon HD Halluzinogene  9,1%  15,2%  27,3%  33,3%  12,1%  3,0%    20,1 33 0,1%
U davon HD Eßstörungen  3,6%  13,9%  11,9%  21,6%  13,0%  21,9%  10,1%  3,1%  0,7% 27,1 1358 6,0%
E davon HD path. Spielverhalten  1,9%  1,9%  1,9%  10,2%  5,6%  40,7%  25,0%  10,2%  2,8% 37,4 108 0,5%
N davon ohne Hauptdiagnose  1,8%  5,3%  5,6%  11,8%  11,1%  30,2%  20,6%  10,4%  3,2% 34,9 1599 7,1%
Familienangehörige  1,4%  1,1%  1,4%  3,4%  4,8%  25,6%  36,6%  17,4%  8,4% 42,6 4569 20,3%
Sonstige Gründe  3,7%  7,0%  5,8%  9,0%  8,0%  28,7%  22,6%  11,2%  4,2% 35,4 1200 5,3%
Abs. 280 794 805 1636 1548 6216 6616 3360 1283 39,1 22538 100%
% 1,2% 3,5% 3,6% 7,3% 6,9% 27,6% 29,4% 14,9% 5,7% 100% 
Gesamt Abs. 657 1984 2757 7694 7726 23620 22449 10293 3313 37,4 80493 100%
% 0,8% 2,5% 3,4% 9,6% 9,6% 29,3% 27,9% 12,8% 4,1% 100% 
Source: EBIS 1999 (Türk & Welsch 2000a)
(to be continued)
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Betreuungsgrund Alter in Jahren Gesamt
-14 15-17 18-19 20-24 25-29 30-39 40-49 50-59 60 - Mittelwert Unbekannt Total
eigene Symptomatik 286 1091 1878 5835 5972 16720 15010 6501 1826 36,8 101 55220
davon HD Alkohol 108 145 307 1393 2346 11733 13048 5938 1669 40,8 83 36770
davon HD Opiate 32 158 462 2132 1950 2379 575 52 8 28,2 6 7754
 davon HD Cannabis 41 566 652 892 330 288 70 15 5 22,3 2 2861
M davon HD Sedativa/Hypnotika 0 1 3 18 28 68 57 29 12 39,1 0 216
Ä davon HD Kokain 1 17 45 237 258 370 75 12 1 29,1 0 1016
N davon HD Halluzinogene 1 13 34 73 23 10 4 0 0 21,1 1 159
N davon HD Eßstörungen 3 14 8 12 15 38 35 13 7 34,7 0 145
E davon HD path. Spielverhalten 8 5 21 132 232 446 160 56 18 33,3 5 1083
R davon ohne Hauptdiagnose 75 108 230 709 642 1239 930 360 96 33,8 3 4392
Familienangehörige 44 27 16 44 41 197 366 216 132 43 2 1085
Sonstige Gründe 47 72 58 179 165 487 457 216 72 36,7 1 1754
M Unbekannt 30 55 66 130 142 463 448 182 65 37,1 6 1587
M Total 407 1245 2018 6188 6320 17867 16281 7115 2095 36,9 110 59646
eigene Symptomatik 173 662 670 1374 1234 4701 4672 2432 851 38,4 15 16784
davon HD Alkohol 39 49 55 157 378 2956 3837 2093 747 43,7 12 10323
davon HD Opiate 12 122 180 491 385 642 129 23 4 27,8 0 1988
 davon HD Cannabis 24 151 98 104 35 51 13 1 3 21,4 2 482
F davon HD Sedativa/Hypnotika 3 7 6 20 22 111 141 67 28 41,5 0 405
R davon HD Kokain 1 10 19 39 24 45 11 1 0 26,8 1 151
A davon HD Halluzinogene 3 5 9 11 4 1 0 0 0 20,1 0 33
U davon HD Eßstörungen 49 189 162 294 177 298 137 42 10 27,1 0 1358
E davon HD path. Spielverhalten 2 2 2 11 6 44 27 11 3 37,4 0 108
N davon ohne Hauptdiagnose 28 85 90 188 178 483 330 166 51 34,9 0 1599
Familienangehörige 63 48 66 154 218 1171 1673 794 382 42,6 5 4574
Sonstige Gründe 44 84 69 108 96 344 271 134 50 35,4 1 1201
F Unbekannt 34 34 24 32 37 152 194 92 42 38,1 1 642
F Total 314 828 829 1668 1585 6368 6810 3452 1325 39,1 22 23201
G Unbekannt 64 89 90 162 179 615 642 274 107 37,4 7 2229
G Total 721 2073 2847 7856 7905 24235 23091 10567 3420 37,4 132 82847
Source: EBIS 1999 (Türk & Welsch 2000a)
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Table 49: Single diagnosis and age (men)
Einzeldiagnose * Alter in Jahren Gesamt
-14 15 - 17 18 - 19 20 - 24 25 - 29 30 - 39 40 - 49 50 - 59 60 - Mittelwert Abs. %
F10 Alkohol  0,3%  0,7%  1,5%  5,9%  8,2%  32,1%  32,6%  14,5%  4,1% 39,5 42743 77,5%
F11 Heroin  0,4%  2,2%  6,0%  26,5%  24,7%  31,4%  8,1%  0,7%  0,1% 28,4 10055 18,2%
Methadon  0,4%  0,5%  3,6%  21,5%  25,4%  38,0%  10,2%  0,5%  29,9 2785 5,1%
Codein-Präparate  0,3%  0,6%  3,6%  19,9%  25,9%  37,7%  11,2%  0,6%  0,1% 30,2 2156 3,9%
Sonstige opiathaltige Mittel  0,4%  0,6%  3,9%  21,1%  20,1%  36,3%  16,6%  0,4%  0,4% 31,1 487 0,9%
F12 Haschisch  0,7%  6,9%  10,8%  27,2%  20,3%  26,6%  6,8%  0,5%  0,1% 26,7 11885 21,6%
Marihuana  0,5%  7,2%  11,7%  27,0%  20,9%  24,8%  7,2%  0,5%  0,1% 26,7 3905 7,1%
F13 Beruhigungsmittel  0,3%  0,8%  3,4%  16,2%  21,2%  37,9%  14,7%  4,2%  1,2% 32,3 3569 6,5%
Schlafmittel  0,3%  0,7%  4,0%  17,1%  23,2%  37,0%  13,9%  3,0%  0,7% 31,7 1749 3,2%
F14 Kokain  0,3%  2,4%  6,9%  25,3%  24,0%  32,7%  7,7%  0,6%  0,1% 28,2 7035 12,8%
Crack  0,6%  2,0%  8,1%  22,5%  28,4%  32,3%  5,9%  0,3%  27,9 356 0,6%
Sonstige Kokain   3,0%  12,2%  30,3%  21,1%  28,3%  5,3%   26,9 304 0,6%
F15 Andere Stimulantien  0,3%  5,1%  12,7%  32,9%  21,1%  22,5%  4,8%  0,5%  0,1% 26,0 2702 4,9%
F16 LSD  0,2%  5,2%  12,0%  32,7%  19,8%  22,4%  6,9%  0,7%  0,2% 26,2 3259 5,9%
Mescalin  0,3%  2,3%  10,1%  27,2%  17,1%  29,5%  12,1%  1,3%  28,6 298 0,5%
Sonstige Halluzinogene  0,3%  7,1%  15,2%  33,7%  19,3%  19,3%  4,5%  0,5%  0,1% 24,5 1023 1,9%
F17 Tabak  0,3%  1,7%  3,7%  11,9%  12,7%  33,3%  25,7%  9,0%  1,7% 35,7 13726 24,9%
F18 Flüchtige Lösungsmittel  1,2%  2,9%  9,9%  15,2%  21,1%  33,3%  9,9%  5,3%  1,2% 30,4 171 0,3%
F19 And. psychotrope Substanzen  0,4%  8,1%  14,9%  38,1%  20,5%  14,2%  3,3%  0,6%  24,3 1240 2,2%
F50 Eßstörungen  0,9%  3,5%  4,2%  11,6%  13,3%  30,2%  24,6%  8,3%  3,5% 35,5 577 1,0%
F55 Antidepressiva   1,1%  1,8%  12,5%  16,6%  29,5%  25,1%  12,5%  0,7% 36,4 271 0,5%
Laxantia     10,7%  14,3%  64,3%  7,1%   3,6% 34,2 28 0,1%
Analgetika   3,4%  2,9%  8,0%  10,3%  31,0%  31,0%  12,1%  1,1% 37,1 174 0,3%
Antazida    7,7%   30,8%  46,2%  15,4%   32,2 13 0,0%
Vitamine     12,5%  17,5%  40,0%  15,0%  12,5%  2,5% 36,3 40 0,1%
Steroide / Hormone   5,3%  5,3%  5,3%  21,1%  31,6%  26,3%  5,3%  34,3 19 0,0%
best. Pflanzen / Naturheilmittel   10,3%  5,9%  19,1%  13,2%  29,4%  13,2%  8,8%  31,5 68 0,1%
andere / n.n. bezeichnete   2,9%  1,5%  10,3%  14,7%  27,9%  32,4%  8,8%  1,5% 37,0 68 0,1%
F63 Automatenspiel  0,5%  0,6%  1,8%  11,7%  22,5%  41,7%  15,4%  4,5%  1,2% 33,2 1433 2,6%
Glücksspiel  0,5%   1,5%  7,4%  21,1%  41,9%  18,9%  7,1%  1,7% 35,0 408 0,7%
Gesamt                              Abs. 286 1091 1878 5835 5972 16720 15010 6501 1826 36,8 55119 100%
% 0,5% 2,0% 3,4% 10,6% 10,8% 30,3% 27,2% 11,8% 3,3% 100% 
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Einzeldiagnose Alter in Jahren Gesamt
-14 15 - 17 18 - 19 20 - 24 25 - 29 30 - 39 40 - 49 50 - 59 60 - Mittelwert Unbekannt Total
F10 Alkohol 130 308 646 2530 3509 13728 13935 6210 1747 39,5 94 42837
F11 Heroin 37 220 601 2667 2483 3156 816 66 9 28,4 8 10063
Methadon 10 13 101 598 707 1058 285 13 0 29,9 1 2786
Codein-Präparate 7 14 78 429 559 812 241 14 2 30,2 2 2158
Sonstige opiathaltige Mittel 2 3 19 103 98 177 81 2 2 31,1 0 487
F12 Haschisch 80 818 1284 3237 2418 3164 810 63 11 26,7 10 11895
Marihuana 19 282 457 1056 818 968 283 19 3 26,7 3 3908
F13 Beruhigungsmittel 12 30 122 577 756 1353 525 151 43 32,3 7 3576
Schlafmittel 6 12 70 299 406 647 243 53 13 31,7 0 1749
F14 Kokain 20 171 484 1780 1690 2302 539 43 6 28,2 8 7043
Crack 2 7 29 80 101 115 21 1 0 27,9 0 356
Sonstige Kokain 0 9 37 92 64 86 16 0 0 26,9 1 305
F15 Andere Stimulantien 9 138 342 890 569 607 130 13 4 26,0 2 2704
F16 LSD 8 168 390 1066 644 729 225 23 6 26,2 7 3266
Mescalin 1 7 30 81 51 88 36 4 0 28,6 1 299
Sonstige Halluzinogene 3 73 156 345 197 197 46 5 1 24,5 2 1025
F17 Tabak 45 232 508 1628 1743 4567 3534 1237 232 35,7 10 13736
F18 Flüchtige Lösungsmittel 2 5 17 26 36 57 17 9 2 30,4 0 171
F19 And. psychotrope Substanzen 5 100 185 472 254 176 41 7 0 24,3 2 1242
F50 Eßstörungen 5 20 24 67 77 174 142 48 20 35,5 0 577
F55 Antidepressiva 0 3 5 34 45 80 68 34 2 36,4 0 271
Laxantia 0 0 0 3 4 18 2 0 1 34,2 0 28
Analgetika 0 6 5 14 18 54 54 21 2 37,1 0 174
Antazida 0 0 1 0 4 6 2 0 0 32,2 0 13
Vitamine 0 0 0 5 7 16 6 5 1 36,3 0 40
Steroide / Hormone 0 1 1 1 4 6 5 1 0 34,3 0 19
best. Pflanzen / Naturheilmittel 0 7 4 13 9 20 9 6 0 31,5 0 68
andere / n.n. bezeichnete 0 2 1 7 10 19 22 6 1 37,0 0 68
F63 Automatenspiel 7 9 26 168 323 597 221 65 17 33,2 5 1438
Glücksspiel 2 0 6 30 86 171 77 29 7 35,0 1 409
Gesamt                                             Unbekannt
Total 286 1091 1878 5835 5972 16720 15010 6501 1826 36,8 101 55220
Source: EBIS 1999 (Türk & Welsch 2000a)
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Table 50: Single diagnosis and age (women)
Einzeldiagnose * Alter in Jahren Gesamt
-14 15 - 17 18 - 19 20 - 24 25 - 29 30 - 39 40 - 49 50 - 59 60 - Mittelwert Abs. %
F10 Alkohol  0,4%  1,0%  1,1%  3,4%  5,0%  29,6%  34,4%  18,5%  6,5% 42,3 12057 71,9%
F11 Heroin  0,6%  6,5%  9,3%  24,5%  19,3%  32,2%  6,7%  0,8%  0,2% 27,7 2538 15,1%
Methadon  0,4%  1,1%  4,3%  23,4%  22,8%  39,5%  7,6%  0,8%  0,1% 29,3 958 5,7%
Codein-Präparate  0,2%  2,4%  5,9%  22,0%  22,3%  34,6%  10,6%  1,6%  0,3% 29,7 613 3,7%
Sonstige opiathaltige Mittel   4,0%  4,7%  20,8%  16,8%  30,9%  17,4%  2,7%  2,7% 32,1 149 0,9%
F12 Haschisch  2,1%  13,0%  12,6%  24,8%  15,6%  24,9%  6,3%  0,5%  0,2% 25,8 2414 14,4%
Marihuana  2,8%  14,8%  12,7%  25,0%  14,7%  23,6%  5,4%  1,0%  25,2 777 4,6%
F13 Beruhigungsmittel  0,6%  2,2%  4,2%  11,8%  12,7%  31,3%  21,9%  10,9%  4,4% 36,2 1759 10,5%
Schlafmittel  0,5%  3,3%  4,8%  14,0%  13,3%  31,3%  19,3%  9,7%  3,8% 35,1 731 4,4%
F14 Kokain  0,5%  7,5%  10,5%  23,2%  19,2%  32,8%  5,8%  0,5%  0,1% 27,3 1524 9,1%
Crack  3,4%  10,2%  25,4%  32,2%  8,5%  20,3%    23,1 59 0,4%
Sonstige Kokain   10,4%  14,9%  34,3%  10,4%  26,9%  3,0%   25,0 67 0,4%
F15 Andere Stimulantien  1,6%  12,9%  15,7%  27,6%  13,3%  22,1%  5,2%  0,8%  0,8% 25,4 630 3,8%
F16 LSD  1,3%  12,5%  16,9%  27,6%  13,8%  19,7%  6,7%  0,9%  0,5% 25,4 638 3,8%
Mescalin   9,1%  15,2%  30,3%  12,1%  27,3%  6,1%   26,2 33 0,2%
Sonstige Halluzinogene  2,1%  18,1%  19,4%  32,1%  11,4%  13,1%  3,8%   22,9 237 1,4%
F17 Tabak  0,9%  3,8%  4,2%  10,5%  10,2%  33,0%  25,4%  9,7%  2,3% 35,8 3177 18,9%
F18 Flüchtige Lösungsmittel   11,8%  5,9%  15,7%  21,6%  17,6%  25,5%  2,0%  30,5 51 0,3%
F19 And. psychotrope Substanzen  2,5%  19,9%  18,4%  27,8%  13,0%  14,4%  2,5%  0,7%  0,7% 23,2 277 1,7%
F50 Eßstörungen  2,7%  10,9%  9,6%  19,6%  11,8%  26,3%  13,2%  4,9%  1,0% 29,3 2040 12,2%
F55 Antidepressiva  0,4%  2,2%  0,7%  6,7%  8,6%  31,2%  30,9%  15,6%  3,7% 39,5 269 1,6%
Laxantia   7,7%  8,7%  18,3%  10,6%  33,7%  15,4%  4,8%  1,0% 31,0 104 0,6%
Analgetika  0,6%  2,2%  1,1%  6,7%  9,0%  36,0%  22,5%  14,6%  7,3% 39,7 178 1,1%
Antazida     25,0%  25,0%   25,0%  25,0%  38,0 4 0,0%
Vitamine  4,8%    9,5%   33,3%  28,6%  23,8%  38,9 21 0,1%
Steroide / Hormone   8,3%  4,2%  20,8%   33,3%  16,7%  12,5%  4,2% 35,5 24 0,1%
best. Pflanzen / Naturheilmittel  1,5%  3,1%   7,7%  10,8%  27,7%  27,7%  20,0%  1,5% 38,2 65 0,4%
andere / n.n. bezeichnete  1,7%  1,7%  3,3%  18,3%  11,7%  16,7%  33,3%  11,7%  1,7% 35,8 60 0,4%
F63 Automatenspiel  1,6%  2,4%  3,2%  10,4%  8,0%  36,8%  22,4%  12,8%  2,4% 37,0 125 0,7%
Glücksspiel     7,9%  7,9%  55,3%  18,4%  7,9%  2,6% 36,9 38 0,2%
Gesamt                              Abs. 173 662 670 1374 1234 4701 4672 2432 851 38,4 16769 100%
% 1,0% 3,9% 4,0% 8,2% 7,4% 28,0% 27,9% 14,5% 5,1% 100% 
Source: EBIS 1999 (Türk & Welsch 2000a)
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Einzeldiagnose Alter in Jahren Gesamt
-14 15 - 17 18 - 19 20 - 24 25 - 29 30 - 39 40 - 49 50 - 59 60 - Mittelwert Unbekannt Total
F10 Alkohol 53 122 138 409 606 3563 4153 2229 784 42,3 12 12069
F11 Heroin 15 165 236 621 490 816 170 21 4 27,7 0 2538
Methadon 4 11 41 224 218 378 73 8 1 29,3 0 958
Codein-Präparate 1 15 36 135 137 212 65 10 2 29,7 0 613
Sonstige opiathaltige Mittel 0 6 7 31 25 46 26 4 4 32,1 0 149
F12 Haschisch 50 313 305 599 376 601 153 11 6 25,8 3 2417
Marihuana 22 115 99 194 114 183 42 8 0 25,2 3 780
F13 Beruhigungsmittel 10 39 73 207 224 551 386 191 78 36,2 0 1759
Schlafmittel 4 24 35 102 97 229 141 71 28 35,1 0 731
F14 Kokain 7 114 160 353 292 500 88 8 2 27,3 1 1525
Crack 2 6 15 19 5 12 0 0 0 23,1 0 59
Sonstige Kokain 0 7 10 23 7 18 2 0 0 25,0 0 67
F15 Andere Stimulantien 10 81 99 174 84 139 33 5 5 25,4 0 630
F16 LSD 8 80 108 176 88 126 43 6 3 25,4 0 638
Mescalin 0 3 5 10 4 9 2 0 0 26,2 0 33
Sonstige Halluzinogene 5 43 46 76 27 31 9 0 0 22,9 0 237
F17 Tabak 28 120 133 335 324 1049 807 308 73 35,8 3 3180
F18 Flüchtige Lösungsmittel 0 6 3 8 11 9 13 1 0 30,5 2 53
F19 And. psychotrope Substanzen 7 55 51 77 36 40 7 2 2 23,2 0 277
F50 Eßstörungen 56 223 196 399 241 536 270 99 20 29,3 0 2040
F55 Antidepressiva 1 6 2 18 23 84 83 42 10 39,5 0 269
Laxantia 0 8 9 19 11 35 16 5 1 31,0 0 104
Analgetika 1 4 2 12 16 64 40 26 13 39,7 0 178
Antazida 0 0 0 1 1 0 1 1 0 38,0 0 4
Vitamine 1 0 0 2 0 7 6 5 0 38,9 0 21
Steroide / Hormone 0 2 1 5 0 8 4 3 1 35,5 0 24
best. Pflanzen / Naturheilmittel 1 2 0 5 7 18 18 13 1 38,2 0 65
andere / n.n. bezeichnete 1 1 2 11 7 10 20 7 1 35,8 0 60
F63 Automatenspiel 2 3 4 13 10 46 28 16 3 37,0 0 125
Glücksspiel 0 0 0 3 3 21 7 3 1 36,9 0 38
Gesamt                                             Unbekannt
Total 173 662 670 1374 1234 4701 4672 2432 851 38,4 15 16784
Source: EBIS 1999 (Türk & Welsch 2000a)
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Inpatient treatment, Germany
Table 51: Main diagnosis and gender
Hauptdiagnose Geschlecht Gesamt
Männer Frauen Abs. %
Alkohol   70,6%   71,6% 11711 70,9%
Heroin   13,2%   12,5% 2153 13,0%
Methadon   1,2%   0,6% 174 1,1%
Codein-Präparate   0,2%   0,2% 28 0,2%
Sonstige opiathaltige Mittel   0,2%   0,2% 29 0,2%
Haschisch/ Marihuana   1,0%   0,4% 139 0,8%
Schlafmittel   0,1%   0,4% 29 0,2%
Beruhigungsmittel   0,3%   1,8% 110 0,7%
Kokain   1,2%   0,6% 175 1,1%
Crack   0,0%   0,0% 6 0,0%
Sonstige   0,0%   0,0% 5 0,0%
Andere Stimulantien   0,4%   0,2% 51 0,3%
LSD   0,1%   0,1% 10 0,1%
Mescalin   0,0% 2 0,0%
Sonstige Designer Drugs   0,1%   0,1% 10 0,1%
Tabak 0 0,0%
Flüchtige Lösungsmittel 0 0,0%
Andere psychoaktive 
Substanzen   0,3%   0,2% 42 0,3%
Substanzen ohne 
Abhängigkeitspotential   0,0%   0,1% 4 0,0%
Eßstörungen   0,0%   1,1% 44 0,3%
Automatenspiel   0,1% 8 0,0%
Glücksspiel   0,0%   0,0% 4 0,0%
Sonstige/ unbekannt   11,2%   9,8% 1793 10,8%
Gesamt                           Abs. 12623 3904 16527 100% 
% 76,4% 23,6% 100% 
Source: SEDOS 1999 (Türk & Welsch 2000b)
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Table 52: Main diagnosis and age
Haupt-
diagnose Alter Gesamt
 - 14 15 - 17 18 -19 20 - 24 25 - 29 30 - 39 40 - 49 50 - 59  ab 60 Mittel Abs. %
Alkohol   0,2%   0,1%   0,3%   2,0%   4,2%   32,1%   38,2%   18,3%   4,4%  42,6 11711 70,9%
Heroin   0,1%   1,3%   4,6%   27,0%   26,6%   34,5%   5,7%   0,1%  28,4 2153 13,0%
Methadon   1,7%   3,4%   29,3%   31,6%   27,6%   5,7%   0,6%  28,0 174 1,1%
Codein-Präparate   28,6%   17,9%   25,0%   25,0%   3,6%  32,5 28 0,2%
Sonstige 
opiathaltige Mittel   3,4%   6,9%   17,2%   17,2%   24,1%   27,6%   3,4%  33,3 29 0,2%
Haschisch/ 
Marihuana   7,9%   17,3%   33,1%   24,5%   13,7%   2,9%   0,7%  24,4 139 0,8%
Schlafmittel   3,4%   17,2%   10,3%   31,0%   31,0%   6,9%  35,5 29 0,2%
Beruhigungsmittel   4,5%   4,5%   29,1%   38,2%   18,2%   5,5%  42,5 110 0,7%
Kokain   0,7%   1,1%   14,7%   18,9%   22,5%   3,5%  28,6 285 1,7%
Crack   16,7%   16,7%   16,7%   50,0%  29,2 6 0,0%
Sonstige   20,0%   80,0%  32,4 5 0,0%
Andere Stimulantien   2,0%   5,9%   45,1%   23,5%   15,7%   5,9%   2,0%  25,9 51 0,3%
LSD   20,0%   50,0%   20,0%   10,0%  22,9 10 0,1%
Mescalin   50,0%   50,0%  34,5 2 0,0%
Sonstige Designer 
Drugs   30,0%   70,0%  21,3 10 0,1%
Tabak  0 0,0%
Flüchtige 
Lösungsmittel  0 0,0%
Andere 
psychoaktive   2,4%   4,8%   21,4%   26,2%   35,7%   9,5%  29,2 42 0,3%
Substanzen ohne 
Abhängigkeits-
potential   25,0%   75,0%  41,7 4 0,0%
Eßstörungen   6,8%   15,9%   31,8%   29,5%   15,9%  29,9 44 0,3%
Automatenspiel   12,5%   37,5%   50,0%  28,6 8 0,0%
Glücksspiel   50,0%   25,0%   25,0%  42,5 4 0,0%Sonstig / 
Unbekannt   0,3%   0,2%   0,8%   7,6%   8,6%   29,2%   33,9%   16,5%   2,8%  39,3 1791 10,8%
Gesamt          Abs. 30 65 204 1172 1426 5265 5316 2469 578 39,8 16525 100% 
% 0,2% 0,4% 1,2% 7,1% 8,6% 31,9% 32,2% 14,9% 3,5% 100% 
Source: SEDOS 1999 (Türk & Welsch 2000b)
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Further Tables
Table 53: Seizures of narcotics
Heroin (kg) Cocaine (kg) Cannabis (kg) LSD (Trips) Amphetamines (kg) Ecstasy (Tablets)
1982 202 33 3156 42170 16
1983 260 106 4583 41848 25
1984 264 171 5632 40951 14
1985 208 165 11498 30536 28
1986 157 186 2675 22237 85
1987 320 296 2998 19487 62
1988 537 496 11350 38033 91
1989 727 1406 12073 10574 67
1990 847 2474 13641 14332 85
1991 1595 964 12344 13887 88
1992 1438 1332 12166 29571 105
1993 1095 1051 11353 23442 117 77922
1994 1590 767 25693 29627 120 239051
1995 933 1846 14248 71069 138 380858
1996 898 1373 9355 67082 160 692397
1997 722 1721 11495 78430 234 694281
1998 686 1133 21007 32250 310 419329
1999 796 1979 19907 22965 360 1470507
Source: Drugs Case Register 1999 (BKA 2000b)
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Table 54:General offences under §29 BtMG („offences related to drug use“)
Heroin Cocaine Cannabis LSD Amphetamines Other
1982 8775 465 26799 3582
1983 9146 617 27410 2878
1984 8659 914 25550 2455
1985 8129 985 25712 2487
1986 9292 1226 29349 299 2145
1987 12164 1396 29568 346 2973
1988 16552 2071 31582 356 1577 1716
1989 20900 2768 33251 289 1625 1651
1990 25536 3100 34811 230 1852 1481
1991 33721 4141 33892 275 2098 1504
1992 38937 4773 32279 267 2653 1963
1993 32789 5854 34752 391 2983 2862
1994 29866 7543 40853 616 3250 3106
1995 30457 9326 49070 980 6951 4446
1996 34146 10151 55600 1657 10744 5470
1997 34473 12167 64456 1528 12687 5897
1998 31433 12835 79495 1035 11899 6043
1999 28157 13810 85668 754 13356 6905
Source: Drugs Case Register 1999 (BKA 2000b)
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Table 55: Illegal trafficking and smuggling of narcotics under §29 BtMG (Cases)
Heroin Cocaine Cannabis LSD Amphetamines Other
1982 6682 584 13993 1845
1983 6884 826 14288 1671
1984 6676 1059 13965 1310
1985 6333 1358 14224 1409
1986 5576 1238 15552 250 1124
1987 6802 1461 15447 252 1525
1988 8356 1945 15473 225 1027 697
1989 10167 2344 15726 238 1187 586
1990 11772 2729 16759 170 1120 490
1991 15742 3170 16375 202 1318 462
1992 17820 3758 14507 204 1534 590
1993 16854 4502 13261 231 1668 696
1994 15674 5818 16144 358 2082 1035
1995 17489 7478 19083 601 3960 1412
1996 18580 8447 23021 1093 7198 2200
1997 18927 9869 24221 984 8006 1955
1998 17149 9858 27188 591 6508 2102
1999 16172 10877 29776 480 7267 2365
Source: Drugs Case Register 1999 (BKA 2000a)
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Table 56: Illegal import of narcotics under § 30 Abs. 1 Nr. 4 BtMG (Cases)
Heroin Cocaine Cannabis LSD Amphetamines Other
1986 650 179 871 34 59
1987 784 299 932 26 136
1988 866 363 893 30 104 56
1989 931 396 857 17 112 50
1990 871 436 1063 27 73 51
1991 982 542 1348 35 96 44
1992 1022 551 1481 24 141 68
1993 1161 651 1662 26 188 83
1994 1107 685 1788 33 237 127
1995 1110 883 2308 55 355 155
1996 824 840 2522 86 595 209
1997 1029 748 2675 62 420 117
1998 1043 698 3180 41 500 136
1999 1249 812 3529 46 503 195
Source: Drugs Case Register 1999 (BKA 2000b)
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Table 57: Summing of crimes (offences in connection with consumption,
trafficking, smuggling, illegal import)
Heroin Cocaine Cannabis LSD Amphetamines Other
1982 15457 1049 40792 0 0 5427
1983 16030 1443 41698 0 0 4549
1984 15335 1973 39515 0 0 3765
1985 14462 2343 39936 0 0 3896
1986 15518 2643 45772 583 0 3328
1987 19750 3156 45947 624 0 4634
1988 25774 4379 47948 611 2708 2469
1989 31998 5508 49834 544 2924 2287
1990 38179 6265 52633 427 3045 2022
1991 50445 7853 51615 512 3512 2010
1992 57779 9082 48267 495 4328 2621
1993 50804 11007 49675 648 4839 3641
1994 46647 14046 58785 1007 5569 4268
1995 49056 17687 70461 1636 11266 6013
1996 53550 19802 81143 2836 18537 7879
1997 54429 22784 91352 2574 21113 7969
1998 49627 23391 109863 1667 18907 8281
1999 45578 25499 118973 1280 21126 9465
Source: Drugs Case Register 1999 (BKA 2000b)
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Table 58: Drug-related deaths in Germany since 1980
1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999Drug-
related
deaths 324 348 442 670 991 1491 2125 2099 1738 1624 1565 1712 1501 1674 1812
Men 124 275 356 548 815 1227 1770 1750 1419 1346 1293 1447 1223 1401 1513
Women 78 73 86 122 176 264 329 332 298 264 254 138 250 258 294
< 14
years
14 -< 18 2 1 2 5 9 9 18 15 15 13 18 9 21 29
18 -< 21 23 15 32 33 51 78 121 108 87 74 97 79 106 93 110
21 -< 25 86 60 86 155 206 317 383 415 292 230 208 241 171 253 247
25 -< 30 119 132 144 196 317 472 645 646 522 486 414 435 341 354 376
> 30
years
94 141 179 265 412 615 941 895 801 805 815 912 846 938 1004
Source: Drugs Case Register 1999 (BKA 2000b)
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Table 59: Drug prices in gramm, by small amounts (g) and large amounts (kg)
Cannabis
Gramm
Cannabis
Kg
Heroin
Gramm
Heroin
kg
Cocaine
Gramm
Cocaine
kg
Amphetamines
Gramm
Amphetamines
kg
1975 3,75 DM 2,40 DM 220,00 DM 80,00 DM 150,00 DM
1976 6,00 DM 2,50 DM 210,00 DM 80,00 DM 150,00 DM
1977 6,00 DM 3,10 DM 450,00 DM 120,00 DM 195,00 DM
1978 7,50 DM 3,75 DM 225,00 DM 115,00 DM 225,00 DM
1979 7,50 DM 4,50 DM 165,00 DM 107,50 DM 225,00 DM
1980 10,00 DM 6,25 DM 225,00 DM 90,00 DM 225,00 DM
1981 12,00 DM 5,54 DM 195,00 DM 140,00 DM 225,00 DM
1982 15,00 DM 8,50 DM 315,00 DM 115,00 DM 350,00 DM 135,00 DM
1983 14,00 DM 10,00 DM 450,00 DM 145,00 DM 275,00 DM 160,00 DM
1984 18,00 DM 9,25 DM 327,00 DM 190,00 DM 298,00 DM 145,00 DM
1985 12,00 DM 7,95 DM 315,00 DM 175,00 DM 261,00 DM 185,00 DM
1986 14,00 DM 9,00 DM 320,00 DM 171,00 DM 295,00 DM 169,00 DM
1987 14,25 DM 8,20 DM 370,00 DM 143,00 DM 213,00 DM 145,00 DM
1988 15,00 DM 7,75 DM 250,00 DM 115,00 DM 200,00 DM 100,00 DM
1989 12,00 DM 7,50 DM 200,00 DM 85,00 DM 200,00 DM 110,00 DM
1990 12,00 DM 6,00 DM 175,00 DM 75,00 DM 200,00 DM 110,00 DM
1991 12,00 DM 6,00 DM 125,00 DM 60,00 DM 150,00 DM 95,00 DM
1992 10,00 DM 5,75 DM 150,00 DM 65,00 DM 155,00 DM 80,00 DM
1993 11,00 DM 5,65 DM 125,00 DM 60,00 DM 163,00 DM 88,00 DM 55,00 DM 25,30 DM
1994 11,00 DM 5,50 DM 130,00 DM 59,80 DM 156,00 DM 84,30 DM 11,00 DM 20,00 DM
1995 11,00 DM 5,04 DM 128,00 DM 52,33 DM 151,00 DM 77,54 DM 20,00 DM 20,12 DM
1996 11,50 DM 5,01 DM 108,00 DM 49,13 DM 141,00 DM 76,67 DM 27,00 DM 17,88 DM
1997 12,00 DM 4,98 DM 88,00 DM 45,92 DM 131,00 DM 75,80 DM 34,00 DM 15,64 DM
1998 12,00 DM 4,60 DM 88,00 DM 44,00 DM 128,00 DM 73,00 DM 32,00 DM 14,60 DM
1999 11,00 DM 4,84 DM 85,50 DM 42,70 DM 125,00 DM 72,50 DM 28,50 DM 11,30 DM
Source: Federal Criminal Police Office 2000
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ANNEX III BROCHURES
Bundeszentrale für gesundheitliche Aufklärung (BZgA) (Hrsg.). (1999) Evaluation –
ein Instrument zur Qualitätssicherung in der Gesundheitsförderung  (Fachheftreihe:
„Forschung und Praxis der Gesundheitsförderung“, Band 8); Köln.
Bundeszentrale für gesundheitliche Aufklärung (BZgA) (Hrsg.). (1998) Prävention
durch Angst? Stand der Furchappellforschung (Fachheftreihe: „Forschung und Praxis
der Gesundheitsförderung“, Band 4); Köln.
Bundeszentrale für gesundheitliche Aufklärung (BZgA) (Hrsg.). (1998)
Geschlechtsbezogene Suchtprävention – Praxisansätze, Theorieentwicklung,
Definitionen  (Fachheftreihe: „Forschung und Praxis der Gesundheitsförderung“,
Band 2); Köln.
Bundeszentrale für gesundheitliche Aufklärung (BZgA) (Hrsg.). (1998)
Geschlechtsbezogene Suchtprävention – Praxisansätze, Theorieentwicklung,
Definitionen (Fachheftreihe: „Forschung und Praxis der Gesundheitsförderung“, Band
5); Köln.
Bundeszentrale für gesundheitliche Aufklärung (BZgA) (Hrsg.). (2000) „Schutz oder
Risiko? Familienumwelten im Spiegel der Kommunikation zwischen Eltern und ihren
Kindern“ (Fachheftreihe: „Forschung und Praxis der Gesundheitsförderung“, Band
11); Köln.
Bundeszentrale für gesundheitliche Aufklärung (BZgA) (Hrsg.) (2000) „Modelprojekt
Qualitätszirkel in der Gesundheitsförderung“ ; Göttingen.
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